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ABSTRACT OF DISSERTATION 
PNEUMOVIRUS INFECTIONS: UNDERSTANDING RSV AND HMPV ENTRY, 
REPLICATION, AND SPREAD 
Pneumoviruses including human metapneumovirus (HMPV) and respiratory 
syncytial virus (RSV) are significant causes of respiratory tract infections globally. 
Children, elderly, and immunocompromised patients are at the greatest risk for 
developing severe infections, which can have devastating outcomes. Although 
these viruses are ubiquitous with significant impacts on human health, there are 
no antivirals or vaccines available. The only FDA approved therapy is a 
monoclonal antibody for RSV, given prophylactically during the infectious season, 
and this treatment is only available for high risk infants. The work presented in this 
thesis aims to increase our understanding of how these viruses enter, replicate, 
and spread to better characterize the basic molecular mechanisms used, opening 
avenues for potential antiviral therapies. We first analyzed the fusion protein of 
HMPV and how low pH is important for entry of some viral strains. We analyzed 
previously uncharacterized strains and found that residues initially hypothesized 
to be critical for low pH fusion are not always required, suggesting a more complex 
regulation of fusion. We then explored the role of the proteolytic cleavage event 
which is required for HMPV F as well as many other important respiratory 
pathogens, including influenza. We found that many proteases involved in 
activating influenza HA are also important for activating HMPV F, which has not 
previously been reported. We then used our understanding of cleavage to employ 
a treatment strategy targeting host proteases involved in this activation to prevent 
entry and spread. We next conducted a side-by-side comparison of infection, 
spread, and inhibition using a physiologically relevant 3-D human airway epithelial 
model system. We found that RSV and HMPV demonstrate significantly different 
infection and spread kinetics as well as phenotypes during infection, highlighting 
an interesting dichotomy between two closely related viruses. We further analyzed 
therapeutic potential for several monoclonal antibodies, finding that prophylactic 
 
 
interventions prevent entry and spread, but treatment after entry suggests that both 
HMPV and RSV can be inhibited during entry. However, RSV likely spreads 
through cellular release and re-entry whereas HMPV utilizes a mechanism that is 
antibody independent after establishing the initial infection. Lastly, we examined 
the concept of viral co-infections, as co-infections with RSV and HMPV have been 
reported to cause more severe disease in patients. We provide evidence that RSV 
and HMPV co-infected cells can occupy the same inclusion bodies, but further 
investigation suggests that HMPV and RSV replication synergy may be limited. 
Collectively, the data presented in this dissertation provide new understanding of 
pneumovirus infections and reveals important information about the molecular 
mechanisms of pneumovirus entry and spread. 
 
KEYWORDS: Human metapneumovirus, Respiratory syncytial virus, human     
airway epithelium, inclusion bodies, co-infection, fusion protein. 
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Chapter 1: Introduction 
Paramyxo- and pneumovirus classification, epidemiology, and human 
health impact 
 Mononegavirales is an order of viruses containing a negative sense, single- 
stranded RNA genome. This Order is made of up eight different families: 
Bornaviridae, Filoviridae, Mymonaviridae, Namiviridae, Paramyxoviridae, 
Pneumoviridae, Rhabdoviridae and Sunviridae (1). Paramyxoviruses, in particular, 
have well known members responsible for significant health and economic burden 
worldwide. Members of paramyxoviridae cause disease in animals and humans, 
with potential for zoonotic transmission (2). One of the most highly pathogenic and 
well-known members is measles virus (MeV), which has become an increasing 
health concern in recent years due to decreased compliance with current 
vaccination regimens (3, 4). MeV is typically contracted during childhood and 
causes respiratory illness that can progress and cause complications such as 
pneumonia and encephalitis. MeV was responsible for severe morbidity and 
mortality until a vaccine developed in the 1960’s led to significant reduction in the 
incidence, associated deaths, and hospitalizations (5). Another paramyxovirus, 
mumps virus (MuV), also causes disease during adolescence but vaccination led 
to fewer deaths and hospitalizations. Recently, particularly in developed nations, 
the vaccine that targets MeV and MuV (MMR vaccine) has been scrutinized and 
therefore, large populations have become non-compliant with the current 
vaccination regimen. This opposition to vaccination has led to a significant 
increase in MeV and MuV outbreaks, particularly in the United States and has once 
again become a major global health concern (3-5). 
Other important members include Hendra (HeV) and Nipah (NiV) which 
cause respiratory disease and encephalitis in horses (HeV) and pigs (NiV). HeV 
and NiV have had reports of zoonotic transmission to humans with mortality rates 
ranging between 40-100%, but the amount of cases has been low (6-13). For these 
viruses, there is no current therapeutic treatment or vaccination in humans. 
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However, there has been a prophylactic treatments and vaccinations developed 
for horses against HeV that has demonstrated strong potential in high risk 
situations (14, 15). Parainfluenza viruses (PIV) cause significant morbidity and 
mortality in humans and PIV1-3 are responsible for respiratory illness in 
immunocompromised patients, infants, and children (16, 17).    
Two other significant viruses are respiratory syncytial virus (RSV) and 
human metapneumovirus (HMPV, further described below), both of which cause 
widespread and severe respiratory tract infections. Both viruses were previously a 
sub-family of paramyxoviridae, but were recently reclassified to a new family, 
pneumoviridae (18). Although this places them in their own family, many aspects 
of viral infection and protein function remain highly conserved between them, 
allowing us to compare and contrast with information currently known about 
paramyxoviruses.  
RSV was first isolated in 1956 from a chimpanzee presenting with a 
respiratory tract infection, and eventually determined to be of human origin (19, 
20). RSV is now known as one of the leading causes of respiratory tract infections 
in infants and children, and it is estimated that there are 34 million infections and 
3.4 million hospitalizations per year in children under 5 years of age (21, 22). In 
addition to infecting children, RSV causes severe infections in premature infants, 
elderly and immunocompromised patients (21-27). Even though this virus was 
identified more than 60 years ago, there are currently no vaccines or antivirals 
available other than a prophylactic treatment given during the infectious season to 
high risk infants that blocks a protein on the surface required for entry (28, 29). 
Therefore, RSV remains one of the most detrimental pediatric viruses.  
Human metapneumovirus  
Another significant but less well-known respiratory virus, HMPV, was 
isolated in 2001 from children exhibiting symptoms similar to those infected with 
RSV (30). Even though it was only recently identified, it is thought to have been 
circulating in humans as early as 1958 (30-32). When examining the origin of 
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HMPV, it is hypothesized that it recently evolved from zoonotic transmission of 
another member of the pneumoviridae family, avian metapneumovirus C (AMPV), 
based on high sequence homology (30). In addition, the genetic mapping of HMPV 
is also closely related to that of RSV, which encodes for the same proteins as well 
as two additional non-structural proteins (33).  
Since its discovery, HMPV has been characterized as a major human 
pathogen, causing significant respiratory illness worldwide. Nearly everyone has 
been infected by the age of 5, is seropositive by the age of 10, and reinfection is 
common throughout life (30, 34-36). It is second to RSV as the cause of lower 
respiratory tract infections in children (36, 37). Similar to RSV, children, elderly, 
and immunocompromised patients are more likely to harbor serious infections. 
Importantly, some infants hospitalized with RSV for severe bronchiolitis showed 
co-infection with HMPV, which suggests co-infection with both viruses may lead to 
more severe disease. (38-40).  Within the normal, healthy population, HMPV 
infection appears symptomatically similar to etiologic agents of upper respiratory 
infections, including cough, sneezing, rhinitis and other symptoms categorized as 
the “common cold” (41). However, in patients with limited capacity to fight infection, 
it causes more severe symptoms including wheezing, croup, bronchiolitis, and 
respiratory distress which can often lead to hospitalization or death (30, 31, 36, 37, 
42-49). In long- term care patients over the age of 65, some studies suggest that 
HMPV can cause illness in up to 72% of patients during outbreaks (50-54). 
Furthermore, HMPV has been associated with myocarditis and those with 
congenital heart defects are at significant risk for developing severe infections (36, 
48, 55-57). Patients with chronic respiratory illness are also at high risk, including 
those with cystic fibrosis, asthma, or chronic obstructive pulmonary disease.  
Severe infection with HMPV during childhood has also been associated with 
complications in adulthood such as increased incidences of asthma or 
hyperresponsiveness in the respiratory tract (58-64). 
Immunocompromised individuals, including those infected with HIV, 
transplant recipients, or cancer patients have a significantly diminished immune 
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system, allowing for opportunistic infections to develop. HMPV infected patients 
with HIV were 5.4 times as likely to be hospitalized compared with HIV negative 
children (65). Additionally, pediatric patients with cancer were hospitalized nearly 
50% of the time due to weakened immunity (66). While HMPV infection is 
transmitted through the respiratory tract, there has been HMPV RNA detected in 
the central nervous system and brain tissues of patients with fatal encephalitis (67-
69). HMPV has also demonstrated mechanisms for establishing viral persistence. 
HMPV infections without respiratory symptoms have been reported in stem cell 
transplant patients, resulting in serious and sometimes fatal illness (70, 71).  In 
animal models, replicating HMPV could be recovered at 60 days post infection 
(dpi) and detected more than 180 dpi by PCR (63, 72, 73). HMPV was shown to 
be present in neuronal processes in the lung suggesting immune privileged sites 
can keep the virus hidden from the immune system. This eventually leads to the 
viral reactivation following decreased immune function such as glucocorticoid 
administration (74). HMPV also demonstrates the ability to prevent apoptosis in 
cell culture which could offer a potential mechanism used to establish persistence 
(75). 
HMPV infections follow behind annual influenza and respiratory syncytial 
virus seasons, with yearly epidemics peaking between November and April (76, 
77) . There are two subgroups of HMPV (A and B) which are further divided into 
A1, A2, B1 and B2 based on viral glycoprotein sequences (78, 79) (Fig. 1A). Both 
A and B can co-circulate and lineage dominance varies from year to year (80-84). 
Most research studies found that between 5 and 15% of respiratory tract infections 
are due to HMPV, trailing behind RSV and influenza (32, 43, 45, 46, 48, 84-86). 
While HMPV is ubiquitous and responsible for severe upper and lower respiratory 
tract infections, there are still no current FDA approved antiviral or vaccinations 
available. Therefore, a more thorough understanding of the viral lifecycle and 
molecular mechanisms required for infection is needed to discover novel antiviral 
targets against this significant human pathogen. 
5 
 
Paramyxo- and pneumovirus structure and the role of glycoproteins in 
infection 
All paramyxo- and pneumoviruses have a negative sense, single-stranded 
RNA genome between 13-19kb in length which encodes for 6-10 proteins. These 
proteins perform all the requirements to enter target cells, recruit host factors, 
replicate, and assemble viral components, and mediate transmission to a naïve 
host (87). These viruses encapsidate the negative sense RNA genome (vRNA) in 
the viral nucleoprotein (N). This encapsidated RNA then associates with the large 
RNA-dependent RNA polymerase (L) and the phosphoprotein (P), a polymerase 
co-factor. vRNA, N, P and L coalesce to make up the ribonucleoprotein (RNP) 
complex which associates with the matrix protein (M) just below the lipid bilayer. 
Within the lipid bilayer are at least two surface glycoproteins: the fusion protein (F) 
and the attachment protein (HN, H or G). The attachment protein nomenclature is 
based on the ability to bind (H) or bind and cleave (HN) sialic acid. Attachment 
proteins that cannot bind or cleave sialic acid are referred to as G (88, 89). These 
proteins are the minimal components required for infection and family members 
encode additional proteins that serve various functions specific for that virus (89). 
HMPV contains a viral genome between 12 and 13kb in length. Within this 
genome, it encodes for 8 viral proteins that make up the infectious particle and 
replication machinery. On the outside of the particle, there is a lipid bilayer derived 
from the infected host cell. Within this membrane are 3 surface glycoproteins: F, 
G and the small hydrophobic protein (SH). Just below the lipid bilayer lies a layer 
of M that is associated with the lipid membrane, membrane glycoproteins, and the 
RNP complex. Two other proteins, M2-1 and M2-2, act as processivity and 
transcription factors for generating genome and messenger RNA for viral protein 
production (Fig. 1B). The genomic layout for HMPV is:  3’-N-P-M-F-M2-SH-G-L-5’ 
(Fig. 1C) (30, 90-93).  
In order for enveloped viruses to enter cells, it must fuse the viral and 
cellular membranes. The initial viral interactions are mediated by viral surface 
glycoproteins. This interaction subsequently promotes the fusion protein to fuse 
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the two membranes and mediate viral entry. F is essential for paramyxo- and 
pneumovirus entry due to the requirement of enveloped viruses for membrane 
fusion to initiate infection (covered in more detail below). Inhibiting F through 
various methods including mutagenesis, small molecule inhibitors and neutralizing 
antibodies prevents its function and subsequently, mitigates infection. This 
mechanism of targeting F is utilized by the immune system in order to neutralize 
the virus. This approach is also one of the leading targets for antiviral therapeutics 
of viruses that require fusion for entry (94-104). Simplistically, the attachment 
protein is thought to bring the virus into close proximity with a target cell, allowing 
F to then mediate entry. However, some fusion proteins in the absence of their 
cognate attachment protein are unable to mediate fusion, suggesting that the 
attachment protein of some viruses is specifically involved in activating F (105-
113). Both HMPV and RSV G proteins have also been implicated in mitigating the 
immune system as well, suggesting other roles in addition to their proposed 
attachment function (114-120).  
Some family members also encode the SH protein, but these demonstrate 
less conservation compared with the fusion or attachment proteins. In addition, 
little is known is known about the specific functions during infection. Some studies 
have shown recombinant viruses lacking SH have minimal growth defects in cell 
culture (121-125). In pneumoviruses, including HMPV, RSV and AMPV, 
recombinant viruses lacking SH showed a decrease in viral fitness and replication 
in animal models, suggesting the role of SH is important in a more physiologically 
relevant system (124, 126, 127) . Further studies focusing on the role of SH have 
suggested a role in modulating the immune system or preventing host cell death 
through inhibition of apoptosis (128-130). Interestingly, both RSV and HMPV SH 
proteins demonstrate viroporin like activity (131, 132) which allows the movement 
of small molecules across the membrane, similar to the ion channel, M2, from 
influenza A virus (IAV) (133). Recombinant RSV and HMPV viruses containing F 
but lacking G and/or SH, still promote infection and spread, albeit less efficiently 
than WT viruses (91, 120, 121, 123, 124, 134-136). These findings support that F 
is the main mediator of entry for pneumoviruses while G and SH are not essential. 
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In some clinical isolates, there has been a duplication in G for both RSV and HMPV 
which suggests a boost in pathogenicity or viral fitness (137-142). More recently 
for RSV, it was suggested that virus grown in cell culture was unaffected by G 
neutralizing antibodies whereas use in 3-D tissue model systems demonstrated 
significantly reduced infectivity (143, 144). Furthermore, all current analyses of 
both RSV and HMPV isolates show G and SH are present, suggesting that keeping 
these genes increases viral fitness (31).  
Fusion protein mediated entry 
 All paramyxo- and pneumoviruses contain a type I fusion protein (89, 145, 
146). Other well studied class I fusion proteins include IAV HA (147), human 
immunodeficiency virus type 1 (HIV) envelope protein (gp160) (148), 
coronaviruses (CoV) including severe acute respiratory syndrome (SARS) (149, 
150) and middle eastern respiratory syndrome (MERS) (150, 151) spike protein 
(S), and EboV glycoprotein (GP) (152, 153). Studies examining these viruses has 
allowed for a significant understanding of how they function and what factors are 
important for mediating entry. Type I fusion proteins are a single pass 
transmembrane protein with a predominantly alpha-helical conformation (154). For 
paramyxo- and pneumoviruses, these proteins contain a similar domain 
organization and protein structure. The N-terminus of the protein contains a protein 
cleavage site, followed by a hydrophobic fusion peptide (FP). Just beyond the FP 
is the heptad repeat A (HRA) region, the HRB region, transmembrane domain (TM) 
and C-terminal tail (CT) (Fig 1.2A) (87, 89, 155-164). After synthesis, these 
monomers subsequently trimerize to form a homo-trimeric protein complex. This 
form of the protein contains of a globular head, composed of the HRA and N-
terminus of the protein, and a helical stalk domain, which contains the HRB, TM 
and CT (Fig 1.2B). These proteins are subsequently trafficked through secretory 
pathways to viral assembly sites through the endoplasmic reticulum and golgi 
apparatus where they are post translationally modified by glycosylation (155, 156). 
Addition of post translational modifications are important for many processes 
including protein folding, trafficking, molecular association, target cell entry, 
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immune evasion, and viral tropism for many viruses that utilize type I fusion 
proteins (165-168).   
Type I fusion proteins of paramyxo- and pneumoviruses require proteolytic 
activation in order to function properly. These cleavage events occur just before a 
stretch of hydrophobic amino acids, termed the fusion peptide (FP). This cleavage 
process cuts the full length F0 precursor to yield a disulfide linked heterodimer 
composed of F1 and F2 subunits (Fig 1.1A). This cleavage activates the protein 
and generates the meta-stable, pre-fusion form presents on the outside of the virus 
(154, 155). The proteases required for cleavage differ greatly depending on the 
virus. For IAV, the pancreatic derived serine protease, trypsin, has been historically 
used to activate the HA protein, but trypsin is not present in the airway (147). More 
recent studies have identified several type-II transmembrane and secreted serine 
proteases which are present in the airway cleave a single basic amino acid residue 
within HA (169-178). Furthermore, these airway proteases demonstrate further 
specificity to specific strains of the virus (173, 175, 176). For highly pathogenic 
pandemic forms of IAV, this cleavage motif has been mutated, allowing 
intercellular cleavage by proteases recognizing multibasic cleavage sites such as 
furin and other furin-like pro-protein convertases (179, 180). These mutations 
completely alter HA cleavage efficiency and subsequently, its pathogenicity. 
Another example is the closely related pneumovirus, RSV, which utilizes this same 
family of pro-protein convertases. Unlike other type I fusion proteins, RSV F is 
cleaved at two separate cleavage motifs, removing a small 27 amino acid peptide 
and creating a fusogenically active fusion protein (155, 181, 182). 
  Coronaviruses, including SARS and MERS, have emerged as significant 
human pathogens in recent history, causing severe morbidity and mortality. 
Studies have identified key aspects of viral infection to better understand how 
these viruses emerged, transmitted to humans, and caused severe disease. More 
recently, a novel coronavirus, SARS-CoV2, emerged in late 2019, leading to a 
global pandemic (183-185). The SARS fusion protein, S, has been shown to be 
proteolytically processed at a single basic residue, similar to the IAV HA protein as 
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well as at an additional aliphatic residue. The novel SARS-CoV2 shares high 
homology to SARS S, where a single basic amino acid arginine (R) cleavage site 
is present at the canonical basic residue cleavage motif (186, 187). Sequencing of 
SARS-CoV2 S revealed an insertion of amino acids n-terminal to the original basic 
cleavage site, which increases recognition by furin-like proteases, similar to 
mutations observed for that of highly pathogenic influenza (188). It has been 
suggested that this small modification to one cleavage site within SARS-CoV2 S 
has increased its cleavage efficiency which likely lead to increased infectivity. 
In HMPV, the fusion protein cleavage has not been extensively 
characterized. HMPV F is proteolytically processed at a motif, RQSR, with 
cleavage occurring just after the c-terminal arginine, allowing the FP to be released 
for fusion (30, 121, 189, 190). This RXXR motif has been previously characterized 
for furin as a minimal recognition sequence (191). However, furin and other pro-
protein convertase family members that recognize this basic motif have not been 
reported to cleave this site in HMPV F. To date, only two proteases have been 
identified: trypsin and TMPRSS2 (192), a type II trans-membrane protease that is 
also involved with processing IAV HA and SARS S (170, 173, 176, 187). The 
majority of HMPV strains require the addition of exogenous trypsin in order to 
propagate efficiently. However, there are some identified strains that possess a 
cleavage site mutation, where RQSR has mutated to RQPR. This single amino 
acid change generates a trypsin independent cleavage site, allowing viruses to 
propagate efficiently in the absence of exogenous trypsin (193, 194) although it 
doesn’t appear to affect cleavage (189). In addition, this motif has been suggested 
as a potential furin cleavage site, similar to that found in pseudomonas endotoxin 
(195). However, what endogenous proteases can cleave HMPV F has not been 
previously examined. 
   After cleavage, these meta-stable fusion proteins must be activated in 
order to initiate fusion. This activated form is important and must be regulated both 
temporally and spatially to ensure that fusion results in entry. However, the pre-
fusion form is dynamic, where intermolecular and intramolecular interactions 
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generate a protein “breathing”, allowing for tolerance of the changing environment 
without prematurely triggering the protein (196, 197). This protein flexibility allows 
the virus to withstand a variety of conditions while keeping the protein active and 
stable until fusion can be initiated. For many paramyxoviruses, this initiation is 
accomplished through the interaction of the attachment protein. When the 
attachment protein interacts with the appropriate cellular factor, it then transduces 
a signal to F which begins a dramatic refolding process from the pre-fusion form 
(87, 89, 94, 95, 106, 145, 155, 156, 163, 164, 198). Crystal structure determination 
of F proteins has been a key factor in our ability to understand how these proteins 
function and recent advances in biochemistry and molecular biology has allowed 
for isolation and modifications of a significant number of proteins. These studies 
have generated pre-fusion [NiV (199), HeV (200), PIV3 , MeV (201), PIV5 (202, 
203), RSV (204), and HMPV (205)] and post-fusion structures [NDV (206), RSV 
(207), and HMPV (208)] for a variety of paramyxo- and pneumovirus fusion 
proteins. Understanding the structural characteristics of these proteins has 
generated tools to better understand the dynamic refolding process and fusion 
intermediates through biochemical analysis in other type I fusion proteins (161, 
209-211).  
 Upon triggering, the F protein inserts the helical hydrophobic FP into the 
membrane of the target cell. Once the FP is inserted, F continues to refold, forming 
a fusion intermediate hairpin structure. This refolding continues, pulling the target 
and viral membranes together. Full fusion is mediated by the interaction of the 
helical HRA and FP with the HRB and TM domains of the protein, which come 
together, forming an energetically stable six-helical bundle (6-HB), indicative of the 
post-fusion form of the protein (Fig 1.2C) (87, 89, 94, 106, 145, 155-164, 198, 211). 
Merging two lipid bilayers requires overcoming a significant energy barrier. 
Membrane fusion mediated by the F protein is an ATP independent process. 
Therefore, it is hypothesized that the energy required to fulfill complete fusion is 
stored as potential energy between the pre- and post-fusion forms and appropriate 
stimulus generates activation energy needed to initiate refolding. This fusion event 
is comparable to SNARE mediated vesicle fusion, where a target and receptor 
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SNARE protein pair interact and “zipper” to merge two membranes (212-214). The 
energetically favorable interaction provides energy to merge two membranes 
together and release the vesicle cargo. This highly stable SNARE protein complex 
must then be separated in an ATP dependent manner to be recycled and used 
again. However, our current knowledge suggests F proteins are unable to revert 
from the post-fusion to pre-fusion state. In addition to this intermolecular 
association, viruses also utilize other mechanisms to overcome energy barriers 
during entry. Enveloped viruses utilize the interface between lipid microdomains 
and the adjacent plasma membrane, which modify the lipid membrane. More 
specifically, cholesterol present in these domains bends the lipid membrane similar 
to that of early hemi-fusion intermediates. This change in membrane architecture 
is favored by viral fusion due to by lowering the energy threshold required for entry 
(215-219). In combination with this, viruses likely utilize multiple copies of the 
fusion protein. For studies looking at HIV gp160, it was suggested that only one 
fusion protein contains enough energy to mediate viral entry whereas other viruses 
require more (220-223). 
Fusion for most paramxoviruses occurs at neutral pH, which suggests that 
viral membrane fusion occurs at the plasma membrane (89, 106, 145, 155). For 
some type I fusion glycoproteins, there is no attachment protein, and entry is 
mediated by a single surface glycoprotein. Alternatively, some viruses contain an 
attachment protein that does not mediate the activation of F and therefore, some 
other stimuli must activate the fusion protein (145). For IAV HA, the virus is taken 
up through endocytosis after binding sialic acid on the surface of target cells. The 
virus traffics through the endosomal pathway where a steady decrease in pH 
occurs. This increase in acidity is used as a timing mechanism, as sufficiently low 
pH will eventually trigger the HA protein to mediate fusion (147, 224-227). Another 
example is GP from EboV. EboV enters through cellular micropinocytosis by 
expressing phosphatidyl-serine on the outside of its viral membrane which is 
recognized by host proteins on the cell surface, such as TIM-1. Once taken up by 
the cells, GP protein is processed by host proteases in the endosomal pathway. 
This cleavage process allows the GP protein to interact with its internal cellular 
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receptor, Neiman-Pick C1 (NPC1), and this interaction initiates fusion (152, 228-
237). In addition to cleavage and receptor interaction, some studies have 
suggested the use of cations such as calcium and potassium as well as low pH as 
a potential trigger to enhance fusion, although there is inconclusive evidence (152, 
235-238).  
  Our lab and others have demonstrated some strains of HMPV (subtype A2) 
utilize a similar mechanism to IAV for fusion activation (239-242). Previous studies 
found that HMPV interacts with its surface attachment and entry factors, heparan 
sulfate and αVβ1 integrin. These interactions allow HMPV to bind and enter 
through clathrin-mediated endocytosis (123, 243). As HMPV moves through the 
endosomal pathway, a steady decrease in pH occurs. This subset of HMPV F 
proteins use an increase in acidity to activate fusion and initiate viral entry (Fig 
1.3). However, low pH induced fusion is only predicted to be in strains harboring 
specific amino acids uniquely found within the A2 subtype (239-242). There are a 
limited number of strains available for analysis and more information is needed to 
further our understanding of these residues involved in fusion. Furthermore, other 
factors that activate F proteins, such as a cellular receptors or cofactors that are 
unaffected by low pH have yet to be elucidated. 
Transcription and Replication 
Once fusion has occurred and the RNP is released into the cytoplasm, the 
L protein of HMPV begins viral replication to generate the positive sense 
antigenomic RNA which acts as a template for replicating the negative sense viral 
genome (vRNA) (89). In addition, L also functions to generate the viral mRNA from 
the genomic template. L follows a start-stop model of transcription, resulting in a 
gradient of mRNA where the 3’ genes are more highly transcribed than 5’ (244-
246). However, the factors that contribute to whether the polymerase chooses to 
generate vRNA, antigenomic RNA, or mRNA has largely remained unknown but 
recent studies have generated interesting hypotheses for how this process may 
occur. For RSV, studies have reconstituted the L and P proteins to study their 
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ability to replicate RNA de novo. In order for transcription or replication to occur, L 
must be loaded with a nucleotide triphosphate, which allows binding to the 
template strand to initiate elongation. The beginning of the genome contains the 
sequence 3’ UGC 5’ and which nucleotide is loaded in the polymerase determines 
whether it will initiate transcription or replication (247). Genome replication occurs 
when an ATP nucleotide is present and binds to the first position and replicates 
the entire genome. Polymerases loaded with GTP will mediate binding to position 
3 and therefore, unable to replicate the entire genome, shifting to transcription of 
viral genes. This finding suggests RSV utilizes the cellular nucleotide pool 
concentrations as a timing mechanism to switch between these two functions (248-
250). While this process has not been published for HMPV yet, these same 
principles likely apply and may help explain the function of all polymerases within 
mononegavirales (250).   
As viral protein synthesis occurs, both RSV and HMPV form punctate 
cytosolic structures which reside close to the nucleus (251, 252). These structures, 
termed inclusion bodies (IBs), are minimally composed of N, P, L, M2-1 and vRNA 
(Fig 1.3) (251-255). It is suggested that IBs function to keep the required viral and 
host factors in close proximity to each other for efficient viral transcription and 
replication. Another hypothesis is that IBs keep the viral RNA sequestered from 
the cellular response factors that recognize double stranded RNA, such as RIG-I 
and MDA5 (253). These structures have been reported for a wide variety of other 
viruses in mononegavirales including plant and animal RabV (256-260), EboV 
(261), Marburg virus (262), vesicular stomatitis virus (263), PIV3 (264, 265), and 
PIV5 (266), suggesting that this type of structure is likely a conserved and 
important function during the viral lifecycle. The origin of these structures is varied 
depending on the virus. For example, PIV3 is able to restructure the endoplasmic 
reticulum membranes, generating viral replication compartments in the cytoplasm 
(265). This same tactic is utilized by many positive sense single stranded RNA 
viruses to meet the needs for viral replication (267, 268). 
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Pneumovirus IBs have been examined more closely and interestingly, they 
do not demonstrate molecular kinetics similar to those structures surrounded by a 
membrane. Instead, these organelles demonstrate dynamics of a phenomenon 
called liquid-liquid phase separation, something that has been also reported for 
RaV, VSV and MeV(269-271). In this process, pH, salt concentration, molecular 
density, and electrostatic interactions are thought to mediate association. These 
molecular aggregates eventually separate out from the surrounding solution 
primarily based on intramolecular interactions that drive an energetically favorable 
process to form a liquid-liquid interface (272-275). This process for RSV and 
HMPV selects for viral specific components, keeping them in close proximity for 
efficient replication. Viral proteins may also recruit other cellular factors that are 
required for these processes and exclude host antiviral factors. Due to the lack of 
lipid membrane, some molecules may diffuse in or out of the organelle much 
quicker, allowing for import of nutrients and export of viral factors. Further 
investigation of IBs in RSV infection demonstrated an internal 
compartmentalization of IBs, termed IB associated granules (IBAGs), serving 
unique functions for RNA synthesis and viral transcription (255). 
While many viral factors have been identified, cellular factors utilized by the 
virus and sequestered in IBs have not yet been elucidated. Understanding the 
components of IBs could reveal important information about viral and cellular 
requirements for efficient transcription and replication. These factors could then be 
targeted for a wide range of viruses that utilize these during infection, offering 
potential for broad-spectrum antiviral therapy. 
Viral Assembly and spread 
 Once viral proteins have reached adequate concentrations, they are 
trafficked to sites of assembly at the plasma membrane (88, 89, 156). The RNP 
complex is then shuttled from IBs where they interact with proteins present at 
assembly sites. Once this association has occurred, there are two methods of viral 
particle formation (Figure 1.3). The first is the classical pathway for enveloped 
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viruses (276, 277). The viral proteins and RNP complex associate and begin 
pinching the plasma membrane, releasing an infectious virus. This virus is then 
able to release from the infected cell and move to a naïve host, bind, and enter to 
start the infectious process. However, recent studies of many viruses have 
demonstrated that this is not always the case (278-280). Other mechanisms for 
these viruses show that while some viral particles are spherical, many tend to be 
pleomorphic in nature. Some viruses are filamentous, generating tubular 
extensions from the cellular membrane composed of viral proteins and RNA (84, 
279, 281-286) and these often lead to varying particle sizes and morphologies. 
Some other viruses remain largely cell associated, with minimal released virus 
detected (279, 287, 288). The current understanding of viral assembly and spread 
for many enveloped viruses is rapidly changing with increases in the technology 
we have to study them.  
 One interesting example is MeV which enters the respiratory tract through 
aerosol droplets, similar to other respiratory viruses. Once inside a naïve host, 
MeV particles bind host dendritic cells and aveolar marcrophages through the 
interaction between the measles fusion protein, H, and cellular receptors CD150 
(also called signaling lymphocytic activation molecule, SLAM), the complement 
system protein, CD46 (also called membrane cofactor protein, MCP) and the 
attachment factor DC-SIGN. CD46 is the receptor for the vaccine strain while 
circulating MeV utilized SLAM for entry. Interestingly, MeV has been shown to 
infect some cell lines independently of either MCP or SLAM, suggesting another 
potential mediator of viral entry (289-291). More thorough analysis determined this 
receptor was Nectin-4, a protein that is expressed primarily in the adherens 
junctions during cellular polarization in the airway epithelial. This basolateral 
restriction prevents MeV from interacting with this factor during entry (292). Upon 
infection, MeV activates the immune system, causing respiratory tract 
inflammation, resulting in damage to the epithelial layer. This disruption allows 
MeV to access the Nectin-4 protein in cell-cell junctions to begin infecting the lung 
epithelial layer. Nectin-4 is then utilized in a mechanism of direct cell-to-cell spread 
of MeV from one cell to a neighboring cell, independent of apical release of the 
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virus (292, 293). However, at later stages of infection, Nectin-4 also plays a role in 
viral release where mediates direct transfer of virus to lymphocytes and 
subsequent exit from the host via aerosols. 
Studies using 3-D human airway epithelial model systems which more 
accurately recapitulate the lung environment (covered in more detail below) have 
further demonstrated the interesting entry and spread dynamics of MeV (292, 294-
297). These have confirmed the importance of Nectin-4 in direct cell-to-cell transfer 
but have also revealed another interesting mechanism of spread. In these 
environments, MeV utilizes F-actin to transfer the RNP complex directly from one 
cell to another. This allows the virus to theoretically bypass the first several hours 
of infection by skipping the need to assemble and release a new viral particle which 
then re-enters a cell to initiate infection. Additionally, multiple replication competent 
complexes are also introduced which increases infectivity and replication efficiency 
before the immune response can inhibit these processes.  
The changing paradigms are seen for both RSV and HMPV as well, as 
recent studies suggest cell-to-cell spread is an important aspect for the 
pneumovirus lifecycle (251, 280, 288, 298, 299).  These methods of spread include 
the formation of syncytia, intercellular extensions, and polyploid virions (Figure 
1.4). It has been widely demonstrated that enveloped viruses ultimately use fusion 
as a means of viral entry (146, 154). This same mechanism also generates 
multinucleated bodies when two or more cells fuse together. Fusion of the 
cytoplasm of a non-infected cell with an infected one subsequently increases 
nutrients and resources. This process also mediates infection of a naïve cell during 
the process. Using this mechanism of spread avoids viral release and reentry 
which greatly benefits infectivity and replication (279, 280, 300). For RSV, syncytia 
formation has been examined in viruses that possess a hyperfusogenic fusion 
protein, forming large syncytia in cell culture. Infection of mice with this 
recombinant virus demonstrated increased pathogenic effects suggesting that this 
increased fusogenicity and syncytia formation is beneficial for virus replication 
(301).  
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Both RSV and HMPV form filamentous structures that extend toward 
neighboring cells. RSV induced the formation of actin based, actin-related protein 
(Arp2) dependent filopodia in A549 lung epithelial cells that is important for viral 
spread (298). HMPV also forms long actin-based extensions that extend from 
infected cells. These structures are important for direct cell-to-cell spread of the 
virus in the presence of neutralizing antibody, where spread was only modestly 
decreased (288). We hypothesize these extensions are likely aiding in direct 
transfer of RNP complexes, similar to that of MeV or aiding in the surfing of viral 
particles from one cell to another along the extensions, which has been seen for 
viruses such as HIV (Fig 1.4) (279, 280, 300).  
These same filamentous structures play another role in the transfer of virus 
released from cells. Viral protein and RNP complexes that coalesce at the plasma 
membrane are associated with the formation of the filamentous form of viruses. 
Filamentous forms of the virus generate virions that contain multiple copies of the 
viral genome within the same particle (Fig 1.4). This creates an infectious particle 
with an increased chance of initiating successful infection by delivering more viral 
templates and replication machinery (302-304). While not demonstrated for RSV 
or HMPV, other paramyxoviruses have shown that polyploid viruses are common, 
suggesting a viral fitness advantage (279, 280, 300).  
Current mechanisms and 3-D model systems for studying respiratory virus 
infections 
  The respiratory tract is a complex organ system that promotes movement 
of air from the nasal passages through the sinuses, down the pharynx, and into 
the lungs. This canal is primarily lined with pseudostratified columnar epithelial 
cells. There are other specific cell types that perform unique functions, such as 
goblet cells that produce mucus, basal cells that differentiate and restore the 
epithelial layer, and ciliated cells that move mucus up and out of the respiratory 
tract. This organ system is critical for gas exchange that not only supplies oxygen 
but also removes carbon dioxide, regulating blood pH, and controlling water 
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balance. In addition to its physiological role, it is also an important immune barrier 
against invading pathogens (305, 306). Cells in the respiratory tract secrete a 
range of proteases that cleave the extracellular matrix and secrete antimicrobial 
proteins. The innate and adaptive immune systems also play a critical role in 
protecting the tissues from infection by recognizing and breaking down invading 
bacteria, viruses or fungi (307-311). Taken together, the complexity of the 
respiratory tract makes it difficult to study infection and more physiologically 
relevant models are needed to further our understanding of infection. 
The current methodology to study viruses uses immortalized cell lines 
grown in 2-D monolayers. These cell lines are often selected for specific features 
that enhance growth, replication and recovery of virus. Infection in cell 
monolayers allows us to better understand viral-host interactions, how the cell 
responds to infection, and how the virus subverts cellular mechanisms to evade 
detection and use cellular components to benefit viral replication. While these 
studies are invaluable and ground-breaking research has been conducted using 
these, ultimately, they lack some key characteristics from tissues that must be 
considered. This pitfall is partially mitigated with the use of animal model systems 
to study infection. While these model systems consider the complexity of entire 
organ systems, humans only share partial conservation of key cellular factors 
that can complicate translation to humans. These limitations make it important to 
explore and develop other model systems that consider both tissue type and 
organism specificity.  
Human airway epithelial tissues (HAE) have been developed as a model 
system to overcome the gap in current methods of research. Primary airway cells 
isolated from the nasal passage or lung, which maintain proliferative ability and 
pluripotency, are seeded on a trans-well (312, 313). After reaching confluency, the 
media from the apical surface is removed, generating an air-liquid interface 
mimicking the environment present in the lung. This then stimulates the 
differentiation of cells into a multi-layer pseudostratified cellular layer composed of 
bronchial or nasal epithelial cells and goblet cells. These cultures can recapitulate 
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the 3-D environment and contain functional cilia as well as mucus production (Fig 
1.5). These tissues are a model system to study respiratory pathogen-host 
interaction and develop anti-viral therapeutics.  HAE tissues have been widely 
utilized to study important pathogens such as IAV, RSV, PIV3 and MeV (107, 144, 
291, 294, 296, 297, 314-332). HMPV infection in these tissues has been examined, 
although few studies have been reported (121, 135, 318, 333). This model system 
offers significant advantage to understand HMPV infection in vivo while 
maintaining a simplistic in vitro approach allowing for validation of important 
aspects of viral infection as well as discovering other important host-viral 
interactions.  
Dissertation overview 
Human metapneumovirus is a recently discovered and important 
respiratory virus that infects nearly everyone during their life. It’s severity ranges 
from mild “cold-like” symptoms to severe respiratory illness or even death. There 
are currently no antiviral or vaccine available and understanding more about the 
viral lifecycle will help to develop novel targets to treat and prevent infection. RSV, 
another important respiratory pathogen similar to HMPV, also lacks a critical 
molecular understanding of viral lifecycle needed to develop novel therapeutics to 
fight infection. The data presented in this dissertation aims to further our 
understanding of the molecular mechanisms of HMPV and RSV infection through 
4-main questions.  
First, we examine the function of the HMPV F fusion protein by analyzing 
molecular interactions at the protein level. It is currently unknown which factors 
contribute to triggering the F conformational changes required for membrane 
fusion.  However, a subset of HMPV F proteins were shown to use low pH as a 
biological sensor to initiate this process. Analysis of F proteins currently available 
in our lab and others suggests there are specific residues that contribute to this 
phenotype. However, there are few strains examined and more are needed to 
better understand which amino acids are critical for this function. We analyzed the 
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F protein from strains of HMPV not previously characterized that contain key 
residues previously implicated in low pH mediated fusion. We find that there are 
key electrostatic interactions involved in this phenomenon and identify novel 
interactions that modulate fusogenic activity and protein dynamics. 
 Next, we then investigated the proteolytic processing of the HMPV F protein 
which is required for activation and the proteases that are able to cleave HMPV F 
have not been previously determined. Exogenous trypsin is able to cleave a basic 
amino acid residue just n-terminal to the fusion peptide. Addition of trypsin has 
traditionally been used to propagate HMPV in cell culture. Another group 
demonstrated that overexpressing a transmembrane serine protease, TMPRSS2, 
also led to efficiently replication in vitro. Here, we demonstrate that HMPV can 
utilize a variety of serine proteases that are also important for other respiratory 
viruses including SARS and influenza A virus. We then explore this conserved 
phenomenon as a means for broad spectrum anti-viral development against 
several viruses that require serine proteases for activation by using a naturally 
occurring protease inhibitor.   
  In addition to understanding the molecular mechanisms of HMPV F, we 
then focused on comparing the two pneumoviruses, HMPV and RSV, in a 3-D 
human airway epithelial (HAE) model system. Using HAE tissues, we find that RSV 
and HMPV infection and spread kinetics are significantly different. To determine 
why these closely related viruses demonstrate drastically different phenotypes, we 
probed several different aspects of viral entry, replication and spread. We then 
explored the use of neutralizing antibodies to examine the therapeutic potential for 
inhibiting entry and spread for both viruses. 
 Co-infections for both RSV and HMPV have been reported, resulting in 
increased disease severity. To better understand this phenomenon, we analyzed 
co-infected cells to identify how both viruses interact during replication and spread 
in vitro. We find that these RSV and HMPV can occupy the same replication 
organelles, where vRNA and protein from both viruses coalesce. We examined 
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several protein interactions involved in replication to understand how coalescence 
in IBs affects viral replication and spread during infection and how this may lead to 
increased disease severity. 
 Altogether, the results presented in this dissertation generate novel 
information on the molecular mechanisms and processing of the HMPV F protein 
not previously known. These findings identify key molecular aspects of low pH 
fusing strains as well as which host factors are involved in proteolytic processing 
for activation. We then examined two closely related pneumoviruses and 
conducted a side-by-side comparison of infection, replication, and spread in HAE 
tissues, which has not been previously examined. We find an interesting dichotomy 
between two closely related pneumoviruses and generate a better understanding 
for how these viruses can mediate infection and spread using an in vitro 3-D airway 
epithelial model system. We then test the therapeutic potential of neutralizing 
antibodies for both RSV and HMPV. Lastly, we examined the synergistic capability 
of cells co-infected with RSV and HMPV and determined how this affects viral 
replication and spread. Overall, we identify novel information at the protein level 
as well as viral infection in a physiologically relevant model system. These findings 
further our understanding of infection and highlight potential for therapeutic 
intervention against RSV and HMPV as well as other respiratory viruses that utilize 
similar molecular mechanisms during infection. 
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Figure 1.1: Schematic representation of the HMPV particle structure and genomic layout. (A) 
Phylogenetic classification of HMPV. (B) HMPV particle depicting the basic structure and protein 
localization of an infectious particle. (C) Genomic layout of the negative sense genome and protein 
open reading frame position. 
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Figure 1.2 HMPV Fusion protein cleavage, structure, and fusion mechanism. (A) HMPV F is 
synthesized as a monomeric 539 aa polypeptide which is then cleaved at single basic amino acid 
residue N-terminal to the fusion peptide (FP). The basic layout is shown for protein domains 
including the heptad repeat A (HRA) and B (HRB) domains, followed by the transmembrane (TM) 
and C-terminal tail (CT). (B) The 3-D protein crystal structure of the pre and post fusion F protein 
demonstrating the globular head and helical stalk domains. Colors correspond to the protein 
schematic in A. (C) Upon appropriate stimulation, HMPV mediates membrane fusion by inserting 
the fusion peptide into a target membrane, undergoing a large conformational change from the pre- 
to post-fusion state (shown in B), mediating fusion of the viral and target membranes.  
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Figure 1.3: Viral lifecycle of HMPV.  HMPV attaches to a target cells and enters through clathrin 
mediated endocytosis where fusion with the endosomal membrane releases the viral 
ribonucleoprotein complex. Transcription of viral proteins mediates the formation of inclusion 
bodies for genomic replication and transcription. Newly synthesized viral genome and proteins then 
accumulate at the plasma membrane at assembly sites where newly synthesized particles will 
undergo budding or mediate the formation of filamentous extensions for cell-to-cell spread. 
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Figure 1.4: HMPV mechanisms of entry and spread. After viral entry and replication, HMPV 
spreads to uninfected cells. Formation of extensions between infected cells mediates direct cell-to-
cell spread. These extensions allow viral particles to (1) move alone the surface (2) directly transfer 
nucleic acid materials or (3) move replication organelles from one cell to another. Alternatively, 
virus fusion may mediate the formation of syncytia (4), which can also infect cells and mediate 
genome or replication body transfer. Infected cells then mediate spread of HMPV through (5) 
formation of intercellular extensions (6) polyploid viruses containing multiple genome copies or (7) 
particle budding which will spread from infected to non-infected cells. 
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Figure 1.5: Human airway epithelial tissue (HAE) culture model system. 3-D HAE tissues 
contain both epithelial and goblet cells present in a pseudostratified tissue layer. These tissues are 
then grown on a trans-well with an air-liquid interface containing an exposed apical surface and a 
nutrient rich media at the basolateral surface. These tissues also contain functional cilia as well as 
mucus production, creating an authentic primary cell culture model system. 
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Chapter 2: Material and Methods 
Cell Lines. VERO (ATCC), BSR (provided b Karl-Klaus Conzelmann, Max 
Pettenkofer Institus) and LLC-MK2 (ATCC) cells were grown in Dulbecco’s 
Modified Eagles Media (DMEM;Hyclone) supplemented with 10% fetal bovine 
serum (FBS; Sigma). For BSRs, 0.5 mg/mL G418 was added every third passage 
to keep selection for cells constitutively expressing the T7 polymerase. BEAS-2B 
(ATCC) and HEp-2 (Medimmune) cells were maintained in Opti-MEM (Invitrogen) 
supplemented with 2% FBS or BEBM supplemented with BEGM Single Quoat Kit 
and growth factors (Lonza). 293 Freestyle cells (Invitrogen) were maintained in 
293 Freestyle expression media on an orbital shaker. All cells were maintained at 
37°C and 5% CO2.  
 
Plasmids, Antibodies and Proteases. HMPV Fusion protein (F) within pGEM-
3Zf (+) was kindly provided by Ursula J. Buchholz (NIAID, Bethesda, Maryland). 
All HMPV F proteins mutants were completed using Quick-Change site-directed 
mutagenesis and confirmed by sequencing (Stratagene). F genes were then 
subcloned to pCAGGS by digesting with EcoR1 and Sph1 (New England Biolabs). 
Plasmids for pcDNA3.1-TMPRSS2-Myc, pcDNA3.1-HAT-Myc and pcDNA3.1-
Matriptase were provided by Dr. Marco Strauss and Dr. Gary Whittaker (Cornell 
University). TMPRSS2 and HAT plasmids were subcloned into pCAGGS by EcoRI 
and NdeI. Colonies were picked and sequenced the determine proper insertion. 
54G10 anti-HMPV F monoclonal antibody plasmid was kindly provided by John 
Williams (University of Pittsburgh, Children’s Hospital; please see recombinant 
antibody production). pTM1 L, M2-1, N, P and CAT-Luciferase minigenome 
reporter assay plasmids for HMPV were a kind gift from Dr. Rachel Fearns (Boston 
University). pCNDA3.1 L, P, M2-1, N and luciferase minigenome were kindly 
provided by Dr. Richard Plemper (Georgia State University). Both reporter gene 
systems utilize the T7 promotor.  
 
Viruses. Recombinant green fluorescent protein expressing human 
metapneumovirus stain CAN 97-83 (rgHMPV) with a codon stabilized SH gene 
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was kindly provided by Peter L. Collins and Ursula J. Buchholz (NIAID, Bethesda, 
Maryland). HMPV (MOI 0.01) was propagated in VERO cells and incubated at 
37°C in Opti-MEM supplemented with 2 mM L-glutamine and 0.3 µg/mL TPCK-
trypsin every other day. After 10 days, 1x SPG (218mM Sucrose, 4.9 mM L-
glutamic acid, 3.8 mM KH2PO4, 7.2 mM K2HPO4) from the 10x stock was added to 
the media and cells were scraped and kept cold. Cell pellets were spun down at 
2500 rpm for 10 min on a Sorvall ST-8R centrifuge (Thermo). Supernatants were 
added to 20% sucrose in TNE buffer (50 mM Tris-HCL, pH 7.4, 100mM NaCl, 0.1 
mM EDTA) cushion. Virus was pelleted at 27,000 rpm in a SW-28 rotor on an 
Optima XPN-90 ultracentrifuge (Beckman). Supernatant was aspirated and 100 µL 
of Opti-MEM was added to each tube and incubated rocking overnight. The next 
day, pellets were fully resuspended and aliquoted and snap frozen. Recombinant 
green fluorescent protein expressing human respiratory syncytial virus A2 (rgRSV) 
long was a kind gift from Medimmune/Astrazeneca. rgRSV MOI 0.1 was added to 
HEp-2 cells in Opti-MEM and after 3 h incubation, Opti-MEM with 2 mM glutamine 
was added and cells were incubated for 4 to 5 days until CPE developed. Cells 
were then scraped and freeze-thawed 1 time. Cell debris was spun at 2500rpm 
and supernatant was mixed with sucrose phosphate from a 10x stock to make 1x 
(Hyclone, special order from Astrazeneca/Medimmune). Virus was then flash 
frozen. Viral titers determined by infected Vero cells and counting fluorescent 
particle formation.  
 
Transfection. All HMPV F and protease constructs were transiently expressed 
using the mammalian expression vector pCAGGS allowing for high levels of 
protein expression in mammalian cell culture. Cell lines were transiently 
transfected with plasmid DNA using either Lipofectamine reagent/ Plus reagent 
(Invitrogen) according to manufacturer’s protocol. Mini-replicon plasmids were 
transiently expressed by transfection using Lipofectamine 3000 reagent 
(Invitrogen). Manufacturer’s protocols were followed accordingly unless stated 
otherwise. 293 Freestyle cells were transfected using 293-fectin according to the 
manufacturers protocol.  
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Syncytia Assay. Vero cells (80-90%) were split into 6-well plates and transiently 
transfected with 2 µg pCAGGS-HMPV F or empty pCAGGS using Lipofectamine 
and Plus Reagent. The next day, cells were washed with PBS and incubated for 
1hr in Opti-MEM with 0.3 µg/mL TPCK-trypsin. Cells were then rinsed once with 
PBS pH 7.2 (GIBCO) before adding PBS buffered with 10 mM HEPES and 5 mM 
MES at low (pH 5) or normal (pH 7) for 4 min. Cells were then placed back in Opti-
MEM with TPCK-trypsin for 2 h. These steps were repeated a total of 4 times. After 
the final treatment, normal culture media was placed on the cells and syncytia 
formation was observed at 24 to 48h post transfection. Images were taken using 
a Nikon Ti2 with a 4x or 10x objective. The fusion index (f) was calculated as f=[1-
(C/N)], where C is the number of cells in a field after fusion and N is the number of 
nuclei. 
 
Luciferase Reporter Gene Fusion Assay. Vero cells in 60 mm dishes were 
transfected with 1.5 µg of HMPV F wild type or variant and 1.5 µg of T7 control 
plasmid containing luciferase cDNA (Promega) under the T7 promoter using 
lipofectamine reagent and plus reagent according to the manufacturers protocol. 
The next day, Vero cells were lifted with trypsin-EDTA, resuspended in DMEM 
supplemented with 10% FBS and overlaid onto two 35 mm dishes or two wells in 
a 6-well plate of confluent BSR cells, which constitutively express the T7 
polymerase. Combined cells were incubated at 37°C for 60 min. Cells were then 
rinsed once with PBS pH 7.2 before adding PBS buffered with 10 mM HEPES and 
5 mM MES low or normal pH. Cells were treated for 4 min and then Opti-MEM 
supplemented with 0.3 µg/mL TPCK trypsin was added and incubated for 1 h at 
37°C. Cells were once again treated as described. After treatment, DMEM 
supplemented with 10% FBS was added and cells were incubated for 4 h at 37°C. 
Cells were analyzed for luciferase activity according to the luciferase activity 
system (Promega) and analyzed on the Spectramax iD3 (Molecular Devices).  
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Gel Electrophoresis and Western Blotting.  Protein samples were analyzed via 
15% SDS-PAGE, unless otherwise noted. For recombinant protein expression, 
protein samples were taken pre- and post-induction to assess expression using in-
stain gels (Bio-Rad) or using Coomassie staining. For Western blot analysis, 
immunoprecipitated protein was transferred to polyvinylidene difluoride (PVDF) 
membrane (Fisher) at 50 V for 80 min at 4°C. After blocking with 5% milk in Tris-
buffered saline with 0.05% Tween-20 (TBS-T), membranes were incubated with 
corresponding antibody. Membranes were washed with TBS-T and incubated with 
anti-mouse or anti-rabbit 700/800 infrared secondary antibody at 1:10,000 
(Jackson). Membranes were washed again with TBS-T and visualized with the Bio-
Rad ChemiDoc system or LiCor imaging systems.  
 
Expression, metabolic labelling and immunoprecipitation. Vero cells (approx. 
80-90% confluent) in 6-well plates were transiently transfected using 
Lipofectamine and Plus reagent (4 µg of total pDNA). 18 to 24 h post-transfection, 
cells were washed with PBS and starved for 45 min in DMEM deficient in cysteine 
and methionine and subsequently labeled for 3h with cysteine/methionine deficient 
DMEM containing Tran35S-label (50 µCi/mL; MP Biomedicals). After labelling, 
wells were washed 2x with PBS and lysed in 500 µL RIPA lysis buffer [100 mM 
Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 1% deoxycholic acid, 
1 mM phenylmethylsulfonyl fluoride, 25 mM iodoacetamide , and complete mini-
EDTA protease inhibitor (Roche)] and frozen. Plates were then thawed and 
scraped. Lysates were centrifuged at 136,500xg for 15 min at 4°C. Supernatants 
were moved to 1.5 mL Eppendorf tubes and mixed with 6 µg of 54G10 antibody 
for HMPV F and incubated rocking for 3 h rocking. Proteins were then 
immunoprecipitated by incubating with 30 µL of Protein A-Sepharose beads (GE 
Healthcare) for 30 min. The beads were washed 2X with RIPA + 0.30 M NaCl, 2X 
with RIPA + 0.15 M NaCl, and 2X with SDS Wash II (150 mM NaCl, 50 mM Tris-
HCl, pH 7.4, 2.5 mM EDTA).  
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Surface biotinylation protein labeling. Vero cells (approx. 80-90% confluent) in 
6-well plates were transiently transfected using Lipofectamine and Plus reagent (4 
µg of total pDNA). 18 to 24h post-transfection, cells were washed with PBS and 
starved for 45 min in DMEM deficient in cysteine and methionine and subsequently 
labeled for 3 h with cysteine/methionine deficient DMEM containing Tran35S-label 
(100 µCi/mL; MP Biomedicals). Cells were washed 3 times with 3 mL of ice-cold 
PBS pH 8.0, and surface proteins were biotinylated using 1 mg/mL EZ-Link Sulfo-
NSH-Biotin (Pierce) in PBS with rocking for 35 min at 4°C followed by incubation 
at room temperature for 15 min. Cells were then washed 2 times with ice-cold PBS 
and lysed with 500 µL of RIPA lysis buffer. Cellular lysates were centrifuged at 
136,500xg for 15 min at 4°C. The supernatant was placed into a 1.5 mL 
microcentrifuge tube, and 6 µg of 54G10 antibody was added and incubated 
rocking for 3h at 4°C. Proteins were then immunoprecipitated by incubating with 
30µL of Protein A-Sepharose beads for 30 min. The beads were washed 2X with 
RIPA + 0.30 M NaCl, 2X with RIPA + 0.15 M NaCl, and 2X with SDS Wash II (150 
mM NaCl, 50 mM Tris-HCl, pH 7.4, 2.5 mM EDTA). Then, 60 µL of 10% SDS was 
added, and the boiled for 10min, removed to a new tube, and repeated with 40 µL 
of 10% SDS for a total of 100µL. Ten microliters of the supernatant was removed 
to analyze the total protein population. To the remaining supernatant, 30 µL of 
Streptavidin beads (Pierce) and 400µL of biotinylation dilution buffer (20 mM Tris 
(pH 8), 150 mM NaCl, 5 mM EDTA, 1% Triton X—100, 0.2% bovine serum 
albumin) were then added for 1 h at 4°C with rocking. HMPV F was analyzed by 
15% SDS-PAGE and imaged using the Typhoon imaging system (GE Healthcare). 
Band densitometry was completed using ImageQuantTL to quantify protein 
expression (% expression= Sum of F0 and F1, normalized to WT). 
 
Rescue of mCherry HMPV. The plasmids for rescue of HMPV strain JPS07E2, 
p(+)JPS07E2, pCITE-76N, pCITE-76P, pCITE-76M2-1 and pCITE-76L were a 
kind gift of Dr. Makoto Takeda (National Institute of Infectious Diseases, Tokyo). 
We replaced the GFP cassette in p(+)JPS07E2 with an mCherry cassette, using 
restriction sites NheI and SacI. For virus rescue, BSR cells were transfected with 
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2.5 µg of p(+)JPS07E2, 1 µg of pCITE-76N, 1 µg of pCITE-76P, 0.5 µg of pCITE-
76M2-1 and 0.5 µg of pCITE-76L using Lipofectamine3000. 48 h post transfection, 
BSR cells were scrapped and overlaid on top of Vero cells growing in a 60 mm 
plate. Co-cultured cells were kept in Optimem supplemented with glutamine 2 mM 
and TPCK-Trypsin 0.3 µg/mL. Virus was harvested at day 6 post-infection and 
tittered in Vero cells as previously described (288).  
 
Inhibition of HMPV viral infection in cell culture by SPINT2. VERO (200,000) 
cells were plated into 24-well plates. The following day, cells were infected with 
MOI  1 rgHMPV for 3 h. Cells were washed with PBS and 500 µL OPTI-mem with 
or without 500nM SPINT2 (Provided by Dr. Gary Whittaker) and 0.3 µg/mL of 
TPCK-trypsin was added and incubated for up to 96 h. The SPINT2 and trypsin 
was replenished in new OPTI-mem every 24 h. For each time point, media was 
aspirated and 100 µL of OPTI-mem was added to cells followed by scraping and 
flash freezing. These samples were then titered on confluent VERO cells up to a 
dilution of 10-6 to calculate viral titer. Graph shows 4 independent replicates with 
internal duplicates plotted as individual points. Some data points not shown are 
due to sample loss during preparation, with a minimum of 6 points per group and 
3 independent replicates.  
 
Cleavage and inhibition of HMPV F by SPINT2. VERO cells were plated into 6-
well plates. The following day, 2µg HMPV F or 1:1 with a plasmid containing 
TMPRSS2, HAT or Matriptase was transfected in using Lipofectamine and plus 
reagent. The following day, cells were radiolabeled with 50 µC of S35 for 4 h and 
exogenous proteases KLK5 (150 µM), KLK12 (150 µM) and Matriptase (200 µM) 
were added during the label. 3 µg/mL of TPCK trypsin was used as a control for 
both transfected and exogenous proteases. For cleavage inhibition, KLK5, KLK12 
and Matriptase were pre-incubated with 0 nm, 10 nm or 500 nm of SPINT2 for 10 
min and then added to cells for 4 h. Cells were washed and lysed in RIPA lysis 
buffer and processed for gel electrophoresis and imaging. 
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Fluorescence-activated cell sorting (FACS) analysis. 50,000 VERO cells were 
plated into 24 well plates and subsequently infected with rgHMPV or rgRSV with 
or without prior treatment in Opti-MEM for 3 h and then washed and placed in 
normal culture media. Cells were then incubated overnight at 37°C. The following 
day, cells were washed with PBS and lifted with 100 µL of Trypsin-EDTA. Lifted 
wells were placed into 5 mL snap-cap tubes and mixed 1:1 with 2x fixation buffer 
[4% paraformaldehyde (PFA), 100 mM EDTA pH 8] for a final concentration of 2% 
PFA and 50 mM EDTA. Samples were mixed by vortexing and then analyzed by 
FACS analysis. 
 
Recombinant antibody production. 54G10 recombinant protein expression 
system was kindly provided by Dr. John Williams (University of Pittsburg, 
Children’s Hospital). Suspension 293F cells were split 1.5x107 cells per T-75 flask 
in 28 mL of expression media. The next day, 60 µL of 293-fectin was mixed with 
60 µg of heavy chain plasmid and 60µg of light chain plasmid in a total of 2mL 
Opti-MEM (per flask). Cells were then incubated for an additional 4 days and then 
spun down at 300xg for 5 min and the supernatant was collected and stored at 4°C 
and the pellet was resuspended in fresh media by vortexing and placed back into 
the flask to incubate for another 4 days. At day 8 post transfection, cells were spun 
down, and the supernatant was taken and placed with the previous supernatant 
and cells were discarded. The supernatant was filtered through a 0.45 µm filter 
and ran over a gravity flow column containing sepharose beads with protein A to 
bind antibody. After binding, the column was washed with wash/bind buffer (0.15 
M NaCl, 20 mM Na2HPO4, pH 7.0). The beads were treated with elution buffer (0.1 
M glycine, pH 3.0) and this was eluted into a tube containing neutralization buffer 
(1 M Tris-HCl, pH 8.5) at roughly 1:10 the volume of elution. Eluted protein was 
then concentrated using a centrifuge filter (Amicon) (3,000 MWCO) in a swing 
bucket rotor according to manufacturer recommendation. Once the volume was 
reduced to 1 mL, an aliquot was tested using the 280nm reading on a nanodrop 
and protein purity was analyzed by blot analysis.  
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Confocal Microscopy. HAE tissues were removed from trans-wells and frozen in 
O.C.T compounding embedding media (EM Sciences). 10-20 µm tissue sections 
were cut using a MICROM HM525cryostat and collected on Superfrost Plus slides 
and heat fixed at 55°C for 30 min. Sections were permeablized in 0.5% Triton X-
100 for 15 min at 4°C followed by blocking in 1% normal goat serum. Sections 
were incubated with primary antibodies for RSV F (1:600), N (1:200), P (1:600) 
(Abcam) or Keratan Sulfate (1:1,200) (EMD Millipore) overnight at 4°C. The 
following day, tissues were washed with 0.05% tween-PBS, secondary antibodies 
(Jackson) and TRITC-Phalloidin (1:1,000) (Invitrogen) were added at room 
temperature for 1 h, washed and mounted using SloFade plus DAPI (Invitrogen). 
Pictures were taken using a Nikon A1 confocal microscope and analyzed with NIS-
Elements software (Nikon). 
 
Stellaris Fluorescent in situ hybridization (FISH) for viral RNA detection. 
Forty-eight DNA probes targeting the HMPV and RSV vRNA genome between nt 
1-5,467 were obtained from BioSearch Technologies (Novato, CA) and designed 
using the software provided by the company. Each probe is 20 nt long and linked 
at the 3’ end to Quasar fluorophore. Cells were fixed for 10-30 min with 4% PFA 
and then permeabilized overnight with 70% ethanol at 4°C. The next day cells were 
washed once with 2x SSC-10% formamide buffer, and then incubated overnight at 
25°C in hybridization buffer (4x SSC, 1x Denhardt’s solution, 150 µg/mL ssDNA, 2 
mM EDTA, 50% formamide in DEPC treated water) containing the probes at a 
concentration of 2.5 mM. After 24 h, cells were washed two times for 20 min with 
2x SSC-10% formamide buffer and slides were then mounted using Vectashield 
mounting media. 
 
Fluorescence threshold analysis. GFP cells present within infected tissues, 
were quantified with either NIS elements “object count” or ImageJ (FIJI) using the 
“adaptive threshold” analysis plugin. Briefly for ImageJ quantification, fluorescent 
microscopy images of HAE tissues were imported, background subtracted for each 
image and converted B&W. Using several test images, the adaptive threshold was 
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set to ensure that all data points with minimal background were obtained, and this 
macro was used for all images within that replicate. Finally, particle density was 
quantified using “analyze particles” and total density was quantified as percent 
area. GFP expression was also analyzed using NIS elements software using 
threshold analysis based on area coverage using the “object count” plug-in and 
selecting a fluorescence threshold. All counts were taken as percent area 
coverage.   
 
Infection of Human Airway Epithelial (HAE) tissues. Human tracheal bronchial 
differentiated airway (Epiairway) tissues were purchased from Mattek and 
maintained in 3 mL of Air-100 media at 37°C for one week prior to infection, with 
the media changed and the apical surface washed with 0.9% NaCl every other day 
to remove mucus. Prior to infection, the basal surface was washed with hepes 
buffered saline (HBS) for 30 min and the apical surface was washed three times 
with 0.9% NaCl every 10 min with incubation. For HMPV, the apical surface 
washes were completed using alpha-lysophosphatidylcholine (Sigma) in HBS (75 
µg/mL). Tissues were infected with either rgRSV or rgHMPV on the apical surface 
and incubated for 3 h at 37°C. The apical side of tissues were then washed once 
with HBS and incubated at 37°C. Media containing 0.3 µg/mL TPCK-trypsin was 
added to rgHMPV infected tissues and replenished daily. Images were obtained 
using a Zeiss Axiovert-100 or a Nikon Ti-2. After the final time point, both apical 
and basal sides were washed with PBS and fixed in 4% paraformaldehyde for 20 
min at room temperature.  
 
Microneutralization and spread in HAE tissues. For microneutralization, rgRSV 
(MOI 1) was preincubated with MEDI8897 or Palivizumab for 1 h at 37°C. rgHMPV 
(MOI 3) was preincubated with 54G10 for one hour at room temperature. Both 
rgRSV and rgHMPV incubations were completed in a total volume of 150 µL TEER 
buffer (Mattek). For spread, HAE tissues were infected with rgRSV (MOI 0.3) or 
rgHMPV (MOI 3.0). Antibody dilutions were completed in 50 µL of TEER buffer 
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and added to the apical surface. The initial antibody was added at 6 hpi and 
replenished every 24 h post inoculation until experiments were completed. 
 
Statistical analysis. Statistical analysis was preformed using Prism7 for Windows 
(Graphpad). A p-value of less than 0.05 was considered statistically significant. 
Multiple comparisons tests were generated using a one-way ANOVA with a 
Bonferroni multiple comparison correction. P values are indicated as defined: * 
P<0.05, ** P<0.005. *** P<0.0005, **** P<0.0001.  
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Chapter 3: Human metapneumovirus fusion protein triggering: Increasing 
complexities by analysis of new strains 
*This work was completed with the help of Andres Chang and Edita Klimyte, who 
both contributed intellectually to this work. Andres generated the HMPV F clones 
from the viral stocks used during all experiments. Edita Klimyte conducted syncytia 
and luciferase assays used in this chapter (shown in Fig 3.1, I generate the figures 
for this data). I performed protein expression and cleavage shown in figure 3.2, the 
protein model for figure 3.3, and the co-expression syncytia and luciferase fusion 
experiments in figure 3.4. This chapter is adapted from a manuscript (Kinder et al. 
Virology. 2019 May;531: 248-254)  
Introduction 
 Human metapneumovirus (HMPV) is a recently discovered enveloped, 
negative-sense, single-stranded RNA virus. Although first identified in 2001, 
HMPV has now been shown to be a cause for respiratory tract infections in humans 
worldwide since at least 1958 (30-32). Nearly everyone is initially infected by five 
years of age and reinfection is common throughout life (34). Infection leads to a 
variety of symptoms ranging from coughing and wheezing to pneumonia and 
bronchiolitis, potentially requiring hospitalization in severe cases. In addition, 
infants, immunocompromised, and elderly patients are most likely to develop 
severe infections (31, 36, 37, 42-46). While HMPV is ubiquitous and responsible 
for severe upper and lower respiratory tract infections, there is still no FDA 
approved antiviral treatment or vaccination available. Therefore, a more thorough 
understanding of the viral lifecycle and molecular mechanisms required for 
infection are needed to discover novel antiviral targets.  
HMPV is phylogenetically classified into two genetic lineages (A and B) and 
further characterized into sub-lineages (A1, A2, B1 and B2) based on the 
sequences of two surface glycoproteins: the fusion protein (F) and the attachment 
protein (G) (78). To infect cells, enveloped viruses fuse their membrane with host 
cell membranes, a process mediated by one or more viral surface glycoproteins. 
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In the instance of HMPV, this process is mediated by F alone in vitro and in vivo, 
whereas closely related paramyxoviruses require both F and G (157, 189, 334). F 
is a homo-trimeric class I fusion protein present within viral membranes as well as 
membranes of infected host cells. To become activated, F is proteolytically cleaved 
from the precursor form (F0), into the metastable, disulfide-linked heterodimer 
(F1+F2) (158, 159). Cleavage can be accomplished by the addition of exogenous 
trypsin in vitro (189), although in vivo it is thought that F is cleaved by secreted or 
cell surface proteases present in the host. Once cleaved, HMPV F can be triggered 
to undergo an essentially irreversible and energetically favorable conformational 
change from the pre-fusion form to the post-fusion state with released potential 
energy driving membrane fusion (189, 240-242).  
HMPV particles have been shown to be internalized via clathrin mediated 
endocytosis in human bronchial epithelial cells through a dynamin dependent 
mechanism (242, 335). Further evidence demonstrated that for HMPV, viral and 
host membrane fusion takes place within the endosomes (335). Some strains of 
HMPV, mainly within clade A, utilize low pH generated through endosomal 
acidification as a mechanism to trigger the fusion protein, similar to HA from 
influenza.  However, this is proposed to not be true for all strains of HMPV (189, 
240-242, 335). For fusion proteins that are triggered by low pH, it is hypothesized 
that repulsive electrostatic forces between critical residues lead to global protein 
destabilization, initiating the conformational transition from the pre-fusion to post-
fusion state (336-338). It has been proposed that specific histidine (H) residues 
become protonated at low pH and subsequently interact with neighboring basic 
residues to destabilize the pre-fusion state and initiate membrane fusion. In HMPV 
F, H435 within the globular head is thought to serve as a pH sensor (241, 242). 
Recently, a high-resolution structure of a stabilized pre-fusion HMPV F 
[NL/1/00(A1)] was solved [PDB: 5WB0] (205). This structure revealed that lysine 
(K) 20 and glutamic acid (E) 433 interact to form a potential salt bridge. Under low 
pH conditions, protonation of the neighboring H435 may lead to cation electrostatic 
repulsion driving conformational changes and promotes membrane fusion. Studies 
with recombinant HMPV containing mutations in this region have confirmed its 
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importance for viral infectivity (239, 241). Additional residues have been identified 
as playing a role in low pH triggered fusion, including K296, W396, and N404. 
Furthermore, studies using F proteins from prototype strains from each clade have 
suggested that fusion induced by low pH is restricted to clade A virus fusion 
proteins, and glycine (G) 294 is critical for low pH triggered fusion (240, 241). 
However, few HMPV F proteins have been studied in each clade and therefore 
additional analysis is needed to further understand this mechanism. 
In this study, we examined three previously uncharacterized HMPV F 
proteins for their fusion activity, protein expression, and cleavage activation levels. 
The first F protein, cloned from TN83-1211, contained a unique H434 residue, 
adjacent to a previously characterized histidine at 435 demonstrated to be critical 
for low pH fusion. Protein mutagenesis in our reference strain supports its 
contribution to increased fusion at low pH and more efficient cleavage by trypsin. 
The second F protein, cloned from TN94-49, is able to promote low pH mediated 
fusion without G294, although this residue was previously identified as critical for 
this mechanism of membrane fusion. The third HMPV F protein, cloned from TN96-
12, contains E at position 294. Interestingly, TN96-12 was unable to mediate fusion 
at either neutral or low pH conditions, or in the presence of the attachment protein, 
G. This finding suggests additional factors are necessary to trigger the F protein. 
Taken together, these results further demonstrate the complexity of HMPV F 
mediated membrane fusion and the significant phenotypic differences observed 
with only a few amino acid changes.  
 
Results 
To examine HMPV fusion, F protein genes were cloned from three available 
HMPV strains: TN94-49, TN96-12 and TN83-1211, all isolated in the Williams 
laboratory and propagated and stored at BEI resources. These F isolates were 
sequenced and compared to a low pH prototype strain, CAN97-83, used as a 
positive control in these studies. HMPV F is highly conserved, and therefore few 
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amino acid changes were detected between strains. The TN94-49 F clone differed 
from CAN97-83 F by only 6 amino acids (Fig 3.1D). One notable difference was 
residue 294, which contained K294 instead of G294, a glycine residue previously 
suggested as essential for low pH triggered fusion for clade A HMPV F proteins 
(240). When comparing TN96-12 F clone to CAN97-83 F, 9 amino acid changes 
were present, including E294 instead of G294. Lastly, the F isolate from TN83-
1211 only differed from CAN97-83 by two amino acids, S175 and H434, and did 
not match the published isolate sequence of TN83-1211. However, this mutation 
was present in several clones analyzed, suggesting the viral stock may have had 
a heterogeneous population of virus present.  For clarity, we refer to this protein 
as S175H434 F. The presence of a unique amino acid in S175H434, H434, instead 
of the highly conserved Q434 in all other published strains, led us to further study 
this F isolate. The neighboring residue H435 is hypothesized to play a critical role 
in electrostatic repulsion with neighboring residues after protonation at low pH, 
acting as a physiologic timing sensor to promote fusion. Based on these findings, 
we hypothesized that the second histidine at position 434 could potentially be 
involved in fusion of S175H434 after exposure to low pH, similar to the function 
observed for H435. In addition, TN94-49 containing K294 and TN96-12 containing 
E294 were of interest to assess the role of these amino acids in low pH mediated 
fusion compared to G294. 
To determine whether these F isolates were able to promote neutral or low 
pH- mediated membrane fusion, we first conducted a syncytia assay. As previously 
reported, CAN97-83 F promoted fusion when exposed to low pH and was therefore 
used as a positive control for low pH triggered fusion (Fig. 3.1A). TN94-49 F 
generated syncytia following low pH treatment, similar to CAN97-83 F, but no 
syncytia formation was observed at neutral pH. Interestingly, TN96-12 F was 
unable to generate cell-to-cell fusion at both neutral and low pH, whereas 
S175H434 F generated minimal background syncytia at neutral pH and robust 
syncytia formation after exposure to low pH that was significantly higher than the 
syncytia observed with CAN97-83 F (Fig 3.1A, quantified in 3.1B). To confirm our 
findings in the syncytia assay, we utilized a luciferase reporter assay as a second 
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cell-to-cell fusion assay metric. Consistent with the syncytia assay, TN94-49 F 
exhibited no fusion above background at neutral pH, and low pH induced activity 
similar to that of CAN97-83 F, while S175H434 F exhibited significantly higher 
(nearly 500%) low pH-induced fusion activity compared to CAN97-83 F. Again, 
TN96-12 F-mediated fusion was undetectable above background levels (Fig 3.1C).   
F S175H434 differs from CAN97-83 F by only two amino acids yet 
demonstrates significantly increased low pH-induced membrane fusion (Fig 3.1 A-
C). H435 has been implicated in low pH-mediated triggering, so it appeared that 
H434 might serve a similar role. To examine the contribution of H434 in fusion, we 
generated a point mutation in CAN97-83 WT F using site-directed mutagenesis, 
changing Q at position 434 to H (CAN97-83 Q434H). We then conducted both 
syncytia and luciferase reporter assays to examine fusion activity of this mutant. 
Interestingly, syncytia assays demonstrated that CAN97-83 Q434H was able to 
recapitulate the high level of fusion observed for S175H434 (Fig 3.1A), and 
quantification of the fusion activity demonstrated a similar fusion profile to that of 
S175H434 (Fig 3.1B). The luciferase reporter assay again confirmed that CAN97-
83 Q434H demonstrated fusion activity similar to S175H434 and significantly 
higher than WT CAN97-83 F (Fig 3.1C). Together, these results demonstrate that 
the hyperfusogenic phenotype observed in S175H434 is primarily mediated by a 
single amino acid change, Q434H. 
Fusion mediated by F requires that the protein is synthesized, trafficked to 
the surface and proteolytically processed. As fusion is correlated with cell surface 
expression and cleavage activation, we utilized radioactive metabolic labelling 
coupled with surface biotinylation to examine both total and surface protein 
expression and cleavage activation profiles for each F isolate. Interestingly, we 
identified significant differences in the total and surface protein expression levels 
between the F proteins. Compared to CAN97-83 WT F, TN94-49 F had similar 
levels of total (F0+F1) and surface expression, (Fig 3.2A and quantified in 3.2B), 
which correlated with the similar fusion activities found for these proteins (Fig 
3.1C). The two F proteins shown to promote high levels of fusion, S175H434 and 
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CAN97-83 Q434H, both displayed higher average total protein expression 
(approximately 6-fold and 3-fold, respectively, compared to CAN97-83 F; Fig 3.2A 
and 3.2B), though this difference was only statistically significant for S175H434 F. 
The two highly fusing F proteins also displayed higher average surface protein 
expression (approximately 10-fold and 7-fold, compared to CAN97-83), though 
again statistical significance was only reached for S175H434 F. These results 
suggest that higher surface expression levels may be at least partially responsible 
for the higher levels of fusion observed for S175H434.  However, TN96-12 F failed 
to promote fusion, despite similarly high surface expression, demonstrating that 
surface expression is only one factor contributing to overall fusion (Fig 3.1B). 
These findings demonstrate that a single amino acid change was able to increase 
the fusion protein expression compared to WT, suggesting that this area of the 
protein is involved in protein stability or turnover and offering a potential 
explanation for the phenotypes observed. 
HMPV F is synthesized as an inactive, monomeric protein that must be 
proteolytically processed into the heterodimeric, disulfide linked F1 and F2, in order 
to mediate fusion. In vitro, exogenous trypsin cleaves the protein within the 
cleavage motif to generate the fusogenically active form. Due to the requirement 
of cleavage for fusion, we examined the relative amount of trypsin cleavage for 
each F variant. To identify a potential role for proteolytic activation by trypsin on 
fusion activity, percent cleavage�� 𝐹𝐹1
𝐹𝐹0+𝐹𝐹1
�× 100� was quantified for the surface 
population of F (Fig 3.2C). Interestingly, F variants that were more highly 
expressed, S175H434, TN96-12, and CAN97-83 Q434H were cleaved at 
significantly higher levels than CAN97-83 or TN94-49, potentially contributing to 
the observed hyperfusogenic phenotypes (Fig 3.2C). Though the higher levels of 
CAN97-83 Q434H protein expression did not reach statistical significance, this 
protein displayed significantly higher levels of protein cleavage compared to 
CAN97-83 WT F. 
These findings suggest the hyperfusogenic phenotypes observed for 
S175H434 F were due in part to the presence of higher levels of F at the surface 
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as well as increased cleavage activation. The finding that CAN97-83 Q434H 
yielded significantly increased membrane fusion and cleavage suggests H434 is 
important for this phenotype. Conversely, TN96-12, which failed to mediate cell-
to-cell fusion in both syncytia and luciferase reporter assays, was significantly 
more abundant in total, and approaching significantly higher surface populations 
(p=0.0685). In addition, it was cleaved significantly higher when compared to 
CAN97-83 F. Although cleaved significantly higher when compared to CAN97-83 
F, TN96-12 F was unable to mediate fusion in cell-to-cell fusion assays suggesting 
there may be other factors necessary for triggering of this F isolate which are not 
present on the cell surface.  
Discussion 
In this study we examined the fusion activity, expression, and cleavage of 
three previously uncharacterized F proteins. Previously, we have reported low pH-
promoted membrane fusion for CAN97-83, and others have reported this 
phenomenon only within clade A strains of HMPV (189, 240-242), with a glycine 
residue at position 294  (G294) described as a requirement for low pH-promoted 
fusion (240). However, TN94-49 F contains a lysine (K) at this position and 
promotes fusion after exposure to low pH, indicating that either of these residues 
can be present at position 294 in an HMPV F protein which promotes low pH-
induced fusion (Fig 3.3). Genetic variability analysis of HMPV F proteins 
demonstrated that position 294 is one of two positively selected sites with relaxed 
selective constraints for the amino acids G, K or E, indicating that when one of 
these are present at this position, viral fitness is unaffected (339). Analyses from 
the Melero group (240, 241) indicated that E294 was present with neutral pH fusing 
F proteins, while previous results from several groups showed low pH fusion with 
F proteins containing G294. Our findings demonstrate that K294 can also be 
present in a low pH induced F protein. Additional amino acids at positions 296, 396 
and 404 (Fig 3.3) have been described to modulate low pH fusion sensitivity (241). 
However, these amino acids are completely conserved in the strains of HMPV 
examined in this study. 
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HMPV F S175H434 displayed a hyperfusogenic phenotype and significantly 
increased protein expression of both total and surface populations compared to 
CAN97-83 F, but only two amino acid changes were present between the two 
proteins. One notable amino acid difference was H434, which is in close proximity 
to a previously identified amino acid, H435, shown to be important for low pH 
triggered fusion.  We generated a CAN97-83 mutant, containing Q434H, and 
demonstrated this single amino acid mutation could recapitulate the 
hyperfusogenic phenotype and expression patterns observed for S175H434 F. 
Due to its close proximity, H434 may contribute to low pH mediated fusion through 
a similar mechanism to H435, which has been hypothesized to interact with 
surrounding residues and, upon protonation, destabilize the pre-fusion form to 
initiate refolding to the post-fusion form. Recently, a high-resolution pre-fusion 
structure of HMPV F was published. Examination of the structure suggests the 
need for destabilization in the heptad repeat B region to trigger the refolding event 
to the post-fusion conformation (205). This structure also suggests a model for the 
role of H435 in fusion, as a potential electrostatic disruption between E433 and 
K20 by protonated H435 upon acidification could provide this destabilization (Fig 
3.3A and 3.3C). Additionally, K438 could play a role given the close proximity of 
the residue to the H434 and H435 amino acid positions, potentially enhancing this 
destabilization and increasing fusion activity (Fig 3.3A and 3.3D) (239). Lastly, 
there are significant differences in the overall protein expression of F from the 
examined strains, suggesting a potential role in protein folding, overall stability, or 
turnover rates for H434. When examining known sequences of HMPV F proteins, 
H434 was not present, which suggests that the hyperfusogenicity conferred by this 
amino acid may not be beneficial to HMPV infectivity. For parainfluenza virus 3 
(PIV3), a closely related paramyxovirus, enhancement of receptor binding and 
fusion within the monolayer was detrimental for replication in human airway 
epithelium and in vivo during infection in cotton rats (328). However, when 
examining a hyperfusogenic F protein mutant from a more closely related 
pneumovirus, respiratory syncytial virus, there were increased viral loads, severe 
lung pathology and weight loss in mice compared to controls (301), so whether 
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hyper-fusogenicity is preferentially selected by HMPV during infection is not well 
understood. Interestingly, when HMPV was incubated with the neutralizing 
monoclonal antibody 54G10, one of the detected escape mutations was Q434H. 
No changes in binding affinity of 54G10 for the Q434H mutant were detected, 
suggesting that this mutation may introduce structural changes into the F protein 
which provide some potential benefit (340).  
Our results show that TN96-12 was also highly expressed in both total and 
surface populations but does not mediate fusion in cell-to-cell fusion assays. Co-
expression of TN96-12 F with G at neutral or low pH was not sufficient to induce 
syncytia formation in cell culture (Fig 3.4A and 3.4B), indicating that lack of the G 
protein is not the reason for the absence of fusion. TN96-12 HMPV is a clinical 
isolate, able to initiate infection in patients as well as propagate in cell culture, and 
thus must have a functional fusion protein. Therefore, our findings point toward the 
need for other host factors required for fusion of some HMPV strains in order to 
escape the endosome and initiate infection, and the lack of fusion in our assays 
suggests these factors may not be present on the cell surface. Currently, heparan 
sulfate proteoglycans and RGD binding integrins are proposed cellular factors for 
association and entry of HMPV through endocytosis (123, 243, 335, 341). It is 
possible that there are other critical factor(s) within the endosome that interact with 
HMPV F and trigger the fusion protein, similar to the use of the endosomal receptor 
NPC-1 by Ebola virus GP (234).  
Taken together, the results in this study highlight the diversity of HMPV F 
activity and the complexity associated with fusion. Our results indicate that the 
contribution of a single amino acid can be responsible for observed phenotypes, 
demonstrating that minor evolutionary changes can lead to significant phenotypic 
differences that alter HMPV infection and tropism. Further studies are necessary 
to better understand and elucidate key contributing factors of fusion protein 
stability, cleavage and host factor interaction required for HMPV infection, as well 
as which key residues and regions of the F protein are vital for fusion and entry of 
the virus. 
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Figure 3.1. HMPV F proteins from different strains exhibit variable fusion activity 
promoted by low pH. (A) Representative images of syncytia formation of cells expressing the 
HMPV F proteins after pulses at pH 5 or pH 7 (n = 3). (B) The fusion index was calculated using 
the equation f = [1 – (C/N)] where C is the number of cells in a field after fusion and N, the number 
of nuclei. Six fields were scored per condition representative of 3 independent experiments. “*”s 
indicate statistical significance compared to fusion for CAN97-83 (A2) F after pH 5 pulses (n=3) [* 
p<0.05, ** p<0.005, *** p<0.0005 and **** p<0.0001]. Graph was broken into two experiments 
(denoted by the graph break and colors: red/orange bars represent independent experiment from 
green/blue). Statistical significance within these assays is compared to CAN97-83 within each 
independent experiment. (C) Luciferase reporter gene assay of Vero cells transfected with HMPV 
F upon which BSR cells were overlaid and subjected to two pH pulses. Data are presented and 
normalized to CAN97-83 (A2) F luminescence (fusion) at pH 5 (n = 3) +/- standard deviation. * 
Indicates statistical significance compared to CAN97-83 F after pH 5 pulses. Graphical 
representation and statistics were conducted as described in B. (D) Partial protein sequence 
analysis of F from 4 strains of HMPV surrounding key residues at positions 294 and 435. Sequence 
alignment was generated using ClustalW. The asterisk “*” indicates identical residues and the colon 
“:” indicates conserved substitutions. 
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Figure 3.2. HMPV F protein expression and cleavage by exogenous trypsin. (A) 
Representative gels of total and surface protein expression in metabolically labeled Vero cells 
expressing empty vector pCAGGS-MCS (Mock), CAN97-83 F, S175H434 F, TN94-49 F, TN96-12 
F, and mutant CAN97-83 Q434H F in the presence of 3.0 μg/ml of TPCK-trypsin. (B) Quantification 
of the total and surface protein populations for F (F0 and F1 forms) in metabolically labeled Vero 
cells. Data are presented as normalization to CAN97-83 (A2) F expression, which was set to 1 (n = 
4). “*”s Indicate statistical significance compared to F for CAN97-83 F (n= 4) [# P<0.07, * p<0.05, 
** p<0.005, *** p<0.0005 and **** p<0.0001]. (C) Quantification of the relative amount of fusion 
protein cleavage within the surface population of F calculated using F1/(F1 + F0) and normalized to 
CAN97-83, set as 1. 
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Figure 3.3: HMPV residues identified thus far involved in low pH mediated fusion. A) The 
pre-fusion homo-trimeric structure of HMPV F of NL/1/00 (pdb: 5WB0) with residue positions 
identified for low pH fusion highlighted including (B) 396 (C) 20, 433, 434, 435(D) 294, 296, 396, 
404 and 438. Images generated using Pymol protein structure software. 
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Figure 3.4: Addition of HMPV G to TN96-12 F is unable to mediate fusion at low pH. A) HMPV 
F (TN 96-12) was co-transfected with or without G at various ratios in VERO cells and fusion activity 
was measured in a luciferase reporter assay. B) Co-transfected cells were subjected to H&E 
staining and bright field microscopy to examine syncytia formation. White arrows indicate presence 
of multinucleated syncytia present in the representative field. Error bars represent the standard 
deviation of two independent replicates completed in duplicate.  
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Chapter 4: SPINT2 inhibits proteases involved in activation of both 
influenza viruses and metapneumoviruses 
* This work was completed in collaboration with Dr. Marco Strauss and Dr. Gary 
Whittaker (Cornell University) who provided constructs for TMPRSS2, HAT and 
Matriptase enzymes as well as completing the peptide cleavage assay and kinetics 
for HMPV F (Table 4.1). In addition, they conducted all of the influenza assays and 
corresponding figures (Figures 4.1, 4.2, 4.4, 4.5, and 4.7). I performed all other 
experiments and generated the associated figures (Figures 4.3 and 4.6). This 
chapter was adapted from a co-written manuscript (Kinder and Straus et al 2020. 
Virology. 543:43-53). 
Introduction 
Influenza-like illnesses (ILIs) represent a significant burden on public health 
and can be caused by a range of respiratory viruses in addition to influenza virus 
itself (342) . An ongoing goal of anti-viral drug discovery is to develop broadly 
acting therapeutics that can be used in the absence of definitive diagnosis, such 
as in the case of ILIs. For such strategies to succeed, drug targets that are shared 
across virus families need to be identified.  
One common cause of influenza, which shaped the term ILI, are influenza 
A viruses (IAV), including H1N1 and H3N2, that cross species barriers from their 
natural avian hosts and infect humans (343, 344). Novel emerging viruses such as 
H7N9 that has caused hundreds of deaths since its appearance in China in 2013 
pose an additional concern (345). The World Health Organization (WHO) 
estimates that each year about 1 billion suffer from flu infections, 3 to 5 million 
people worldwide are hospitalized with severe illness and approximately 290,000 
to 650,000 people die from the disease (346). Mortality rates can dramatically rise 
during influenza pandemics as observed with the Spanish flu of 1918, the Asian 
pandemic of 1957 and the Hong Kong pandemic of 1968 (344, 347). Vaccinations 
can provide an effective protection against seasonal and pandemic outbreaks but 
provide limited or no protection when viruses evolve and/or acquire mutations 
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resulting in antigenically distinct viruses.  This antigenic drift or shift requires that 
new vaccines be produced quickly and in vast amounts which can be problematic 
especially during pandemics. In addition to vaccines, several antiviral therapies 
have been applied to treat influenza A infections such as adamantanes acting as 
M2 ion channel blockers (amantadine, rimantadine) and neuraminidase inhibitors 
which block the cleavage of sialic acid in newly formed virions (oseltamivir, 
zanamivir) (348). However, several influenza subtypes including the most common 
H1N1 and H3N2 have emerged globally that are resistant against adamantanes 
and similar observations were made with respect to oseltamivir (348). More 
recently, baloxavir marboxil (BXM) which is an inhibitor of the influenza polymerase 
acidic subunit (PA) was approved as an antiviral therapy (349). Although it is fully 
effective against currently circulating influenza A and B viruses clinical trial studies 
have already shown that treatment with BXM selects for influenza virus with 
specific amino acid substitutions in PA resulting in reduced susceptibility to the 
drug (350, 351). 
Another common cause of ILI are pneumo- and paramyxoviruses, including 
human metapneumovirus (HMPV), respiratory syncytial virus, and parainfluenza 
viruses. Clinical presentation of these viruses resembles many of the symptoms of 
influenza, where they cause significant morbidity and mortality as well as a large 
economic burden (352, 353). HMPV is ubiquitous, with nearly everyone infected 
by the age of 5 and reinfection is common throughout life, impacting children, the 
elderly and immunocompromised individuals (30, 36, 354). While HMPV is a 
common cause of ILI, there are currently no approved vaccines or antiviral 
therapeutics. Further research is needed to establish targets for intervention, and 
factors required for infection need to be examined in more detail. 
Certain influenza viruses and HMPV appear to share common activating 
proteases. The influenza fusion protein hemagglutinin (HA) is synthesized as a 
precursor that needs to be cleaved by host cell proteases to exert its fusogenic 
activity (355, 356). Cleavage separates the precursor HA0 into HA1 and HA2, which 
remain associated via disulfide bonds and leads to exposure of the fusion peptide 
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at the N-terminus of HA2 (355, 356). Low pathogenicity avian influenza (LPAI) 
usually possess a monobasic cleavage site which consists of 1 – 2 non-
consecutive basic amino acids and which is generally cleaved by trypsin-like serine 
proteases such trypsin, as well as members of the type II transmembrane serine 
protease (TTSP) family including TMPRSS2, TMPRSS4, HAT (TMPRSS11D) and 
matriptase (355-357). In addition, some other proteases such as KLK5 and KLK 
12 have been implicated in influenza pathogenicity (177). In humans these 
proteases are localized in the respiratory tract and therefore influenza infections 
are usually confined to this tissue. In contrast, highly pathogenic avian influenza 
(HPAI) viruses are defined by a polybasic cleavage site which consists of 6 – 7 
basic residues allowing them to be activated by members of the proprotein 
convertase (PC) family such as furin and PC6 (358). These proteases are not 
confined to a specific tissue and dramatically increase the risk of a systemic 
infection.  
Similar to influenza HA, HMPV requires the fusion protein (F) to be 
proteolytically processed at a single basic residue to generate the active, 
metastable form. Without this cleavage process, the F protein is unable to mediate 
viral entry into the target cell. However, to date, only trypsin and TMPRSS2 have 
been shown to effectively cleave HMPV F and other proteases have yet to be 
identified (189, 192). 
In addition, other respiratory viruses have been reported to utilize similar 
proteases for activation, including SARS-CoV and MERS-CoV, demonstrating that 
targeting these proteases would inhibit multiple respiratory pathogens (359). The 
fact that proteolytic activation is such a crucial step for several respiratory viruses 
that predominately require a specific class of proteases makes these proteases a 
viable target for the development of novel antiviral therapies (360). Earlier studies 
described the administration of the serine protease inhibitor aprotinin to inhibit 
influenza replication and demonstrated that aprotinin successfully inhibited IAV 
activation and replication (361). However, when targeting host specific factors 
there are potential off target effects, and therefore the potential side effects of 
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targeting host proteases requires further investigation. Hamilton et al. reported that 
the hepatocyte growth activator inhibitor 2 (HAI-2) effectively inhibited trypsin-
mediated cleavage of H1N1 and H3N2 in vitro and in vivo (362). HAI-2 is encoded 
by the SPINT2 gene and hereafter we will also refer to the protein as SPINT2. 
SPINT2 is 225 KDa plasma membrane-localized serine protease inhibitor found in 
epithelial cells of various tissues including the respiratory tract and all major organs 
(363). In most tissues, SPINT2 co-localizes with matriptase suggesting a 
regulatory role of SPINT2 on matriptase-mediated cleavage events. However, the 
finding that SPINT2 is also expressed in brain and lymph node cells indicates that 
it might regulate other proteases than matriptase (363). Recent reports associated 
the physiological role of SPINT2 with the inhibition of human serine-type proteases 
such as matriptase, plasmin, kallikreins (KLK) and coagulation factor Xia (364-367) 
. SPINT2 possesses one transmembrane domain and two kunitz-type inhibitor 
domains that are exposed to the extracellular space and which are believed to 
facilitate a potent inhibition of target proteases. Wu et al. recently described that 
the kunitz-type domain 1 of SPINT2 is responsible for matriptase inhibition (367). 
A major function of SPINT2 is its role as a tumor suppressor because down-
regulation diminishes the prospect of survival of several cancers such as 
hepatocellular carcinoma, gastric cancer, prostate cancer or melanoma (368-371). 
However, SPINT2 was also associated with placenta development and epithelial 
homeostasis (372, 373). 
A previous study from our lab described the effective inhibition of trypsin by 
SPINT2 resulting in dramatically reduced cleavage of influenza A HA using a 
model protease and subsequently reduced viral growth in cell culture and  mouse 
studies (362). Here, we report that purified SPINT2 protein inhibits several host 
proteases found in the human respiratory tract, such as matriptase and TMPRSS2, 
that are relevant for the activation of influenza viruses currently circulating and 
causing significant disease outbreaks. To demonstrate broad applicability, we also 
tested the potential of SPINT2 to inhibit the activation of the fusion protein (F) from 
human metapneumovirus (HMPV), a member of the pneumovirus family. We 
confirm the original findings that HMPV F is proteolytically processed by trypsin 
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and TMPRSS2. In addition, we found that HAT, KLK5 and matriptase were able to 
cleave F, but KLK12 could not. Our results show that SPINT2 can inhibit the 
activation of proteases that are responsible for the activation of influenza H1N1, 
H3N2 and H7N9 HA as well as HMPV F. In a cell culture model, we demonstrate 
that viral loads are significantly reduced in the presence of SPINT2 when infections 
were conducted with A/CA/04/09 and A/X31. Moreover, the application of SPINT2 
24 h post infection inhibited the activation of influenza A viruses with the same 
efficacy as when SPINT2 was added to cell culture medium at the time of infection. 
Thus, SPINT2 exhibits the potential to serve as a novel and efficient antiviral 
therapeutic to relieve patients from influenza A, human metapneumovirus, SARS-
CoV and potentially other respiratory viruses that require these host factors for 
entry. 
Results 
SPINT2 inhibits recombinant human respiratory tract proteases that cleave 
HMPV F and HA cleavage site peptide mimics 
Using a fluorogenic peptide cleavage assay that utilizes fluorogenic 
peptides mimicking the HA cleavage site we previously tested the ability of SPINT2 
to inhibit proteases shown to cleave HAs from seasonal and pandemic influenza 
A strains that infected humans (171, 374). We found that certain HA subtypes such 
as H1, H2 and H3 are cleaved by a wide variety of human respiratory proteases 
while others such H5, H7 and H9 displayed more variability in cleavage by 
proteases and seemed less well adapted to proteases present in the human 
respiratory tract (171). Here, we extended our previous study and tested a peptide 
mimicking the cleavage site of the pneumovirus fusion protein of HMPV F using a 
variety of proteases known for their ability to cleave the peptide mimic (Table 4.1A) 
(189, 190). When we tested the cleavage of a peptide mimicking the HMPV F 
cleavage site using trypsin, matriptase, KLK5, KLK12, HAT or plasmin we found 
that all proteases except KLK12 were able to proteolytically cleave the peptide 
(Table 4.1A). However, the Vmax values for matriptase (9.24 RFU/min), KLK5 (5.8 
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RFU/min) and HAT (2.99 RFU/min) were very low compared to trypsin (135.2 
RFU/min) suggesting that the three proteases have a low affinity interaction and 
processivity for HMPV F.  
Next, trypsin, matriptase and KLK5 were selected for the SPINT2 inhibition 
assays as described below. For the SPINT2 inhibition assays, trypsin (which 
typically resides in the intestinal tract and expresses a very broad activity towards 
different HA subtypes and HMPV F) served as a control (375). In addition, furin 
was used as a negative control that is not inhibited by SPINT2. As none of the 
peptides used in combination with the aforementioned proteases has a furin 
cleavage site we tested furin-mediated cleavage on a peptide with a H5N1 HPAI 
cleavage motif in the presence of 500 nM SPINT2 We continued by measuring the 
Vmax values for each protease/peptide combination in the presence of different 
SPINT2 concentrations and plotted the obtained Vmax values against the SPINT2 
concentrations on a logarithmic scale. Using Prism7 software, we then determined 
the IC50 that reflects at which concentration the Vmax of the respective reaction is 
inhibited by half. SPINT2 cleavage inhibition of a representative H1N1 cleavage 
site by trypsin results in an IC50 value of 70.6 nM (Table 4.1B) while the inhibition 
efficacy of SPINT2 towards matriptase, HAT, KLK5 and KLK12 ranged from 11 nM 
to 25 nM (Table 4.1B). However, inhibition was much less efficient for plasmin 
compared with trypsin (122 nM). We observed a similar trend when testing 
peptides mimicking the H3N2 and H7N9 HA cleavage sites using trypsin, HAT, 
KLK5, plasmin and trypsin, matriptase, plasmin, respectively (Table 4.1B). With 
the exception of plasmin, we found that human respiratory tract proteases are 
inhibited with a higher efficacy compared to trypsin. We expanded our analysis to 
peptides mimicking HA cleavage sites of H2N2, H5N1 (LPAI and HPAI), H6N1 and 
H9N2 that all reflected the results described above (Table 4.1B). Only cleavage 
inhibition of H6N1 HA by KLK5 did not significantly differ from the observation 
made with trypsin (Table 4.1B). When we tested the inhibition of HMPV cleavage 
by trypsin, matriptase and KLK5, SPINT2 demonstrated high inhibition efficacy for 
all three tested proteases with measured IC50 for trypsin, matriptase and KLK5 of 
0.04 nM, 0.0003 nM and 0.95 nM, respectively (Table 4.1C). Compared to the IC50 
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values observed with the peptides mimicking influenza HA cleavage site motifs the 
IC50 values for the HMPV F peptide were very low.   
Cleavage of distinct full-length HA subtypes and HMPV F is efficiently 
inhibited by SPINT 
Cleavage of peptides mimicking cleavage sites of viral fusion proteins do 
not always reflect the in vivo situation and requires validation by expressing the 
full-length fusion proteins in a cell culture model to test cleavage and cleavage 
inhibition of the respective protease (171). However, before conducting these 
experiments we wanted to ensure that SPINT2 does not have a cytotoxic effect on 
cells. Therefore, 293T cells were incubated with various concentrations of SPINT2 
over a time period of 24 hours. PBS and 500µM H2O2 served as cytotoxic negative 
and positive controls respectively. We observed a slight reduction of about 10 -15 
% in cell viability when SPINT2 was added to the cells (Fig 4.1). 
To test SPINT2-mediated cleavage inhibition of full-length HA we 
expressed the HAs of A/CA/04/09 (H1N1), A/x31 (H3N2) and A/Shanghai/2/2013 
(H7N9) in 293T cells and added recombinant matriptase or KLK5 protease that 
were pre-incubated with 10nM or 500nM SPINT2. Trypsin and the respective 
protease without SPINT2 incubation were used as controls. Cleavage of HA0 was 
analyzed via Western Blot and the signal intensities of the HA1 bands were 
quantified using the control sample without SPINT2 incubation as a reference point 
to illustrate the relative cleavage of HA with and without inhibitor (Fig 4.2A and 
4.2D). Trypsin cleaved all tested HA proteins with very high efficiency that was not 
observed with matriptase or KLK5 (Fig 4.2B- 4.2D). However, H1N1 HA was 
cleaved by matriptase and KLK5 to a similar extent without and with 10nM SPINT2. 
500nM SPINT2 led to a relative cleavage reduction of about 70% and 50% for 
matriptase and KLK5, respectively (Fig 4.2A and 4.2B). KLK5-mediated cleavage 
of H3N2 HA was reduced by about 10% when KLK5 was pre-incubated with 10nM 
SPINT2 and by about 60% when 500nM SPINT2 was used (Fig 4.2A and 4.2C). 
When we tested the cleavage inhibition of matriptase with H7N9 HA as a substrate 
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we found that 10nM and 500nM SPINT reduced the cleavage to 40% and 10% 
cleavage, respectively, compared to the control. (Fig 4.2A and 4.2D). In contrast, 
10nM SPINT2 had no effect on KLK5-mediated cleavage of H7N9 HA while 500nM 
reduced relative cleavage by approximately 70% (Fig 4.2A and 4.2D). 
In order to determine whether SPINT2 also prevented cleavage of HMPV F 
we first examined which proteases, in addition to trypsin and TMPRSS2, were able 
to cleave HMPV F. First, we co-transfected the full length TMPRSS2, HAT and 
matriptase with HMPV F in VERO cells. The F protein was then radioactively 
labeled with 35S methionine and cleavage was examined by quantifying the F0 full 
length protein and the F1 cleavage product.  We found that TMPRSS2 and HAT 
were able to efficiently cleave HMPV F while matriptase decreased the expression 
of F, though it is not clear if this was due to general degradation of protein or lower 
initial expression. However, matriptase demonstrated potential low-level cleavage 
when co-transfected (Fig 4.3A and 4.3B). We then examined cleavage by the 
exogenous proteases KLK5, KLK12 and matriptase. Compared with the trypsin 
control, KLK5 and matriptase were able to cleave HMPV F, while KLK12 was not 
(Fig 4.3C and 4.3D). In agreement with the peptide assay, cleavage of HMPV F by 
KLK5 and matriptase was less efficient than for trypsin and both peptide, and full-
length protein assays demonstrate that KLK12 does not cleave HMPV F. This also 
serves as confirmation that matriptase likely cleaves HMPV F, but co-expression 
with matriptase may alter protein synthesis, stability or turnover if co-expressed 
during synthesis and transport to the cell surface. Next, we tested SPINT2 
inhibition of exogenous proteases trypsin, KLK5 and matriptase. We pre-incubated 
SPINT2 with each protease, added it to VERO cells expressing HMPV F and 
analyzed cleavage product formation. SPINT2 pre- incubation minimally affected 
cleavage at a concentration of 10nM but addition of 500nM SPINT2 resulted in 
inhibition of trypsin, KLK5 and matriptase-mediated cleavage of HMPV, similar to 
our findings for HA (Fig 4.3E and 4.3F). 
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SPINT2 inhibits HA mediated cell-cell fusion 
The above presented biochemical experiments demonstrate that SPINT2 is 
able to efficiently inhibit proteolytic cleavage of HMPV F and several influenza A 
HA subtypes by a variety of proteases. For a functional analysis to determine 
whether SPINT2 inhibition prevents cells to cell fusion and viral growth, we 
examined influenza A infection in cell culture. While HMPV is an important human 
pathogen, Influenza grows significantly better in cell culture compared with HMPV. 
First, we tested whether cleavage inhibition by SPINT2 resulted in the inhibition of 
cell-cell fusion. As described above, matriptase and KLK5 were pre-incubated with 
10nM and 500nM SPINT2 and subsequently added to VERO cells expressing 
A/CA/04/09 (H1N1) HA or A/Shanghai/2/2013 (H7N9) HA. Cells were then briefly 
exposed to a low pH buffer to induce fusion and subsequently analyzed using an 
immune fluorescence assay. When matriptase and KLK5 were tested with 10nM 
SPINT2 and incubated with VERO cells expressing H1N1 HA, we still observed 
syncytia formation (Fig 4.4A). However, 500 mM SPINT2 resulted in the abrogation 
of syncytia formation triggered by cleavage of the respective HA by matriptase and 
KLK5. We made the same observation when we tested KLK5 and H7N9 HA (Fig 
4.4B). Matriptase-mediated H7N9 HA syncytia formation was inhibited by the 
addition of 10nM SPINT2 (Fig 4.4B). To ensure that cell-cell fusion inhibition is a 
result of HA cleavage inhibition through SPINT2 but not a side effect of SPINT2 
treatment per se we expressed A/Vietnam/1204/2004 (H5N1) HA in VERO cells 
and treated them with the inhibitor. H5N1 HA possesses a HPAI cleavage site and 
is cleaved intracellularly by furin during its maturation process. SPINT2 does not 
inhibit furin and is not able to cross cell membranes. Thus, SPINT2 can not 
interfere with the proteolytic processing of H5N1 HA and therefore this control 
allows to examine whether SPINT2 interferes with cell-cell fusion. Figure 4.4C 
shows that H5N1 HA forms large syncytia in the absence of SPINT2 as well as in 
the presence of 500 nM SPINT2. Hence, we conclude that SPINT2 does not have 
a direct inhibitory effect on cell-cell fusion. 
SPINT2 reduces viral growth in cell culture 
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To understand whether SPINT2 was able to inhibit or reduce the growth of 
virus in a cell culture model over the course of 48 hours we transfected cells with 
human TMPRSS2 and human matriptase, two major proteases that have been 
shown to be responsible for the activation of distinct influenza A subtype viruses. 
TMPRSS2 is essential for H1N1 virus propagation in mice and plays a major role 
in the activation of H7N9 and H9N2 viruses (176, 376, 377). Matriptase cleaves 
H1N1 HA in a sub-type specific manner, is involved in the in vivo cleavage of H9N2 
HA and our results described above suggest a role for matriptase in the activation 
of H7N9 (177, 376). At 18 hours post transfection we infected MDCK cells with 
A/CA/04/09 (H1N1) at a MOI of 0.1 and subsequently added SPINT2 protein at 
different concentrations. Non-transfected cells served as a control and exogenous 
trypsin was added to facilitate viral propagation. The supernatants were harvested 
48 hours post infection and viral titers were subsequently analyzed using an 
immuno-plaque assay.  
SPINT2 initially mitigated trypsin-mediated growth of H1N1 at a 
concentration of 50nM and the extent of inhibition slightly increased with higher 
concentrations (Fig 4.5A). The highest tested SPINT2 concentration of 500nM 
reduced viral growth by about 1 log (Fig 4.5A). We observed a similar pattern with 
cells transfected with human matriptase (Fig 4.5B). Growth inhibition started at a 
SPINT2 concentration of 50nM and with the application of 500nM growth was 
reduced by approximately 1.5 logs (Fig 4.5B). When we infected cells expressing 
TMPRSS2 with H1N1 and added SPINT2, viral growth was significantly reduced 
at a concentration of 150nM. Addition of 500nM SPINT2 led to a reduction of viral 
growth of about 1.5 logs (Fig 4.5C). We also tested whether SPINT2 could reduce 
the growth of a H3N2 virus because it is major circulating seasonal influenza 
subtype. However, TMPRSS2 and matriptase do not seem to activate H3N2 
viruses (175, 177). Hence, trypsin and SPINT2 were added to the growth medium 
of cells infected with A/X31 H3N2. Compared to control cells without added 
inhibitor SPINT2 significantly inhibited trypsin mediated H3N2 growth at a 
concentration of 50nM (Fig 4.5D). At the highest SPINT2 concentration of 500nM 
viral growth was reduced by about 1 log (Fig 4.5D). 
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We also examined the effect of SPINT2 inhibition of HMPV spread over 
time. VERO cells were infected with rgHMPV at MOI 1 and subsequently treated 
with 500nM of SPINT2 and 0.3µg/mL of TPCK-trypsin. Every 24 hours, cells were 
scraped, and the amount of virus present was titered up to 96hpi with SPINT2 and 
trypsin replenished daily. We find that un-treated cells are infected and 
demonstrate significant spread through 96hpi. Conversely, cells infected and 
treated with SPINT2 had no detectible virus up to 48hpi and very minimal virus 
detected at 72 and 96hpi, demonstrating that SPINT2 significantly inhibition HMPV 
viral replication and spread (Fig 4.6).  
Antiviral therapies are often applied when patients already show signs of 
disease. Therefore, we tested if SPINT2 was able to reduce viral growth when 
added to cells 24 hours after the initial infection. Cells were infected with 0.1 MOI 
of A/CA/04/09 (H1N1) and trypsin was added to promote viral growth. At the time 
of infection, we also added 500nM SPINT2 to one sample. A second sample 
received 500nM SPINT2 24 hours post infection. Growth supernatants were 
harvested 24 hours later, and viral growth was analyzed. We found that viral 
growth was significantly reduced by regardless whether SPINT2 was added at the 
time of infection or 24 hours later (Fig 4.7).  
Discussion 
Influenza A virus has caused four pandemics since the early 20th century 
and infects millions of people each year as seasonal ‘flu, resulting in up to 690,000 
deaths annually (346) . Vaccination efforts have proven to be challenging due to 
the antigenic drift of the virus and emerging resistance phenotypes (378). 
Moreover, the efficacy of vaccines seems to be significantly reduced in certain 
high-risk groups (379). Prevalent antiviral therapies to treat influenza A virus-
infected patients such as adamantanes and neuraminidase inhibitors target viral 
proteins but there is increasing number of reports about circulating influenza A 
subtypes that are resistant to these treatments(348). HMPV causes infections in 
the upper and lower respiratory tract expressing very similar symptoms as 
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influenza infections and resulting in significant morbidity and mortality (352, 353). 
The most susceptible groups are young children, older adults and people that are 
immunocompromised (30, 36, 354). Currently, there are not treatment against 
HMPV infections available. In this study we focused on a novel approach that uses 
antiviral therapies targeting host factors rather than viral proteins offering a more 
broad and potentially more effective therapeutic approach (360). We demonstrate 
that SPINT2, a potent inhibitor of serine-type proteases, can significantly inhibit 
cleavage of HMPV F and HA, impair HA-triggered fusion of cells and hence, 
reduce the growth of various influenza A strains in cell culture.  
We assessed cleavage of the HMPV fusion protein in vitro using a peptide 
cleavage assay modified from previously work on other viral fusion proteins (171, 
374). The HMPV F peptide was cleaved by trypsin, plasmin, matriptase and KLK5 
but was unable to be cleaved by KLK12. To confirm these findings in a system in 
which the entire HMPV F protein was subject to cleavage, we co-expressed the 
fusion protein with TMPRSS2, HAT and matriptase proteases, or treated F with 
exogenous proteases KLK5, KLK12 and matriptase. These findings are the first to 
identify proteases besides trypsin and TMPRSS2 that are able to cleave HMPV F. 
In addition, HMPV appears to utilize many of the serine proteases that influenza 
uses for HA processing and therefore, offers strong potential for an antiviral target.  
SPINT2 demonstrates greater advantage over other inhibitors of host 
proteases such as e.g. aprotinin that was shown to be an effective antiviral but 
also seemed to be specific only for a subset of proteases (361). It can be argued 
that a more specific protease inhibitor which inhibits only one or very few proteases 
might be more advantageous because it may result in less side effects. With 
respect to influenza A infections, TMPRSS2 could represent such a specific target 
as it was shown to a  major activating proteases for H1N1 and H7N9 in mice and 
human airway cells (176, 376, 377, 380, 381). However, there is no evidence that 
that application of a broad-spectrum protease inhibitor results in more severe side 
effects than a specific one as side effects may not be a consequence of the 
protease inhibition but the compound itself may act against different targets in the 
62 
 
body. The reports demonstrating that TMPRSS2 is crucial for H1N1 and H7N9 
virus propagation in mice and cell culture suggest that it also plays a major role in 
the human respiratory tract. So far, however, it is unclear whether the obtained 
results translate to humans and other studies have shown that for example human 
matriptase is able to process H1N1 and H7N9 (177, 382). 
Our peptide assay suggests that SPINT2 has a wide variety of host 
protease specificity. With the exception of plasmin, all the tested proteases in 
combination with peptides mimicking the cleavage site of different HA subtypes 
expressed IC50 values in the nanomolar range.  Interestingly, the IC50 values 
obtained for cleavage inhibition of HMPV F were substantially lower, in the 
picomolar range. This suggests that the HMPV cleavage may be more selectively 
inhibited by SPINT2.  However, the western blot data showed that addition of the 
lowest concentration (10 nM) of SPINT2 did not result in cleavage inhibition of 
HMPV F by the tested proteases. Differences in sensitivity of SPINT2 between 
influenza HA and HMPV require further investigation.   
SPINT2 poses several potential advantages over other inhibitors that target 
host proteases. Cell culture studies showed that, for example, matriptase-
mediated H7N9 HA cleavage was efficiently inhibited at a concentration of 10nM 
SPINT2. In contrast, the substrate range for aprotinin, a serine protease inhibitor 
shown to reduce influenza A infections by targeting host proteases, seemed to be 
more limited (361). Other synthetic and peptide-like molecules designed to inhibit 
very specific serine proteases such as TMPRSS2, TMPRSS4 and TMPRSS11D 
(HAT) were only tested with those proteases and their potential to inhibit other 
proteases relevant for influenza A activation remains unclear (383-385). Currently, 
the most promising antiviral protein inhibitor is camostat which is already approved 
in Japan for the treatment of chronic pancreatitis (386). Recently, it was 
demonstrated that camostat inhibited influenza replication in cell culture and 
prevented the viral spread and pathogenesis of SARS-CoV in mice by inhibition of 
serine proteases (385, 387). However, camostat was applied prior to the virus 
infection and it was administered into the mice via oral gavage (387).  
63 
 
A previous study showed that SPINT2 significantly attenuated influenza A 
infections in mice using a concentration that was 40x lower than the described 
camostat concentration and intranasal administration was sufficient (362). Our 
current study suggests that SPINT2 is able to significantly inhibit viral spread 
during an ongoing infection and does not need to be applied prior or at the start of 
an infection. The mouse study also showed that SPINT2 can be applied directly to 
the respiratory tract while camostat that is currently distributed as a pill and 
therefore less organ specific. In addition, camostat is synthetic whereas SPINT2 is 
a naturally occurring molecule which may attenuate potential adverse effects due 
to non-native compounds activating the immune system. Future research will be 
conducted to test if SPINT2 can be applied more efficiently via an inhaler and to 
explore potential side effects in mice studies. However, when we tested the 
potential of SPINT2 to inhibit viral replication in a cell culture model we were only 
able to achieve growth reductions of approximately 1 -1.5 logs after 48 hours with 
a concentration of 500nM SPINT2. One potential explanation is that 500nM 
SPINT2 was unable to saturate the proteases present in the individual experiments 
and was not sufficient to prevent viral growth. In addition, the continuous 
overexpression of matriptase and TMPRSS2 may have produced an artificially 
high quantity of protein that exceeded the inhibitory capacities of SPINT2. This 
problem could be solved either by using higher concentration of SPINT2 or by 
optimizing its inhibitory properties. However, the data also demonstrates that 
SPINT2 has the ability to inhibit proteases that expressed on the cell surface and 
that inhibition is not limited to proteases that were added exogenously and pre-
incubated with the inhibitor (Fig 4.5). SPINT2 did not express any cytotoxic effects 
up to a concentration of 10 mM, significantly above the therapeutic dosage 
required for inhibition. In comparison with other studies, the SPINT2 concentration 
we used here were in the nanomolar range while other published inhibitors require 
micromolar concentrations (383-385). However, we believe that future research 
will allow to fully utilize the potential of SPINT2 as a broad-spectrum antiviral 
therapy. Wu et al., recently described that the Kunitz domain I of SPINT2 is 
responsible for the inhibition of matriptase (367). In future studies we will explore 
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whether the inhibitory capabilities of SPINT2 can be condensed into small peptides 
that may improve its efficacy. Its ability to inhibit a broad range of serine protease 
that are involved in the activation of influenza A suggest that a SPINT2 based 
antiviral therapy could be efficient against other pathogens too. TMPRSS2, for 
example, not only plays a major role in the pathogenesis of H1N1 but is also 
required for the activation of SARS-CoV and MERS-CoV and HMPV (388, 389). 
Currently, treatment options for these viruses are very limited and therefore 
SPINT2 could become a viable option if its potential as an antiviral therapeutic can 
be fully exploited.  
However, while SPINT2 has a therapeutic potential to treat ILIs caused by 
viruses that require activation by trypsin-like serine proteases it may have its 
limitation to provide a treatment option for infections caused by influenza HPAI 
viruses, such as H5N1 (390) . These viruses are believed to be activated by furin 
and pro-protein convertases that belong to the class of subtilisin-like proteases 
(358) . Preliminary data from our lab demonstrated that SPINT2 did not inhibit furin-
mediated cleavage of HPAI cleavage site peptide mimics as well as peptides 
carrying described furin cleavage sites (data not shown). In addition, furin acts 
intracellularly and we have no evidence that SPINT2 is able to penetrate the cell 
membrane and thus inhibiting proteases located in intracellular compartments. 
Therefore, it seems unlikely that SPINT2 is able to inhibit furin in cell culture-based 
studies or in vivo experiments. 
In conclusion we believe SPINT2 has potential to be developed into a novel 
antiviral therapy. In contrast to most similar drugs that are synthetic, SPINT2 is an 
endogenously expressed protein product that confers resistance to a variety of 
pathogenic viruses which can potentially be delivered directly into the respiratory 
tract as an aerosol. Most importantly, SPINT2 demonstrated the ability to 
significantly attenuate an ongoing viral infection in cell culture and further research 
will be conducted to explore the time period during which SPINT2 demonstrates 
the highest efficacy. 
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Table 4.1: Cleavage of HMPV F and SPINT2 inhibition of peptide cleavage of various 
proteases: (A) A fluorogenic peptide mimicking the cleavage site of HMPV F was incubated with 
the indicated proteases and cleavage was monitored by the increase of fluorescence at 390 nm. 
RFU = relative fluorescence units. StDev = Standard Deviation. Fluorogenic peptides mimicking 
the cleavage sites of A/CA/04/09 H1N1, A/Japan/305/1957 H2N2 HA, A/Aichi/2/68 H3N2 HA, 
A/Vietnam/1203/2004 H5N1 LPAI HA,  A/Vietnam/1204/2004 H5N1 HPAI HA, A/Taiwan/2/2013 
H6N1 HA, A/Shanghai/2/2013 H7N9 HA, A/Hong Kong/2108/2003 H9N2 HA and HMPV F were 
incubated with the indicated proteases and different SPINT2 concentrations. Cleavage was 
monitored by the increase of fluorescence at 390 nm and the resulting Vmax values were used to 
calculate the IC50 values. (B) IC50 values of influenza A fluorogenic cleavage site peptide mimics. 
Concentrations are in nanomolar. (C) IC50 values of the HMPV F cleavage site peptide mimic. 
Concentrations are in picomolar. NT = Not tested. 
A VMAX (RFU/MIN) STDEV 
TRYPSIN 135.25 17.55 
MATRIPTASE 9.24 0.39 
KLK5 5.80 0.12 
HAT 2.99 0.41 
KLK12 0.00 0.00 
PLASMIN 37.86 2.07 
   
       
B IC50 values (nM) 
IAV HA Trypsin Matriptase HAT KLK5 KLK12 Plasmin 
H1N1 HA 70.57 25.00 24.08 28.34 11.70 122.10 
H2N2 HA 155.40 NT 34.74 8.27 6.88 NT 
H3N2 HA 207.90 NT 15.33 9.54 NT 106.00 
H5N1 
HPAI HA 1135.00 194.10 NT NT NT 1166.00 
H5N1 
LPAI HA 145.80 5.32 23.56 6.38 3.66 160.10 
H6N1 HA 30.52 NT NT 29.93 14.04 NT 
H7N9 HA 20.97 8.00 NT NT NT 77.59 
H9N2 HA 99.16 9.02 12.74 11.79 NT 134.00 
       
C       
 IC50 values (nM) 
 Trypsin Matriptase HAT KLK5 KLK12 Plasmin 
HMPV F 0.04 0.0003 NT 0.95 NT NT 
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Figure 4.1: Cytotoxicity assay to evaluate the cytotoxic effect of SPINT2. 293T cells were 
incubated with indicated SPINT2 concentrations for 24 hours. DMEM and 500 µM H2O2 served as 
controls. After 24 hours cell viability was determined via a spectrophotometric assay. 
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Figure 4.2: SPINT2 inhibits cleavage of HA protein expressed in 293T cells. Cells were 
transfected with plasmids encoding for the indicated HA and allowed to express the protein for ~18 
hours. The recombinant proteases were incubated for 15 minutes with the indicated SPINT2 
concentrations and subsequently added to the cells for 10 minutes (trypsin) or 90 minutes 
(matriptase and KLK5). Western blots were performed and the HA1 band was quantified using 
ImageJ. (A) Quantification of the HA1 band comparing the signal intensity of the 0 nM SPINT2 
samples against 10 nM and 500 nM SPINT2 of the respective HA/protease combination. Three 
independent experiments were carried out and the western blots of each experiment were 
analyzed. Quantifications were conducted as described in the methods section. (B – D) Western 
blots showing the cleavage of (B) A/CA/04/09 H1N1 HA by matriptase and KLK5 at different 
SPINT2 concentration, (C) A/Aichi/2/68 H3N2 HA by KLK5 at different SPINT2 concentration and 
(D) A/Shanghai/2/2013 H7N9 HA by matriptase and KLK5 at different SPINT2 concentrations. 
Statistical analysis was performed using a non-paired student’s t-test comparing the samples tested 
with 10 nM SPINT2 against the respective sample incubated with 500 nM SPINT2. Error bars 
indicate standard deviation. * indicates p = < 0.05. 
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Figure 4.3: TMPRSS2, HAT, matriptase and KLK5 cleave HMPV F and SPINT2 is able to 
prevent cleavage by exogenous proteases. HMPV F was either expressed alone or co-
transfected with protease and allowed to express for ~ 18 hours. Cells were then metabolically 
starved of cysteine and methionine followed by radioactive S35 labeling of protein for 4 hours in 
the presence of TPCK-trypsin or specified protease. SPINT2 treated proteases were incubated at 
room temperature for 10 minutes and placed onto cells for 4 hours. Radioactive gels were 
quantified using ImageQuant software with percent cleavage equal to �� 𝐹𝐹1
𝐹𝐹0+𝐹𝐹1
� 𝑥𝑥100�. (A) and (B) 
Co-transfected proteases TMPRSS2, HAT and matriptase are able to cleave HMPV F (n=4) while 
(C) and (D) exogenous proteases KLK5 and matriptase but not KLK12 are able to cleave HMPV F 
(n=5). (E) and (F) SPINT2 prevented cleavage of HMPV F by trypsin, KLK5 and matriptase at nm 
concentrations demonstrated by the loss of the F1 cleavage product (n=3). Statistical analysis was 
performed using a one-way ANOVA followed by a student’s t-test with a bonferroni multiple 
comparisons test correction. P<0.05 *, P<0.005 **, P<0.005 ***, P<0.001 ****. N values represent 
independent replicates for each treatment group. Error bars represent SD. 
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Figure 4.4: SPINT2 inhibits HA-mediated cell-cell fusion. VERO cells were transfected with 
plasmids encoding for (A) A/CA/04/09 H1N1 HA or (B) A/Shanghai/2/2013 H7N9 HA and allowed 
to express the protein for ~18 hours. Recombinant matriptase and KLK5 were incubated with 
different SPINT2 concentrations for 15 minutes and then added to the HA-expressing cells for 3 
hours. After 3 hours the cells were briefly treated with cell fusion buffer at pH5, washed, 
supplemented with growth medium and returned to the incubator for 1 hour to allow fusion. HA 
protein was detected using HA-specific primary antibodies and a secondary fluorogenic Alexa488 
antibody. Nuclei were stained using DAPI. Magnification 40x. (C) VERO cells expressed 
A/Vietnam/1204/2004 H5N1 HA that was cleaved during its maturation process in the cell. SPINT2 
was added at 0 nM or 500 nM at the time of transfection. Magnification 25x. 
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Figure 4.5: SPINT2 reduces IAV growth in cell culture. MDCK cells were transfected with 
plasmids encoding for human matriptase or human TMPRSS2 and allowed to express the proteins 
for ~18 hours. Cells expressing human matriptase (B) or human TMPRSS2 (C) were then infected 
with A/CA/04/09 H1N1 at a MOI of 0.1 and different SPINT2 concentration were added to each 
well. Non-transfected cells to which trypsin was added served as a control (A). (D) MDCK cells 
were infected with A/X31 H3N2 at a MOI of 0.1 and trypsin was added to assist viral propagation. 
Different SPINT2 concentration was added as indicated. After 48 hours of infection the 
supernatants were collected and used for an immuno-plaque assay to determine the viral loads. 
Experiment was repeated three times and each dot represents the viral titer of a single experiment. 
Statistical analysis was performed using a non-paired student’s t-test comparing the control (0 h) 
against the respective sample. Error bars indicate standard deviation. * indicates p = < 0.05. 
Extended horizontal line within the error bars represents mean value of the three independent 
replicates. 
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Figure 4.6: SPINT2 mitigates the spread of HMPV in cell culture. VERO cells were infected with 
a MOI 1 of rgHMPV. SPINT2 and TPCK-trypsin were added at 500nM and 0.3µg/mL respectively 
and spread was monitored up to 96hpi. Cells not treated with SPINT2 demonstrated significant 
spread up through 96hpi whereas treated samples did not show any detectable virus up to 48hpi. 
However, there was minimal detected virus at 72 and 96hpi. Error bars indicate standard deviation 
of 4 independent samples completed in duplicate (all data points plotted within the graph).   
Statistical analysis was performed using a student’s t-test. P <0.05 *, P <0.005 **, P <0.005 ***, P 
<0.001 ****. ND indicates that the sample was below the limit of detection. 
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Figure 4.7: SPINT2 reduces viral growth when added 24 hours post infection. MDCK cells 
were infected with A/CA/04/09 H1N1 at a MOI of 0.1 and trypsin was added. 500nM SPINT2 were 
added at the time of infection or 24 hours post infection. Supernatants were collected 48 hours post 
infection and used for an immuno-plaque assay to determine the viral titers. Statistical analysis was 
performed using a non-paired student’s t-test comparing the control (0 h) against the respective 
sample. Error bars indicate standard deviation. * indicates p = < 0.001. Extended horizontal line 
within the error bars represents mean value of the three independent replicates. 
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Chapter 5: Respiratory syncytial virus and human metapneumovirus 
infections in 3-D airway tissues expose an interesting dichotomy in viral 
replication, spread, and inhibition by neutralizing antibodies 
* This work was completed in collaboration with Medimmune/Astrazeneca who 
provided the RSV virus and RSV antibodies used during these studies. I performed 
all experiments, data analysis, and figure creation. Dr. Carole Moncman helped 
with imaging and image processing, post fixation processing of HAE tissues, and 
data acquisition. This section was adapted from a manuscript (Kinder et al J Virol, 
2020: JVI.01068-20)  
Introduction 
Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) 
are single-stranded, negative-sense RNA (nsRNA) enveloped viruses in the 
Pneumoviridae family (18).  As leading causes for respiratory infections in children, 
95% of children by the age of two are infected with RSV (21) and nearly all are 
seropositive for HMPV by the age of 5 (30, 354). Children, immunocompromised, 
and elderly populations are at significant risk for contracting and developing severe 
lower respiratory tract infection, with infants at the greatest risk (21-23, 26, 27, 30, 
354, 391-397). While both RSV and HMPV cause severe morbidity and mortality, 
no vaccines are available and only limited treatment options exist. For RSV, the 
only FDA -approved therapy is palivizumab, a humanized monoclonal antibody 
given prophylactically to high risk infants during the infectious season (28, 29). To 
better understand how to target these viruses therapeutically, a deeper 
understanding of viral infection in physiologically relevant model systems is 
needed.  
Pneumoviruses initiate infection by attaching to target cells via their surface 
glycoproteins, the fusion protein (F) and /or the attachment protein (G), which 
interact with host receptors and attachment factors. Subsequently, F undergoes a 
large conformational change to mediate membrane fusion, after which the viral 
nucleocapsids are released into the cytoplasm of the infected cell (99, 398). This 
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membrane fusion process is critical, and inhibition of the fusion protein blocks entry 
and infection. Interestingly, both HMPV and RSV mutants lacking surface 
glycoproteins G and SH but containing F can mediate entry and infection, albeit 
attenuated to some degree (121, 123, 399, 400), demonstrating that F has a critical 
role for entry and is involved in attachment. Based on its critical role for infection, 
targeting the fusion protein is one of the most common strategies for developing 
therapeutics against HMPV and RSV (100-102, 401).  
After entering the target cell, HMPV and RSV nucleocapsids are released 
and used as templates for synthesis of viral mRNAs and genomic RNA (vRNA) by 
the viral RNA dependent RNA polymerase. Research from our lab and others 
suggests these processes occur in punctate cytosolic structures, termed inclusion 
bodies (IBs), which are minimally composed of the nucleoprotein (N), the 
phosphoprotein (P), and vRNA (251, 255). IB-like structures have also been 
described for other nsRNA viruses, including ebola virus (261, 402), marburg virus 
(262), rabies virus (256, 403), vesicular stomatitis virus (263), parainfluenza virus 
3 (264) and parainfluenza virus 5 (266), suggesting a broadly conserved 
mechanism for viral transcription and genome replication. Once newly 
synthesized-nucleocapsids assemble in IBs, they traffic to assembly sites at the 
plasma membrane. For HMPV, it has been suggested that the actin cytoskeleton 
might play a crucial role in nucleocapsid transport and inclusion body coalescence 
during infection (251), similar to what has been reported for ebola virus (404). In 
addition, the actin cytoskeleton has been reported to have a role in movement of 
ribonucleocapsids to sites of assembly in RSV and measles virus-infected cells, 
further supporting the importance of the cytoskeleton for viral infection and spread 
(320, 405, 406). After transport, the nucleocapsids coalesce with other viral 
proteins at the plasma membrane, the proposed assembly site for pneumoviruses, 
although recent research suggests a cell-to-cell dependent mechanism may play 
an important role in pneumovirus spread (407). This mechanism allows for the 
transfer of infectious particles via en bloc transmission by forming syncytia (395, 
396, 408, 409), intercellular extensions (288, 298)  or polyploid viruses (30, 84, 
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410-412) to allow for transmission of multiple genomes from one cell to another, 
compared with the traditional method of single particle release and reentry. 
HMPV has been shown to be primarily cell-associated and induce the 
formation of long, actin-based filamentous extensions, which are important for 
direct cell-to-cell spread in vitro, even in the presence of neutralizing antibodies 
(288). RSV has also been shown to form actin-based extensions involving Actin 
Related Protein-2 (ARP2) , suggesting a potential role for these structures during 
budding and spread in cell culture monolayers (298). RSV additionally induces cell-
to-cell fusion in immortalized cell monolayers, generating multinucleated cells 
termed syncytia which are also a hallmark of other enveloped virus infections 
(396). Similarly, HMPV has been shown to generate syncytia, although to a much 
lesser extent compared to RSV (413, 414). While RSV replication is enhanced 
through the formation of syncytia in vitro (301), the formation of these structures in 
animal models and patients is not well understood. A few reports have described 
the presence of syncytia in postmortem autopsies of patients infected with either 
RSV or HMPV (395, 409). Currently, the roles of intercellular extensions and 
syncytia have yet to be fully elucidated in more physiologically relevant model 
systems in order to further understand how viruses enter and spread within 
infected tissue.  
Human airway epithelial (HAE) tissues have been used previously as model 
systems to examine respiratory biology and pathogen interactions in cell culture 
(136, 143, 144, 313, 315, 316, 321-325, 327, 415-419). This model system utilizes 
primary human cells differentiated on a trans-well with an air-liquid interface to 
generate polarized bronchial epithelial tissue composed of multilayered epithelial 
cells including basal, apical ciliated, and goblet cells. This composition allows for 
a more accurate recapitulation of the lung environment including cellular 3-D 
structural organization, functional cilia, and mucus production.  This method 
provides a more accurate model system to study respiratory viruses in vitro, 
offering significant advantages compared to traditional 2-D cell monolayers (312, 
313, 319, 415, 417-420). These tissue models have been used to study both RSV 
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(143, 144, 314, 316, 319, 323-326, 420, 421) and HMPV (135, 136, 318, 333) 
infections. For RSV, HAE models have demonstrated that apical ciliated cells are 
the primary target cell, although occasional infection of non-ciliated cells was also 
observed (323, 324, 326, 421). RSV-induced syncytia, a hallmark in 2-D cell 
culture, have been observed in several HAE studies, but with varied results. No 
syncytia were reported in several studies, even up to 36 days post infection (323, 
324), whereas another study observed infrequent syncytia (326). For HMPV, very 
few studies have been conducted using HAE tissues as a model system (135, 136, 
318, 333). Consistent with findings from RSV, the primary target for HMPV is also 
apical ciliated cells (136). However, there are limited studies examining viral and 
host interactions for both HMPV and RSV in HAE tissues. 
In this work, we performed a detailed analysis of RSV and HMPV infection 
in 3-D HAE cultures, exploring aspects of the viral lifecycles that have not been 
examined previously in HAE tissues. RSV demonstrated significantly higher rates 
of infection, spread, and apical release than HMPV. Apical ciliated cells infected 
with either RSV or HMPV generated large cytosolic IBs, consisting of at least N, 
P, and vRNA, suggesting that these structures are critical replication complexes 
formed during viral infection in vivo. No syncytia formation was observed for either 
virus in our HAE studies. Interestingly, HMPV efficiently induced the formation of 
filamentous extensions in HAE cultures, while RSV formed significantly fewer 
extensions.  
Lastly, we examined monoclonal antibody inhibition of entry and spread in 
HAE tissues for RSV and HMPV. The only approved FDA treatment against RSV, 
palivizumab, was able to inhibit RSV entry and spread. We also tested nirsevimab, 
a novel monoclonal antibody against RSV that has demonstrated potent efficacy 
against RSV in 2-D cell culture and animal models (422-424). We find that in HAE 
tissues, nirsevimab is able to block entry and spread of RSV with greater potency 
than palivizumab, supporting the findings in other model systems and supports its 
potential as a novel antiviral therapeutic against RSV. The anti-HMPV antibody 
54G10 effectively inhibited the entry of HMPV but only modestly, though 
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significantly, reduced viral spread. Together, our results highlight the conserved 
and varied aspects of entry, replication, and assembly between two closely related 
pneumoviruses within HAE tissues and demonstrate an interesting dichotomy 
between HMPV and RSV and their lifecycles. 
Results 
 Both HMPV and RSV have been studied extensively in 2-D non-polarized 
monolayers to analyze virus-host interactions. RSV has also been studied in 3-D 
HAE tissues to assess viral infection and pathology (143, 144, 314, 316, 321, 324-
326, 421). In contrast, only a few reports examined HMPV in 3-D model systems 
(135, 136, 318, 333). While many important aspects of infection have identified 
been studies in 2-D cell studies, additional analysis in more physiologically relevant 
model systems is needed to further our understanding of the viral lifecycle. To 
address this, we utilized HAE tissues, a 3-D tissue model system which more 
accurately recapitulates the lung environment, including cellular polarization, 
mucus production, and functional cilia.  
To compare the two pneumoviruses, we first assessed RSV and HMPV 
infection, spread, and apical release side-by-side in HAE tissues. Tissues were 
infected with recombinant green fluorescent protein (GFP) expressing RSV-A2 
(rgRSV) or HMPV-A2 CAN97-83 (rgHMPV). At 24 hours post infection (hpi), GFP 
expression was analyzed, and showed that both HMPV and RSV initiated infection 
in this model system (Fig 5.1A). Initial infection was equivalent between both 
viruses, but HMPV infection was less efficient compared to RSV, requiring a MOI 
of 3 and 0.3 respectively to generate a comparable infection at 24 hpi (Fig 5.1B). 
We then examined viral spread within tissues as well as release from the apical 
surface up to 144 hpi. Using fluorescence threshold analysis (NIS elements) to 
quantify GFP expression, we found that RSV efficiently spreads from 24 hpi 
through 144 hpi, with the largest increase in infection seen from 24 to 48 hpi. 
However, minimal changes in spread were observed past 72 hpi, suggesting 
spread has plateaued (Fig 5.1A, quantified in 5.1C). In contrast, HMPV infected 
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cells increased significantly, but modestly, from 24 hpi to 48 hpi, followed by a 
decrease from 72 hpi to 144 hpi, with minimal infection remaining at later time 
points (Fig 5.1A, quantified in 5.1C). Analysis of apical release of viral particles 
showed a 3-log difference in the amount of released virus at 24 hpi between HMPV 
and RSV, even though the number of infected cells were similar between the two 
viruses (Fig 5.1B and 5.1D). In addition, there was no detectable release of HMPV 
after 24 hpi. This result demonstrates a rapid spread and sustained release of high 
titers of RSV particles from the apical surface whereas HMPV spread and particle 
release was minimal at all time points with a decrease in spread after 48 hpi.  
 Previously, both RSV (323, 324, 326, 421) and HMPV (136) were reported 
to primarily infect apical ciliated cells in HAE cultures. To verify this in our side-by-
side analysis, infected tissues were cryo-sectioned and stained for keratan sulfate 
(KS), a marker for ciliated airway cells. RSV and HMPV both exclusively infected 
ciliated cells, confirming this as the primary target cell type for both pneumoviruses 
(Fig 5.1E). In a few instances, infected cells appeared below the apical surface. 
However, staining with KS demonstrated that these cells were ciliated, though they 
had not yet reached the apical surface. Based on these findings, the minimal 
spread and release of HMPV compared to RSV cannot be attributed to a difference 
in the type of cells infected, or the initial rates of infection. Therefore, we examined 
other aspects of the viral lifecycle to better understand how both viruses interact 
with host cells during infection.  
HMPV and RSV induce the formation of replicative inclusion bodies 
The formation of inclusion bodies (IBs) in 2-D cell monolayers has been 
shown to be critical for viral genome replication and transcription for HMPV and 
RSV (251, 255). However, to our knowledge, the presence of IBs has not been 
examined in 3-D HAE tissues or in vivo. To verify these structures are found in 
HAE infected tissues and to assess whether differences in the early stages of 
infection were observed for RSV and HMPV, we examined the formation of IBs by 
fluorescently staining RSV or HMPV N and P proteins, the minimal components 
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required for IB-like structure formation (252, 253). Co-localization of both N and P 
proteins was observed in cytoplasmic structures for RSV (Fig 5.2A and 5.2B) and 
HMPV (Fig 5.3A and 5.3B) suggesting that IBs form in infected HAE tissues.  
To confirm these structures were IBs, we conducted fluorescence in situ 
hybridization (FISH) staining for vRNA, known to be localized to IBs during 
infection of 2-D cells (251, 255). We observed strong co-localization of N and P for 
both RSV (Fig 5.2C- 5.2F) and HMPV (Fig. 5.3C-5.3F) with their respective signal 
of vRNA, confirming the formation of IBs in infected tissues for both viruses. These 
findings are, to our knowledge, the first report of the formation of these structures 
in 3-D HAE tissues for both RSV and HMPV, and thus strongly support the 
hypothesis that these structures are critical for replication and spread of the viruses 
in 3-D models and likely in vivo, thus providing a viable therapeutic target for 
pneumoviruses.  
N, P and vRNA had strong colocalization at inclusion bodies and at the 
plasma membrane, suggesting the coalescence of these viral factors at sites of 
assembly for both RSV and HMPV. In addition, P also demonstrated localization 
at the plasma membrane independently of N and vRNA, often associated with cilia-
like structures at the apical surface for both RSV and HMPV infected cells. 
However, the presence of P at these sites was much stronger for RSV compared 
to HMPV. P has been previously reported to associate with IBs and the plasma 
membrane to form extensions for HMPV (288) and in proposed assembly 
complexes  for RSV (425), which is supported by our findings. These suggest that 
differences seen in spread dynamics of the viruses are not a result of differences 
in the ability to cause initial infection or generate replicative structures.   
HMPV and RSV form extensions but no syncytia in HAE tissues 
There are numerous reports of actin cytoskeletal involvement in infectious 
cycles for both HMPV (288, 335, 426) and RSV (298, 427-431). We have 
previously shown that HMPV forms actin-based extensions, which were identified 
as a mechanism for direct cell-to-cell spread in BEAS-2B bronchial epithelial cells 
82 
 
(288). HMPV P co-localized with actin, and transient expression of P alone 
recapitulated some extension formation. Recent reports examining RSV 
demonstrated that viral infection leads to the formation of actin-based extensions 
in A549 cells (298). RSV-induced extensions were suggested to be filopodia and 
could be induced by the expression of F alone. Additionally, disruption of actin 
architecture in RSV infected cells decreased viral spread, suggesting that these 
extensions are critical for infecting new cells.  
To compare the formation of actin-based extensions between the two 
pneumoviruses in different cell types, we infected Vero (monkey kidney), HEp-2 
(human laryngeal carcinoma) and BEAS-2B (human bronchial epithelial, non-
diseased) cells and analyzed extension formation. For all three cell types, both 
RSV (Fig 5.4A) and HMPV (Fig 5.4B) induced the formation of filamentous 
extensions at 24 hpi. Interestingly, a previous study did not observe extension 
formation in RSV-infected Vero cells (298). These differences may be, due in part, 
to other factors such as reagents or cell culture methodology.  
We next examined extension formation of RSV and HMPV in 3-D HAE 
tissues. When phenotypically examining cross-sections of HAE tissues, HMPV-
infected cells demonstrated a high percentage of extensions compared with RSV, 
where only a small number of infected cells with extensions were observed for 
RSV (Fig 5.4C). RSV and HMPV-induced extensions had similar morphology, but 
were infrequent in RSV-infected HAE tissues. The presence of extensions in HAE 
tissues was further confirmed by microtome sectioning two full tissues at the peak 
of infection with either HMPV (48 hpi) or RSV (72 hpi). Extensions were defined 
and counted as thin protrusions extending from the cell body which were ≥ 0.5 of 
the cell body diameter. For HMPV, 35.8% of infected cells contained extensions 
(1541 total infected cells counted), while only 4.4% of RSV infected cells had 
extensions (3859 total infected cells counted) (Fig 5.4D). Although both RSV and 
HMPV have been shown to extensively modify the actin cytoskeleton in non-
polarized cell monolayers, RSV rarely forms extensions in HAE tissues, suggesting 
these extensions are less important for infection and propagation in vivo. 
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Conversely, HMPV generated intercellular extensions in both 2-D and 3-D model 
systems, supporting the idea that HMPV is primarily cell-associated and may utilize 
extensions for direct cell-to-cell spread (288).  
A hallmark characteristic of RSV infection is the formation of multinucleated 
cells, termed syncytia, which has been shown to be prominent in 2-D cell 
monolayers. For HMPV, syncytia formation is less common compared with RSV, 
but is observed in 2-D culture (241, 413). Studies on RSV-mediated syncytia  
formation in HAE tissues have been inconclusive (321), while for HMPV, no reports 
have reported  formation in HAE models for HMPV. At the peak of infection for 
both RSV (72 hpi) and HMPV (48 hpi), we examined syncytia formation in two fully 
microtome sectioned HAE tissues. Interestingly, no syncytia were observed for 
HMPV or RSV in either tissue examined nor was syncytia visible from the apical 
side. However, the lack of syncytia did not hinder the infectivity or spread of RSV. 
Since cell-to-cell fusion for both viruses is mediated by the fusion glycoprotein, we 
examined the localization of F in cryo-sections using immunofluorescence staining 
to determine if this finding was due to the localization of the F proteins. RSV F was 
predominantly localized to the apical surface of infected cells but was also present 
within extensions and throughout the infected cell, with a similar staining pattern 
observed for HMPV F (Fig 5.4C). Since both viral fusion proteins were present at 
locations beyond the apical surface, there are likely other variables that may 
contribute to the lack of syncytia formation for HMPV and RSV. Further 
investigation into the mechanisms that underlie fusion in tissues is required to 
better understand the factors that contribute to this phenomenon and whether 
syncytia formation impacts viral replication and spread in vivo. 
 Nirsevimab, palivizumab and 54G10 block viral entry and spread in HAE 
tissues 
Recently, a novel monoclonal anti-F antibody, nirsevimab, showed 
significantly more potent neutralizing capacity in 2-D cultures and animal models 
with an extended serum half-life compared with palivizumab (422, 423, 432). 
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Conversely, no FDA approved anti-F antibodies are available against HMPV, but 
a neutralizing monoclonal antibody, 54G10, has been described that has sub-
nanomolar efficacy in vitro against all clades of HMPV and also has cross reactivity 
to RSV, although efficacy against RSV is 6x less potent compared with 
palivizumab (340). To better understand how HMPV and RSV infection might be 
targeted in HAE tissues, we compared nirsevimab and palivizumab for RSV, and 
54G10 for HMPV, for their ability to inhibit viral entry and spread in 3-D HAE 
tissues. 
We first conducted a microneutralization assay to assess the neutralizing 
capacity of palivizumab and nirsevimab on RSV in HAE tissues. We pre-incubated 
the virus in the presence or absence of neutralizing antibody for 1 hour and then 
inoculated tissues at the apical surface. As expected, both nirsevimab and 
palivizumab were able to completely neutralize RSV entry at a concentration of 0.5 
µg/mL and 10 µg/mL respectively (Fig 5.5A and 5.5B).  Congruent with previous 
findings, nirsevimab demonstrated significantly higher neutralizing potency 
compared with palivizumab (approximately 20-fold) (Fig 5.5C). Similarly, 54G10 
demonstrated a complete block of infection at 10 µg/mL (Fig 5.6A and 5.6B, 
quantified in 5.6C), indicating therapeutic potential for 54G10 against HMPV.   
The effect of neutralizing antibodies on RSV and HMPV spread at the apical 
surface of tissues after infection was examined. We inoculated tissues at the apical 
surface with RSV or HMPV and then monitored fluorescence after infection. RSV 
infection alone had a significant increase in spread from 24 hpi through 72 hpi (Fig 
5.1A, 5.1B, 5.7A-5.7C). In the presence of palivizumab and nirsevimab, RSV 
spread was almost completely inhibited compared with the 24 hpi time point, 
demonstrating that RSV spread occurs mostly through apical release and reentry 
which can be blocked by antibody present at the apical surface. Our results also 
confirm previous observations for palivizumab and its ability to prevent spread in 
HAE tissues (324). Nirsevimab again demonstrated a significantly higher potency 
(approximately 10-fold) compared with palivizumab, showing similar inhibition of 
spread at lower concentrations (Fig 5.7A-5.7C).   
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  We also examined 54G10 inhibition of HMPV spread from 24 hpi through 
48 hpi. There was a modest, but statistically significant inhibition in HMPV spread 
with increasing amounts of 54G10 (Fig. 5.8A-5.8C). Spread in the presence of 2.5 
µg/mL and 25 µg/mL of neutralizing antibody was only reduced by 25%, 
suggesting that a large fraction of HMPV spread likely still occurs via a direct cell-
to-cell transmission mechanism likely utilizing extensions as shown in 2-D cell 
monolayers (288). Further investigation into the mechanisms for HMPV cell-to-cell 
spread in 3-D tissues will help to elucidate how HMPV spread can be targeted 
therapeutically. Altogether, our results indicate the mechanisms by which 
neutralizing antibodies act to prevent RSV infections, although, a different strategy 
may be needed to fully inhibit HMPV spread.  
Discussion 
In this study, we conducted a comparative analysis of HMPV and RSV 
infection in HAE tissues. Altogether, our results demonstrate that two closely 
related human respiratory pathogens may utilize significantly different 
mechanisms of spread in a 3-D model system. RSV can infect, replicate, and 
release large amounts of virus apically, resulting in very efficient spread. In striking 
contrast, HMPV is also able to infect ciliated cells in the HAE tissue, and productive 
establishment of replication centers is seen, as judged by production of viral RNA, 
but little apical release of virus was observed, leading to poor spread in this system.  
Initial infection mediated by HMPV required higher MOIs to achieve similar 
infection rates, suggesting that RSV infects HAE tissues more efficiently than 
HMPV. RSV spread in HAE tissues increased significantly from 24 hpi up to 72 
hpi, compared with HMPV which reached a peak of infection at 48 hpi and 
significantly decreased thereafter. HMPV has been demonstrated to establish 
persistent infection (75, 433-437). Thus, it is possible that the low replication rates 
of HMPV in HAE tissues may drive the virus toward persistence rather than an 
acute infection. In support of this, HMPV peaked at 48 hpi but a low, residual 
infection was present up to 144 hpi. When examining infected tissues, both HMPV 
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and RSV primarily infected apical ciliated cells, as previously demonstrated (136, 
319, 321, 324). Therefore, the differences observed in entry and replication 
between HMPV and RSV do not appear to be due to the cell types infected. A 
recent publication utilized HMPV CAN97-82 (B strain) infection in human airway 
epithelium obtained from nasal biopsies and showed limited apical release up to 
five days post-infection (318). These studies and ours suggest strain differences 
may affect how HAE tissues release and spread virus to some degree. The 
presence of both the HMPV SH and G proteins, as well as the strain used, was 
recently reported to impact spread in HAE tissues (135), with the deletion of HMPV 
G especially deleterious. Interestingly, HMPV infection occurred at a higher level 
in these studies and further investigation is needed to understand differences 
involved in efficient HMPV entry in 3-D tissues (135, 136, 318, 333) . 
Once cells have been infected, both HMPV and RSV form IBs. The 
formation and characterization of these replication organelles in 2-D model 
systems have been previously reported (251, 255), but IB formation has not been 
previously examined in 3-D tissues. We showed that these IB structures form 
within HAE-infected cells and contain markers for IBs, including P, N and viral 
RNA. This is the first report of the formation of these structures in 3-D HAE tissues 
for both RSV and HMPV, and suggests these structures are broadly important for 
pneumovirus infection. As these structures appear in 2-D models for a number of 
negative-sense, single-stranded RNA viruses (251, 256, 261-264, 266, 402, 403), 
identifying and understanding critical host and viral components of these 
organelles may provide a unique anti-viral approach against a wide range of 
human viral pathogens. 
Recent reports have shown both RSV and HMPV form actin-based 
filamentous structures, important for viral spread within 2-D monolayers (288, 298). 
Viral titer for RSV was significantly reduced when these structures were inhibited 
(298). For HMPV, these filamentous structures were shown to be involved in cell-
to-cell spread of the virus, independent of neutralizing antibodies in BEAS-2B cells. 
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Similar to RSV, when these cytoskeletal structures are inhibited, viral spread was 
significantly reduced (288). 
To assess the importance of cellular polarization on extension formation in 
2-D monolayers, we examined extensions formation in 3-D HAE tissues. 
Interestingly, extensions similar to those observed in 2-D cells were also detected 
in approximately a third of HMPV-infected cells within HAE tissues, whereas RSV-
infected cells had few extensions. Thus, we hypothesize that infection by RSV 
relies primarily on abundant release of particles from the apical side of tissues and 
re-infection of new target cells. However, the low apical release of virus and high 
percentage of cells with extensions suggests that HMPV infection of new target 
cells is likely dependent primarily on direct cell-to-cell contacts, similar to previous 
findings in 2-D models. Furthermore, HMPV was also demonstrated to be primarily 
associated with minimal release, and therefore extensions may be the primary 
mechanism of spread (288). However, even with the formation of extensions, 
spread of HMPV was minimal, suggesting that additional factors may be needed 
for efficient cell-to-cell spread in HAE tissues.  
RSV forms large, multinucleated cells termed syncytia, which are a hallmark 
of infection in 2-D monolayers. In addition, while not as prominent, HMPV also 
mediates cell-to-cell fusion during monolayer infection (413, 414). Some studies 
have indicated that RSV can form minimal and infrequent syncytia in HAE tissues; 
however, there are conflicting results (314, 321). Analysis of lung autopsy 
specimens for both viruses suggested that syncytia formation can occur in vivo 
(395, 409). We were unable to identify any syncytia in either the fully sectioned 
tissues or apical images for RSV or HMPV. Studies in polarized cell monolayers 
or in HAE tissues demonstrated that RSV F was primarily localized to the apical 
surface (321, 438). Here, we also found that RSV and HMPV F were primarily 
localized to the apical surface. In addition, we also observed the presence of 
staining at the basolateral portion of infected cells. Other factors for cell-to-cell 
fusion may be required in order to mediate the formation of syncytia in addition to 
the cellular distribution of F. It is also unknown if syncytia formation is beneficial 
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for viral replication. A RSV strain containing a hyperfusogenic fusion protein led to 
larger syncytia in 2-D monolayers and higher pathogenesis in vivo, suggesting that 
higher fusion is beneficial for viral replication and spread (301).  
One caveat in HAE tissues that is different from in vivo studies is the lack 
of immune cells, which play a major role during infection. Their absence may 
contribute to our observations related to initial infection rate, apical release, spread 
kinetics, and lack of cytopathic effects. The inflammatory response has been 
suggested to be important for RSV infection (439), and may also play roles in 
HMPV infection as well. The inflammatory response yields damage to the lung 
epithelium layer, which may expose proteins and other factors present in tight 
junctions, not normally accessible to the virus (440, 441), and this could aid in 
HMPV spread. Further experiments are needed to understand how immune cells 
and the inflammatory response could modulate HMPV infection of airways.  
Lastly, therapeutic monoclonal antibodies against RSV and HMPV were 
evaluated for their inhibition of viral infection and spread in this study. Pre-
incubation of RSV with palivizumab or nirsevimab showed neutralization and 
spread inhibition for RSV in HAE tissues. Nirsevimab demonstrated a significantly 
higher neutralizing capacity compared to palivizumab (423). These results confirm 
the potential for nirsevimab, which is currently in late stage clinical study, for 
immunoprophylaxis against RSV. Studies in 2-D in vitro cultures and in vivo studies 
has demonstrated increased efficacy and potency against RSV compared with the 
only available therapeutic, palivizumab (422, 423, 432), which are further 
supported by the results of this study.  
We also examined the effect of 54G10, a potent neutralizing monoclonal 
antibody against HMPV F (340) for inhibition HMPV infection and spread in HAE. 
Pre-incubation of HMPV with 54G10 at a concentration of 5 µg/mL completely 
inhibited viral entry. However, spread was only modestly, but significantly at 2.5 
µg/mL and increasing the concentration of 54G10 to 25 µg/mL did not result in 
further spread reduction.  These results suggest that at least a portion of HMPV 
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spread in HAE tissues may occur by a neutralizing antibody-independent cell-to-
cell mechanism. Thus, targeting the F protein of HMPV may not be the most 
effective antiviral therapy. The RSV and HMPV antibodies have different potencies 
in 2-D cell culture and bind the F protein at different sites (palivizumab: site II, 
nirsevimab: site 0 and 54G10: site IV). It is unclear if the modest inhibition of spread 
by 54G10 is related to a certain F binding mechanism of action. Future studies 
evaluating a large panel of antibodies could help to determine if this phenomenon 
is specific for HMPV or related to F protein binding.  
While this study furthers our understanding of two important respiratory 
pathogens in a more physiologically relevant model, there is further research 
needed to characterize pneumovirus infection. Here, we utilize A2 subtypes of both 
HMPV and RSV to model viral replication in HAE tissues. However, it is possible 
there is strain-to-strain variation which can only be determined with additional 
studies in this model system. We also exploited monoclonal antibodies to 
understand entry and spread of RSV and HMPV in HAE tissues and examined the 
efficacy these antibodies as potential antiviral therapeutics. However, additional 
antibodies against both RSV and HMPV should be analyzed to determine which 
viral protein sites are more important to entry and spread and use this information 
to identify optimal sites for antiviral targets. HAE tissues offer a unique model 
system to better understand viral infection in 3-D human tissue using an in vitro 
culture method, with caveats. An important role of the respiratory tract is a 
protective barrier for invading pathogens. In response, the lung signals the immune 
system to fight infection. This results in the inhibition and clearance of infection, 
but also generates tissue damage as a result of inflammation and infection. This 
critical aspect is absent in the HAE system and therefore, this level of complexity 
is inaccessible using this method. 
Altogether, these results demonstrate a significant dichotomy between two 
very closely related pneumoviruses and illustrate important aspects of their viral 
lifecycles. RSV spreads primarily through release and re-entry of viral particles. 
Current approaches to combat RSV entry and spread by targeting the F protein 
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are a promising avenue for RSV antiviral therapeutics. However, HMPV spread is 
poorly affected via this approach, suggesting other aspects of viral lifecycle may 
be more effective. Both RSV and HMPV, in addition to other nsRNA viruses, form 
punctate replication organelles in the cytoplasm of infected cells. It is possible 
that targeting components involved in the formation and maintenance of these 
viral organelles may prove to be a potent, broad spectrum antiviral for many 
significant viral pathogens. As there are limited studies analyzing these 
structures, more research is needed to better understand their formation, 
function, and key role in viral replication. 
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Figure 5.1: RSV and HMPV infection, spread and release in HAE tissues. (A) HAE tissues were 
infected with MOI 0.3 of rgRSV or MOI 3.0 of rgHMPV, and initial infection and spread was 
examined up to 144 hours post infection (HPI). (B) RSV and HMPV infection at 24hpi time point 
(C) Spread analysis of HMPV and RSV were determined using fluorescence threshold analysis. 
(D) Apical release of virus was determined by washing the apical surface of HAE tissues, titering 
the viral wash in 2-D monolayers, and calculating fluorescence-forming units (FFU).  (E) Infected 
cells for HMPV (48hpi) and RSV (72hpi) were stained for actin cytoskeleton, as well as keratan 
sulfate (KS) to stain for ciliated cells. Error bars represent SEM of 6 different tissues. Scale bar = 
10µm. 
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Figure 5.2: RSV inclusion body formation in HAE. (A) HAE tissues were infected with rgRSV 
and stained for the nucleoprotein, N, and phosphoprotein, P, to assess the formation of inclusion 
bodies in HAE tissues. (B) Co-localization of N and P was analyzed using co-localization 
chromatography from NIS elements. (C) To confirm inclusion body formation in HAE tissues, FISH 
analysis was conducted to label vRNA. (D) Both vRNA and RSV N colocalize to cytosolic punctate 
structures in infected cells. (E) vRNA was also assessed in relation to RSV using fluorescence 
microscopy. (F) Chromatogram analysis demonstrates that P and vRNA co-localize with one 
another in infected cells. Scale bar = 10µm for combined images with DIC and 5µm for fluorescence 
insets. Arrows indicate the cross-section measurement for the corresponding chromatograms. 
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Figure 5.3: HMPV inclusion body formation in HAE. (A) HAE tissues were infected with rgHMPV 
and stained for the nucleoprotein, N, and phosphoprotein, P, to determine the formation of inclusion 
bodies in HAE tissues. (B) Co-localization of N and P was analyzed using co-localization 
chromatography from NIS elements. (C) To confirm inclusion body formation in HAE tissues, FISH 
analysis was conducted to label vRNA. (D) Both vRNA and HMPV N colocalize to cytosolic punctate 
structures in infected cells. (E) vRNA was also assessed in relation to HMPV using fluorescence 
microscopy. (F) Chromatogram analysis demonstrates that P and vRNA co-localize with one 
another in infected cells. Scale bar = 10µm for combined images with DIC and 5µm for fluorescence 
insets. Arrows indicate the cross-section measurement for the corresponding chromatograms. 
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Figure 5.4: HMPV forms intercellular extensions significantly more than RSV. BEAS-2B, Vero 
and HEp-2 cells infected with rgRSV (A) or rgHMPV (B) demonstrate the formation of long 
filamentous extensions. (C) HAE tissues infected with either rgRSV or rgHMPV demonstrate the 
formation of these filamentous extensions in a 3-D model system. (D) Extension formation is 
significantly more common in rgHMPV infected tissues compared with those infected with rgRSV. 
Statistical significance represented with p<0.05 *, P<0.005 **, P<0.0005 *** and P<0.0001 ****. 
Scale bar = 25µm for 2-D cell culture and 10µm for HAE tissues, 5 µm for higher magnification 
insets.  
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Figure 5.5: Nirsevimab and palivizumab inhibition of RSV entry. (A) HAE tissues were infected 
with rgRSV at MOI 1.0 preincubated with or without palivizumab (pali) or nirsevimab (nirsevi) for 1 
hour at 37°C. After 48hours post infection, fluorescence was examined by inverted or confocal 
microscopy to determine inhibition of infection as well as microtome cross sections (B) of infected 
tissues to examine infection inhibition. (C) Threshold analysis of inverted fluorescence microscopy 
images were quantified using ImageJ adaptive threshold analysis. Scale bar = 10µm. Error bars 
represent SEM of 4-6 tissues for each treatment group.  
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Figure 5.6: 54G10 inhibition of HMPV entry. (A) HAE tissues were infected with rgHMPV at MOI 
3.0 preincubated with or without 54G10 for 1 hour at 25°C. After 48hours post infection, 
fluorescence was examined by inverted or confocal microscopy to determine inhibition of infection 
(B) as well as microtome cross sections of infected tissues to examine infection inhibition. (C) 
Threshold analysis of inverted fluorescence microscopy images were quantified using ImageJ 
adaptive threshold analysis. Scale bar = 10µm. Error bars represent SEM of 4-6 tissues for each 
treatment group.  
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Figure 5.7: Nirsevimab inhibits spread significantly more potently than palivizumab. (A) HAE 
tissues were infected with rgRSV at MOI of 0.3. Tissues were treated apically with either 
palivizumab or nirsevimab 6 hours post inoculation in 50µL of TEER buffer. Fluorescence 
microscopy images were taken up to 72 hours post infection. (B) Tissues were fixed at 72hpi and 
microtome-sectioned for each treatment group and examined for viral spread. (C) Fluorescence 
threshold analysis of inverted fluorescence microscopy images demonstrate that both pali and 
nirsevi are able to prevent the spread of rgRSV in HAE-infected tissues, with nirsevi able to inhibit 
spread at lower concentrations compared with pali. Scale bar = 10um. Error bars represent SEM 
of 6 tissues per treatment group. Statistical significance represented with p<0.05 *, P<0.005 **, 
P<0.0005 *** and P<0.0001 ****. 
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Figure 5.8: 54G10 significantly inhibits spread of HMPV. (A) HAE tissues were infected with 
rgHMPV at MOI of 3.0. Tissues were treated apically with 54G10 6 hours post inoculation in 50µL 
of TEER buffer. Fluorescence microscopy images were taken up to 72 hours post infection. (B) 
Tissues were fixed at 48hpi and microtome-sectioned for each treatment group and examined for 
viral spread. (C) Fluorescence threshold analysis of inverted fluorescence microscopy images 
demonstrate that 54G10 modestly but significantly prevents the spread of rgHMPV in HAE infected 
tissues. Scale bar = 10µm. Error bars represent SEM of 6 tissues per treatment group. Statistical 
significance represented with p<0.05 *, P<0.005 **, P<0.0005 *** and P<0.0001 ****. 
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Chapter 6: RSV and HMPV viral co-infections 
* This chapter was completed with the help of Dr. Nicolas Cifuentes and Rachel 
Thompson. Nicolas and Rachel generated the transfection inclusion body counts 
(Figure 6.5) and Nicolas generated the recombinant mCherry virus for HMPV, 
examined the co-infection potential over time, and conducted microscopy (Figure 
6.1-6.4). I generated all figures as well as performed experiments in figure 6.6. 
Nicolas contributed to the initial drafts of the written portion.  
Introduction 
The Pneumoviridae is a recently created viral family that harbors two 
important pediatric respiratory pathogens, human metapneumovirus (HMPV) and 
respiratory syncytial virus (RSV) (18). Pneumoviruses cause upper and lower 
respiratory tract infections, symptomatically presenting as a mild cold-like disease 
which can progress to severe pneumonia and bronchiolitis (21-23, 26, 27, 30, 354, 
391-397). Despite the high prevalence of these viruses, no FDA-approved 
vaccines are available against either RSV or HMPV. Only one prophylactic 
therapeutic, palivizumab, is available for RSV (28, 29), and none are available 
against HMPV. However, palivizumab is given only to high risk infants born during 
the infectious season. An important, yet highly understudied feature of 
pneumoviruses is the occurrence of viral co-infections, which have been 
associated in some cases with a more severe outcome of the disease for these 
two viruses (38, 40).   
Pneumovirus particles are enveloped and contain a non-segmented, 
negative-sense single-stranded RNA genome (nsNSV) coated by the 
nucleoprotein (N), giving rise to helical nucleocapsids (442, 443). The 
nucleoprotein interacts with the viral phosphoprotein (P), which recruits both the 
large RNA-dependent RNA-polymerase (L) and the M2-1 protein onto 
nucleocapsids forming the replication complex. During initial infection, a 
membrane fusion step mediated by the viral surface glycoproteins allows entry into 
target cells, releasing the viral nucleocapsids into the cell cytoplasm. The viral 
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RNA-dependent RNA polymerase then initiates transcription and replication of the 
viral genome to generate messenger RNA (mRNAs) as well as the genomic RNA 
(vRNA) (444). An important feature observed in pneumovirus infected cells is the 
formation of perinuclear structures named inclusion bodies (IBs) (251, 445). The 
available evidence indicates that IBs are the sites of pneumovirus genome 
transcription and replication, producing both genomic material for viral particle 
formation and mRNA for viral protein production (251, 254, 255, 445, 446). 
Additional robust evidence linking IBs to genome transcription and replication has 
been reported for other nsNSVs including rhabdoviruses (256, 263), filoviruses 
(261, 262, 447) and paramyxoviruses (264, 266), further supporting an important 
role for IBs in viral infections within the negative sense RNA viruses.  
Here, we explored the dynamics of co-infections by RSV and HMPV in 
immortalized cell lines. Infection experiments using both viruses showed the 
population of HMPV-RSV co-infected cells was only a minor fraction of the total 
infected cells and required significantly more HMPV compared to RSV. However, 
the fraction of co-infected cells did show increases over time. Interestingly in co-
infected cells, we found the presence of IBs with positive co-localizing signal for 
both HMPV and RSV genomes, suggesting that replication and transcription of 
both viruses can occur in the same specialized compartment. We recapitulated IB 
formation by homologous and heterologous co-expression of pneumovirus N and 
P proteins and found that HMPV P can complement RSV N to facilitate IB 
formation. However, various permutations of N and P proteins yielded changes in 
the minigenome replication efficiency for both viruses. Furthermore, using a 
minigenome replication assay, we find that RSV N and P are able to partially 
complement replication in addition to HMPV proteins and genome, but are less 
efficient compared with homologous HMPV protein expression only. Conversely, 
RSV again showed significant replication deficiency when HMPV N and P are 
present, supporting a potential dominant negative phenotype where HMPV 
interferes with RSV replication. To our knowledge, this is the first demonstration of 
pneumovirus coinfections at a cellular level, providing new insights into the 
consequences of viral coinfections in vivo. 
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Results and Discussion 
HMPV and RSV coinfections in immortalized cell lines 
To quantitatively evaluate the frequency of HMPV-RSV co-infections by flow 
cytometry, we created a recombinant HMPV carrying a mCherry cassette, located 
between the N and P genes (Fig 6.1A). The recombinant virus, named rJPS02-
76mCherry (denoted rmcHMPV), was grown in the presence of TPCK-trypsin to 
titers comparable to the previously reported rJPS02-76EGFP (192) (Fig 6.1B). 
Human bronchial epithelial cells (BEAS2B) were infected with the rmcHMPV, with 
a recombinant RSV carrying a GFP cassette (denoted rgRSV), or with 
combinations of both at different multiplicities of infection (MOI), with infection by 
both viruses carried out at the same time. The presence of coinfected cells was 
initially evaluated by microscopy at 24, 48 and 72 hpi and subsequently analysed 
by flow cytometry. Initially, we evaluated singly infected cells in three different cell 
types: LLC-MK2, Vero, and BEAS-2B, to understand infection and spread kinetics 
for each virus. rmcHMPV demonstrated a more robust infection and spread in LLC-
MK2 cells compared with both BEAS-2B or Vero cells, and the percent of infected 
cells increased through 72hpi (Fig 6.2A). This result was not surprising since 
HMPV has been described as a poor growing virus in vitro, and some cell lines 
including BEAS2B are not as suitable for viral growth and Veros show lower 
kinetics compared with LLC-MK2 (448). For RSV, LLC-MK2 and Vero cells 
demonstrated similar percentage of infection and rates of spread, but BEAS-2B 
cells again showed decreased permissiveness to infection and increased cell 
death was observed at late times of infection when high MOIs were used (Fig 
6.2B).  
 
To examine for cells co-infected with HMPV and RSV, the levels of HMPV 
were kept at a constant MOI of 1, and RSV was used at MOIs of 0.01, 0.1 or 1.  
The highest levels of co-infected cells were observed when using infection ratios 
of 1:1 of HMPV to RSV in BEAS-2B cells, but with much lower percentages of co-
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infected cells observed when less RSV was used (Fig 6.3A). When examining 
infection in Vero and LLC-MK2 cells, we observed a relatively low number of co-
infected cells similar to that observed in BEAS-2B, although more abundant in 
comparison. (Fig 6.3A). By 48 and 72 hpi, the number of co-infected cells 
increased significantly, indicative of viral spread through infection a naïve cell or 
entry of one virus into a cell previously infected by another virus (Fig 6.3B). In 
addition, singly infected HMPV cells were almost undetectable at 72hpi, but the 
total number of co-infected cells observed suggests that HMPV is still able to 
spread, but eventually, almost all HMPV infected cells are present in a co-infection. 
When analysing co-infections of singly vs co-infected cells infected at the same 
time, RSV demonstrated a decrease in the number of infected cells at 24hpi. This 
suggests that the presence of HMPV significantly alters initial entry and replication 
of RSV, but is unaffected at later times post infection. Conversely, HMPV appears 
to be unaffected and the infection percentage at 24hpi remains largely unchanged. 
This phenomenon of viral interference has been reported for other viruses and 
remains poorly understood (449-451), but offers one explanation for our 
observations during co-infection. Similar reductions in viral loads were reported 
clinically for co-infections of RSV and HMPV as well, further supporting our 
observations in vitro (452-454).. 
HMPV and RSV heterologous protein complementation 
In order to better understand how these viruses are interacting, we first 
examined co-infected cells in detail beginning with effects on replication. We 
conducted fluorescence in situ hybridization (FISH), using probes that hybridize to 
either the vRNA from HMPV or the vRNA from RSV. Different patterns of vRNA 
signals were found in co-infected cells, the most striking being the colocalization 
of signals in structures that resemble what has been described as IBs (Fig 6.4). Z-
stack analysis demonstrated that signals of vRNA from both viruses occupied the 
same location within co-infected cells (Fig 6.4). One intriguing possibility for the 
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observed co-localization is the heterologous complementation of viral proteins for 
IB formation and/or RNA synthesis.  
For pneumoviruses, IB formation can be minimally recapitulated by 
homologous expression of P and N (254, 455), therefore, we decided to test if 
heterologous protein expression between viruses would complement IB formation. 
As a control, HMPV N and P, as well as RSV N and P, were verified to induce 
formation of IBs when co-expressed in Vero cells. Interestingly, a significant 
percentage of cells expressing HMPV P and RSV N still formed IBs, while cells 
expressing HMPV N and RSV P formed no IB-like structures (Fig 6.5). In order to 
test if heterologous proteins could be incorporated into already formed IBs, triple 
transfections were performed. Upon HMPV N and P co-expression, the additional 
expression of either RSV N or P had a strong deleterious effect on IB formation, 
appearing to act in a dominate negative mechanism (Fig 6.5). Instead of large IBs 
(>500nm), cells displayed speckles, consisting of small and abundant cytosolic 
puncta for both signals but significantly smaller in size (<500nm) compared to 
normal IBs. In contrast, RSV N and P still formed IBs in the presence of either 
HMPV N or P, though to reduced levels (Fig 6.5). However, these experiments are 
preliminary, and more investigation is needed to better understand the effects of 
protein complementation for both viruses on IB formation. 
 To further examine the functional consequences of heterologous IB 
formation, we employed HMPV and RSV mini-replicon assays. Here, the 3’ leader 
region from the viral genomic RNA is placed in front of a luciferase reporter. 
Successful binding and initiation by the viral replication complex results in the 
production of luciferase transcript, resulting in luciferase protein production which 
can be measured quantitatively.  Heterologous expression of RSV N or P in place 
of HMPV proteins in the mini-replicon assay resulted no replication, suggesting 
these are not able to take the place of the cognate protein of HMPV. However, 
expression of both RSV N and P did result in a 10% increase in luciferase activity, 
which indicates that heterologous IBs were functional, but significantly less than 
cognate protein expression (Fig 6.6A). Similarly, when examining HMPV N or P 
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expression in the RSV mini-replicon assay, single complementation of N or P 
resulted in no luciferase activity whereas both HMPV N and P expression resulted 
in a 10% increase in luciferase activity (Fig 6.6B). Lastly, we conducted mini-
replicon assays using all HMPV proteins and co-expressed RSV N, P or all 4 of 
the RSV proteins (including M2-1 and L) to determine if there were synergistic or 
dominant negative effects on replication. Compared with the HMPV proteins alone, 
addition of RSV P mildly decreased replication by 20%, whereas the addition of N 
decreased it to nearly 50%. Co-expression of N/P from RSV or the addition of all 
mini-genome components resulted in only 30% reduction in replication, suggesting 
that RSV proteins do not completely inhibit HMPV replication, but these 
components are less efficient in comparison. Conversely, the addition of any 
HMPV components to the RSV mini-replicon resulted in significant reduction of 
RSV replication to 20% compared with RSV components alone, suggesting HMPV 
proteins are able to act in a dominant negative fashion instead of complementation, 
where they inhibit the function of RSV proteins by competing for substrate and 
prevent replication. 
 HMPV P (294 aa) and RSV P (241 aa) share only 37% amino acid identity. 
However, their overall domain structure is highly similar and includes the presence 
of N- and C-terminal intrinsically disordered regions (IDRs) and a central α-helical 
tetramerization domain (456, 457). Most of the identical amino acids between 
HMPV P and RSV P are in the tetramerization domain, but our results suggest that 
these proteins are unlikely to form heteromeric protein complexes that complement 
replication. Additionally, the deleterious effect of RSV N or P over HMPV IBs could 
be explained by their higher affinity for critical cellular components, including actin 
and/or actin related proteins which are important for virus lifecycle (251, 288, 406, 
431, 458-460), but this remains to be further examined.  
From 24 to 72hpi, singly infected HMPV cells are almost completely gone 
and instead, only found in co-infected cells. However, the number of infected cells 
that contain HMPV increased, suggesting that HMPV is able to spread, but also 
results in more co-infected cells. One possibility is that RSV is able to infect nearly 
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100% of cells, and although the initial infection rates are altered when both viruses 
are present, they are unaffected at later times post infection. This allows HMPV to 
spread but permissiveness of RSV entry gives rise to an increase in both HMPV 
positive and co-infected cells. Another explanation is a cooperative effect of these 
viruses at the cell surface. RSV and HMPV proteins and nucleic acids move to the 
plasma, aggregating at viral assembly sites. As both pneumoviruses bud, there 
may be an interaction occurring, where HMPV and RSV particles travel closely 
associated, leading to entry of both viruses into a single cell. Another purely 
speculative idea is the presence of chimeric viruses. HMPV and RSV demonstrate 
high similarity, with homologous proteins performing similar functions during the 
viral lifecycle. We have also shown that there are some potential interactions of 
replication components from one virus interacting with the genetic material of 
another using the mini-replicon system. Therefore, as nucleic acids are being 
packed into virions for spread, there could be a heterologous nucleic acid 
population, containing genomes from both RSV and HMPV in newly formed 
virions. This chimeric virus then delivers both genomes to a naïve cell, which 
increases the number of HMPV and subsequently, co-infected cells. However, 
there needs to be further investigation of assembly and spread to better 
understand spread kinetics in co-infected populations and how this increase in co-
infected cells is occurring and how it affects the replication efficiency of each virus. 
In addition, there is no current evidence for the presence of chimeric viruses and 
therefore, this mechanism needs to be examined further to identify if this is 
possible. 
The RSV genome is 2 kb larger than the HMPV genome, and contains two 
non-structural proteins NS1 and NS2, absent in HMPV. Both proteins have anti-
interferon activities, representing an additional advantage of RSV infections over 
HMPV. However, while purely speculative, in the event that viral chimeras were 
generated from co-infected cells, this offers a potential explanation of why co-
infections between these two viruses are able to generate a worse clinical outcome 
in patients, although this severity varies (39, 41, 44, 452-454, 461-472). It may also 
offer one potential explanation for why co-infected cells are more prevalent at later 
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times post infection and singly infected HMPV cells are absent. Our current data 
suggests that HMPV and RSV have a potentially reduced synergy, but these are 
examined in transfection and not infection experiments, where a host of other viral 
proteins may interact to favour replication and spread for both viruses. However, 
one study examined the amounts of RSV and HMPV viral loads in co-infected 
patients and saw no change for HMPV but a small, significant decrease in RSV 
titer (452), similar to our findings using the mini-replicon assay and suggested by 
other studies as well (453, 454).  In addition, there may be synergistic crossover 
of HMPV and RSV proteins involved in other aspects of viral lifecycle, but further 
studies examining key components needs to be conducted to better understand 
interactions between pneumoviruses. Future work will define if these co-infections 
are beneficial for viral infection and spread and the molecular mechanisms 
underlying this phenomenon.    
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Figure 6.1: Recombinant mCherry HMPV shows efficient growth. (A) Recombinant mCherry-
expressing HMPV strain JPS07E2 (rmcHMPV) was created by placing the gene for the fluorophore 
between the N and P gene segments. (B) rmcHMPV growth kinetics were similar to those observed 
for the JPS07E2 strain expressing GFP. Growth was seen when exogenous trypsin was added at 
3 and 0.3µg/mL but no growth when trypsin was not present (n=3).  
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Figure 6.2: HMPV and RSV growth in infected cells. LLC-MK2, Vero, and BEAS-2B cells were 
infected with (A) rmcHMPV and (B) rgRSV to observe infection and growth over time. LLC-MK2 
cells demonstrated the highest infection and growth rate for both viruses (n=3). 
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Figure 6.3: Analysis of HMPV and RSV co-infections. (A) rgRSV (MOI 0.01, 0.1 or 1) and 
rmcHMPV (MOI 1) were added simultaneously to LLC-MK2, Vero, or BEAS-2B. At 24 hpi, the 
percent of co-infected cells was determined using flow cytometry. (B) Co-infected cells were then 
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analysed over time up to 72 hpi, showing that co-infected cells increase over time. (C) 
Simultaneous infection of pneumoviruses affects RSV but not HMPV at 24hpi (n=3). 
 
Figure 6.4: HMPV and RSV in co-infected cells can occupy the same IB. Vero cells infected 
with rgRSV and wild type HMPV. Co-infected cells were examined using FISH against the RSV 
and HMPV genomes which demonstrated co-localization within inclusion body like structures.  
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Figure 6.5: Recombinant RSV or HMPV N and P expression alter inclusion body formation. 
Permutations of RSV and HMPV N and P were co-expressed in Vero cells and inclusion bodies 
were examined using fluorescence microscopy. Both RSV N and P contained an HA tag used for 
staining. HA tagged HMPV P was used in conditions 1,4 and 9. Untagged HMPV P was used in 
conditions 5,6, and 8. 100 cells were counted per transfection group and each was categorized 
as containing large inclusion bodies (>500 nm), small inclusion bodies (<500 nm), or cytosolic 
protein distribution.  
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Figure 6.6: HMPV and RSV mini-replicon complementation, synergy, and dominant negative 
effects.  The HMPV (H) or RSV (R) mini-replicon plasmids along with genes for viral proteins in 
the indicated permutations were transfected into BSR cells. Luciferase activity was measured 24 
hours post transfection for each of the complementation and synergy/dominant negative groups 
(n=3-5).  
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Chapter 7: Discussion and Future Directions 
The topics covered in this dissertation create a better understanding of key 
molecular interactions for pneumovirus entry, spread, and inhibition. We identified 
novel information about how HMPV strains can utilize low pH as a timing 
mechanism for triggering and what residues within the protein contribute to this 
phenomenon (Chapter 3). We further analyzed other known aspects of HMPV 
lifecycle, identifying previously unknown proteases that process HMPV F and 
using this new information to target multiple viruses therapeutically (Chapter 4). 
Further exploring pneumovirus lifecycles, we employed a 3-D human airway tissue 
model system to directly compare and contrast infection, spread, and phenotypes 
associated with infection, identifying important information for potential therapeutic 
development (Chapter 5). Lastly, we explored the phenomenon of viral co-
infections, allowing us to better understand how these closely related 
pneumoviruses co-occupy replication compartments in co-infected cells and 
explore a potential synergy for these in vitro (Chapter 6). While our results 
generate interesting and novel information about pneumovirus lifecycles, there 
remain many more research questions that need to be explored.  
Low pH mediate triggering of HMPV F: Analysis of new strains reveals 
complex requirements for fusion 
Understanding requirements for viral entry is an important aspect for preventing 
entry as a therapeutic approach. Prior to research conducted during this thesis, 
only a few fusion proteins from different HMPV strains had been shown to promote 
low pH triggered fusion (189, 240-242). However, other HMPV F proteins had been 
found to promote membrane fusion independent of pH while others are unable to 
mediate fusion at all in cell-based assays. Analysis of specific residues that 
contribute to low pH-mediated fusion had been examined using site directed 
mutagenesis, recombinant viral strains, or viral strains with conserved amino acid 
sequences reported for fusion phenotypes.  Together, these results led to the 
hypothesis that low pH fusion requires a glycine (G) at position 294, as well as 
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lysine (K) at 296, tryptophan (W) at 396, asparagine (N) at 404, and histidine (H) 
at 435, which are primarily associated with the A2 viral strain subtype and 
therefore, a rare strain dependent phenomenon (189, 240-242). However, work 
presented in this thesis has examined newly available strains of HMPV to better 
understand low pH mediated fusion and the role for specific residues in this 
process (chapter 3).  
 Fusion protein triggering is a complex phenomenon and its temporal and 
spatial regulation is vital for viral spread.  For many viruses, interactions between 
the attachment protein and a cellular receptor trigger the fusion protein. 
Alternatively, the fusion protein can directly interact with cellular factors to promote 
fusion. For viruses that are neither triggered by receptor binding or signaling by the 
cognate attachment protein, they must utilize some environmental signal, often 
using low pH present in cellular endosomes (154). Low pH triggering is utilized by 
the fusion proteins from many viruses, including members of Orthomyxoviridae, 
Flaviviridae, Togaviridae, Rhabdoviridae, Bunyaviridae, Filoviridae, and 
Arenaviridae, although there are families containing members with mixed 
requirements (154). These fusion proteins utilize specific residues, typically 
involving a histidine salt bridge, to disrupt electrostatic interactions to promote the 
conformational changes needed for fusion. In addition, there are direct, indirect, or 
a combination of factors required to trigger fusion and entry. This process becomes 
more complicated when factoring in the complex lipid membrane environment, 
which is both a barrier for viruses to cross and subsequently a hijacked resource 
to produce enveloped viral progeny.  
For the closely related paramyxoviruses, it has been hypothesized that 
many members enter at the plasma membrane due to pH-independent entry (94, 
145, 157). When examining the pneumovirus family, results describe a more 
complex entry pathway. RSV has been shown to mediate cell-to-cell fusion 
independent of the other surface glycoproteins, G and SH (91, 399, 400). Reports 
suggest RSV is also able to utilize multiple cellular factors for attachment and 
entry, including CX3CR1, heparan sulfate, L-sign, DC-Sign, nucleolin, and TLR4 
120 
 
(316, 473-478). These interactions subsequently allow RSV to enter via 
micropinocytosis where it fuses with the endosomal compartment for genome 
release (479). For HMPV, the fusion protein is able to mediate infection without G 
or SH as well (121, 123), similar to RSV. However, HMPV lacking G or SH still 
spreads in animal models whereas no detectible virus is recovered from animals 
infected with RSV lacking G or SH, suggesting HMPV is more independent of other 
surface glycoproteins, requiring only F for infection.  While no receptor has been 
reported, there have been two attachment factors that are critical for HMPV entry: 
heparan sulfate and αvβ1 integrin (123, 243, 398). Subsequent entry of HMPV is 
mediated by endocytosis in a dynamin- and clathrin-dependent manner in 
bronchial epithelial cells (335). For the subtypes of HMPV that utilize low pH as a 
trigger, this trafficking pathway provides a trigger for fusion. However, it remains 
unexplored what factors are important for strains that do not use this mechanism. 
Using chemicals, such as ammonium chloride, to prevent endosomal 
acidification blocks entry of viruses such as influenza and VSV which require low 
pH for triggering (480-482). When endosomal acidification was blocked prior to 
addition of HMPV, TN94-49 (A1) about 50% inhibition in infection was observed, 
whereas TN96-12 (A2) was still able to mediate efficient infection independent of 
pH (335). The observation that TN94-49 requires low pH was recapitulated using 
the isolated F protein, where low pH mediated cell-to-cell fusion was 
demonstrated. However, we did not observe any fusion activity for TN96-12 F, 
suggesting that other requirements are required independent of pH. TN96-12 was 
also examined in the presence of the homotypic attachment protein, G, but failed 
to promote fusion suggesting a further level of unexplored regulation (Fig 3.4). 
Despite entry being mediated by F, independent of other viral surface 
glycoproteins, strains of both HMPV and RSV have recently been identified that 
contain a duplication site in the attachment protein, hypothesized to increase the 
number of glycosylation sites present, potentially aiding in attachment to promote 
viral fitness (138, 142). In addition, G is still retained in all clinical strains of HMPV, 
suggesting an essential role that has not been fully understood in vivo.   
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Both HMPV F S174H434 and HMPV F TN96-12 demonstrated significantly 
higher overall and surface expression but showed significantly different fusion 
phenotypes. The addition of a histidine at 434, in addition to the previously reported 
435, appeared to enhance the fusogenic activity when exposed to low pH. H434 
may therefore act to enhance de-stabilization, creating interactions that are more 
sensitive to pH changes. Despite the significantly higher expression of TN96-12, 
fusion was still unable to be mediated under any conditions, suggesting other 
important factors required for fusion are still to be discovered. 
Future experiments should explore the potential of a cellular receptor for 
HMPV, potentially elucidating a common factor needed for strains not requiring low 
pH for entry. Such a receptor would likely be present within the endosome, as 
strains that are do not require low pH are also taken in by endocytosis, similar to 
the multistep entry process required for Ebola (234, 236). There is currently limited 
information on and resources available for clinical isolates of HMPV. Further 
analysis of strain sequences and phenotypic characterization of HMPV F would 
lead to a deeper understanding of which amino acids are important for fusion and 
establish if low pH mediated fusion is a rare, strain dependent phenomenon or part 
of a more complex regulatory interaction during infection for some strains.  
Identifying and targeting proteases for antiviral treatment of HMPV  
Viruses containing class I and II fusion glycoproteins require a cleavage 
event of the fusion protein or accessory protein, respectively, during the infectious 
process. This cleavage event allows priming of the fusion complex, creating a 
metastable form to promote fusion upon appropriate signaling (483). One of the 
most well studied respiratory viruses, influenza A, requires cleavage at a single 
basic amino acid residue to prime its class I fusion protein, HA. Historically, trypsin 
is used to promote cleavage in vitro (484, 485). Endogenous proteases required 
for activation were not reported until recently when a variety of serine proteases 
present in the lung that mediate cleavage of HA were identified (170, 173, 174, 
176, 177, 376, 377, 380, 381, 383). Studies examining in vitro and animal model 
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systems further demonstrated that influenza subtypes also have variable protease 
specificity depending on the strain, but why this preference is present requires 
more research (173, 176, 375, 377, 381). Highly pathogenic influenza strains have 
a mutation in this cleavage site, converting it to a multi-basic stretch. This allows 
recognition and cleavage by more abundant, non-tissue specific intracellular 
proteases like furin (355). Identifying and understanding these proteases is 
important for characterizing pathogenicity and tropism during infection and spread. 
Similar to influenza, all HMPV strains contain a cleavage motif where a single basic 
amino acid is cleaved to release the fusion peptide (189). There is only one 
reported variation in the consensus sequence and these strains are considered 
trypsin independent, but few strains harbor this modification (190, 193). Trypsin 
independent strains did not grow to higher titers compared to strains requiring 
trypsin or those with an inserted furin cleavage motif, suggesting that this mutation 
does not enhance pathogenicity (190, 193).  
Prior to our studies, it was known that trypsin and TMPRSS2 were able to 
cleave HMPV F (189, 192). The hypothesis that other proteases could also 
promote HMPV F cleavage led us to investigate other proteases identified for 
influenza which may also be utilized by HMPV or other respiratory viruses that 
have similar cleavage requirements. Other human respiratory viruses with class I 
fusion proteins requiring cleavage at a basic amino acid include paramyxoviruses 
such as parainfluenza virus 1-4 (486) and Sendai virus (486). In addition, 
TMPRSS2 was shown to cleave one of the two cleavage sites present in 
coronaviruses (CoV) such as 229-E (487),EMC (488), SARS-CoV (489, 490), 
MERS-CoV (491) and the novel SARS-CoV-2 (492). SARS-CoV and MERS-CoV 
have both been shown to be cleaved by TMPRSS2 and this protease plays an 
important role in infection. One cleavage site of MERS-CoV has the basic furin 
recognition motif (RXXR) for proteases recognizing multi-basic cleavage motifs, 
suggesting some potential cleavage by more abundant, endogenous proteases 
such as furin. However, HMPV shares a similar basic motif (RQSR) and is unable 
to be cleaved by furin, suggesting a more restricted motif requirement for efficient 
cleavage. The novel SARS-CoV-2 has a similar mutation compared with highly 
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pathogenic influenza (493), where an addition of basic amino acids residues at 
one of the cleavage sites (RRAR) which has a higher affinity for proteases that 
recognize a multi-basic amino acid stretch for cleavage, ultimately leading to more 
efficient processing. This mutation is a major contributing factor that lead to a 
global pandemic that emerged in late 2019. Studies also support the use of 
TMPRSS2 by SARS-CoV-2, but studies also suggest cleavage by furin and other 
proteases that cleave at multi-basic amino acid motifs (494). However, there are 
limited options available to target this specific aspect of the viral life cycle. 
Therefore, a better understanding of how these respiratory viruses utilize host 
proteases to activate their fusion proteins and initiate infection is important for 
developing novel therapeutic targets against a broad range of viruses requiring this 
class of proteases.  
Targeting pathogen specific factors often leads to the development of drug 
resistance. Using an approach that targets a broadly used host factor not only 
prevents drug resistance from developing, but also could identify broad-spectrum 
inhibitors of multiple pathogens using a single chemical and dosage. In our studies, 
we used HAI-2 (362) (referred to as SPINT2) as a broad-spectrum serine protease 
inhibitor that prevents spread of influenza and HMPV and therefore, inhibits the 
cleavage of HA and F, respectfully (Chapter 4). Inhibiting serine proteases has 
been explored previously including aprotinin (361, 495, 496) and camostat (385, 
491, 495, 497). While aprotinin was able to inhibit entry and is an approved therapy 
in Russia, the pharmacokinetics as a competitive inhibitor of several serine 
proteases makes it an unfavorable treatment (496). Camostat has been approved 
for use in Japan for the treatment of pancreatitis and postoperative reflux 
esophagitis (386, 498). This protease inhibitor also demonstrates significant 
potential for other morbidities, including some viral infections, but the limited 
availability makes it difficult to rapidly achieve the use of camostat on a global 
scale. Recently, the SARS-CoV-2 pandemic led to emergency drug repurposing 
where camostat was a highly sought-after contender for treating SARS-CoV-2 
patients (492). Camostat has been shown to inhibit SAR-CoV-2 infection in vitro 
and there are several on-going clinical trials examining this protease inhibitor for 
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effectiveness against SARS-CoV-2. However, a significant amount of research 
needs to be conducted to better understand efficacy and safety. This 
unprecedented time has allowed for the use of camostat world-wide which could 
result in its use against influenza, CoV, and HMPV soon. 
Identifying proteases involved in HMPV infection has revealed novel and 
very important information about this ubiquitous pathogen. We show that targeting 
cleavage is a significant mechanism for developing antivirals. However, other 
proteases need to be identified and examined in more physiologically relevant 
model systems to better understand how our findings translate to more complex 
systems of infection. In addition, analyzing SPINT2 compared to camostat in 
various model systems would help understand how advantageous this method 
would be in comparison. The advantage of SPINT2 is that it is endogenously 
expressed in humans, whereas camostat is a synthetic compound. This offers the 
potential for less side effects and administration of higher, more efficacious doses 
that may be needed to prevent infection. However, the generation of a protein 
inhibitor on a large scale presents a significant challenge that must be overcome. 
Identification of novel naturally occurring and synthetic protease inhibitors that 
inhibit viral infection would provide for broad protection and prevention of viral 
spread while simultaneously mitigating side effects to prevent and treat multiple 
respiratory pathogens. Some of this research has already begun, but there is 
significantly more needed to ensure an effective treatment (495, 496).  
Complex 3-D human airway epithelial tissues as a model system of 
infection. 
Historically, RSV and HMPV infections have been studied using 2-D cell 
monolayers, leading to a better understanding of infection. Because these viruses 
are evolutionarily similar and share several key characteristics during the lifecycle, 
we examined previous 2-D findings using a complex, more physiologically relevant 
3-D human airway epithelial (HAE) model system. RSV has had multiple reports 
using HAE tissues (143, 144, 314, 316, 319, 323-326, 420, 421), but only four 
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HMPV studies have utilized HAE tissues (135, 136, 318, 333). However, none of 
these reports have done extensive molecular characterization of these viruses 
during the stages of infection. Using these models, other reports have suggested 
that viruses grown in 2-D culture undergo adaptations, altering infection dynamics 
in more complex models. For RSV, there is evidence suggesting growth of virus in 
monolayers results in less infection when the virus is subsequently added to HAE 
tissues (143, 144, 421), compared to virus initially grown on tissues which infects 
with higher efficiency. These observations are true for many other viruses including 
measles and PIV, where studying them out of context prevents important, tissue 
specific information from being obtained (294, 297, 499-501). It is possible that 
growth of RSV and HMPV in HAE tissues could alter the infectivity and spread 
kinetics compared with strains grown in 2-D monolayers. Growing viruses in HAE 
issues would generate strains with more physiologically relevant adaptations and 
these studies would be important for understanding how this contributes to entry, 
spread, and replication as well as how to target these more effectively. However, 
growth of virus in these complex models is costly and therefore difficult to achieve 
with current methods. 
Other reports have demonstrated that cell polarity is an important factor for 
determining where viral factors localize during infection. Polarized cell monolayers 
infected with RSV showed F localized to the apical surface and this was 
recapitulated using 3-D tissues. In comparison, 2-D cells demonstrate a general 
localization to the plasma membrane (438). Having F localized at the apical 
surface is consistent with proposed locations for viral assembly and budding sites 
in vivo, which has been difficult to characterize using non-polarized models. 
Similarly, RSV and HMPV have been demonstrated to form actin-based 
extensions in 2-D cultures and chemically inhibiting actin dynamics in these 
systems profoundly affects viral replication and spread (288, 298). However, when 
we examined infection in our 3-D model, we found that these extensions were 
significantly less prevalent in RSV infected cells compared to HMPV (Fig 5.4).  
Therefore, it is possible that RSV-induced extensions in 2-D monolayers are a 
result of cells lacking polarization, where the actin cytoskeleton is important for 
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other functions not found in this system. Previous unpublished work in our lab 
studying HMPV examined the effect of actin cytoskeletal inhibitors on HAE infected 
tissues. We found that inhibition, similar to 2-D cells, significantly inhibited 
replication and spread (El Najjar and Dutch, unpublished results), but further 
analysis is needed to understand how it affects extension formation. Both HMPV 
and RSV proteins are able interact with the actin cytoskeleton, supporting a critical 
role for viral function (288, 427, 502). Actin and actin-related proteins are present 
in isolated virus when analyzed by mass spectrometry, further supporting the role 
of actin in viral assembly and spread (288, 503, 504). The role of extensions during 
HMPV and RSV infection in HAE tissues needs to be analyzed to understand what 
the purpose of these extensions is during assembly and spread. 
We used this HAE system to analyze the therapeutic potential of 
monoclonal antibodies (mAbs) for entry and spread inhibition. While both HMPV 
and RSV were neutralized to prevent viral entry, there was a large difference 
observed in the effect of neutralizing antibodies on spread kinetics (Fig 5.5 - 5.8). 
RSV spread was completely inhibited when mAbs were added to the apical surface 
after infection, but HMPV spread was only inhibited approximately 25%. These 
findings were also shown for both viruses in 2-D monolayers where RSV entry and 
spread were blocked but only entry was inhibited for HMPV and an approximately 
50% reduction was seen for spread. These observations in both 2-D and 3-D 
models highlight an interesting dichotomy between RSV and HMPV infections. Our 
results support previous work that shows HMPV can spread directly from cell-to-
cell in monolayers, independent of neutralizing mAbs (288). Interestingly, HMPV 
infection peaked at 48 hours, and spread was only observed within this 24-hour 
window. HMPV is primarily cell associated and therefore, sloughing of apical cells 
carrying infected HMPV may result in loss of infectious particles, potentially 
explaining why limited spread was seen at later times post infection. In addition to 
RSV and HMPV, there have been other respiratory viruses studied including 
influenza, parainfluenza, measles virus, and adenoviruses and while our results 
are preliminary, comparing and contrasting other well studied viruses also allows 
for understanding how previously identified phenotypes in pneumoviruses may 
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manifest in our model system (136, 143, 144, 313, 315, 316, 321-325, 327, 415-
419). 
Even though using tissue systems allows for understanding infection in a 
more physiologic context, there are some pitfalls. RSV spread inhibition was 
observed for both palivizumab and nirsevimab in 2-D and 3-D models. However, 
palivizumab is only effective when given prophylactically, but is not effective when 
given during an already active infection. Therefore, this work suggests the 
antibodies have strong potential as novel therapeutics, but the complexity of 
systems present in other models is needed to fully explore the potential window 
for therapeutic intervention. One major drawback of the HAE model is the lack of 
an immune system, which is critical for understanding infection progression, 
clearance, and treatment. Establishing more complex model systems that 
incorporate both organ and immune system specific constituents would aid our 
understanding of viral infections and the antiviral response. Further studying 
pneumovirus infections in the presence of other important factors present within 
lung tissue will be critical for understanding how the phenotypes reported here are 
altered with increasing model system complexity.  
Viral co-infections: Potential synergy for HMPV and RSV co-infected cells 
Co-infections occur when opportunistic hosts are susceptible to one or more 
pathogens which infect a specific organ system. Often, there combination of 
fungal-bacterial-viral co-infections which result in one pathogen invading while 
creating an environment that allows another pathogen to thrive in a synergetic 
manner (505-507). There is a significant number of reports documenting the 
simultaneous presence of one or more respiratory viruses that can result in 
significant morbidity compared with single species infections. However, there is 
also evidence of viral interference, infection with where one virus prevents the 
entry of another. This phenomenon suggests co-infections often cannot occur and 
therefore they have been infrequently studies so they remain poorly understood 
(449-451). However, there is likely a benefit that arises from co-infection which 
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promotes some fitness advantage for both viruses instead of competition, which 
would only promote the growth and spread of one species.  
More specifically, RSV and HMPV have been reported to co-infect 
individuals, leading to increased disease severity as a result (38, 40), though co-
infection at a cellular level has not been examined. These viruses also share many 
similarities both genetically and in protein function during infection. We aimed to 
better understand how RSV and HMPV were resulting in more severe pathology 
by examining viral co-infected cells and the potential for synergy during infection. 
We observed minimal amounts of co-infected cells initially, but these population 
increased over time (Fig 6.3). We observed the phenomenon of viral interference 
where initial infection with one virus affected the entry of another. Upon closer 
examination, IB formation was observed, minimally composed of N, P and viral 
RNA. Interestingly, RSV and HMPV vRNA and proteins co-localized to the same 
inclusion bodies in co-infected cells, suggesting the potential for viral protein 
complementation. The N and P proteins of each virus serve similar functions and 
the overall structures compared with one another are quite similar, despite minimal 
sequence conservation. However, testing various combinations of N and P 
resulted in mixed results for IB formation (Fig 6.5). More interestingly, using a 
minigenome replicon system, only 10% of replication efficiency was retained when 
swapping out N and P from both viruses, but adding them in addition to all cognate 
replication proteins suggests that HMPV is primarily unaffected whereas RSV still 
has a significant reduction (Fig 6.7).  
Our observations generate more questions about why RSV and HMPV 
proteins and viral RNA in co-infected cells would occupy the same replication 
organelle given that we currently observe minimal synergy for replication. We 
primarily studied co-infections using protein expression in eukaryotic cells, which 
takes away the complexity of other viral factors that may be important during 
infection in addition to the replication complex. This could offer an explanation as 
to why co-infected cells show IB co-habitation, but transfection experiments 
resulted in minimal functionality. Both RSV and HMPV hijack cellular factors, many 
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of which have not been identified, and these may promote a synergistic 
environment within these cells. This suggests another potential scenario where 
sequestration of these host factors into inclusion bodies draws HMPV and RSV 
proteins together into these replication organelles and not be driven by viral 
synergy which would explain the limited synergy observed in replication. However, 
this still leaves the question of whether co-infections are a consequence of chance, 
or if there is a benefit of two viruses co-infecting the same cell.  
To examine this further, co-infected samples will need to be analyzed to 
characterize replication and spread compared to singly infected cells. More 
interestingly though, is the potential for the formation of viral chimeras, where 
budding viruses contain multiple genomes from both viruses that can pass on and 
co-infect other cells. Our time course data supports that at 72 hours, singly infected 
HMPV appears to decrease and overall co-infected cells increase. However, more 
analysis will need to be conducted to determine if this is due to chimera formation 
or other potential mechanisms of spread. Additionally, critical host factors utilized 
by both RSV and HMPV to form inclusion bodies is poorly understood due to the 
high volatility and dynamic nature. Identifying key viral and host factors that are 
critical for the formation and function of IBs would be critical to help elucidate the 
interactions that govern the coalescence of both RSV and HMPV genomes in the 
same IB and whether this is driven by a synergistic interaction or a co-dependence 
on specific host factors that are critical for both viruses during infection. 
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Appendix 1: Designing a clinical testing platform for the merging SARS-
CoV-2 (COVID-19) pandemic 
* This chapter was completed with the help of David B. Cobb and Dr. Morgan 
McCoy from the University of Kentucky microbiology clinic, who assisted with 
validation and testing in the clinic. In addition, Dr. Kate Wolf from the University of 
Kentucky, Department of Microbiology, Immunology, and Molecular Genetics 
helped with design, testing, and troubleshooting. All data and graphs presented 
here were generated by me.  
Introduction 
The emergence of viral epidemics and pandemics is difficult to 
predict, leading to devastating and unforeseen outcomes (508). Historical 
viral pandemics include smallpox (509), measles (510), yellow fever (511), 
Zika (512), Ebola hemorrhagic fever (513), severe acute respiratory 
syndrome/Middle Eastern respiratory syndrome (514, 515), human 
immunodeficiency virus (516, 517), and influenza virus (518-521). However, 
there have been significant advances in scientific research that have 
allowed us to combat some potential outbreaks. Historically, both smallpox 
and measles viruses were a significant health burden. This ultimately led to 
the development of vaccines resulting in the complete eradication of 
smallpox in 1979 (509). For measles, worldwide vaccination efforts led to a 
significant decrease of infections and subsequent hospitalizations and 
death. However, recent movements in the modern era challenging 
vaccinations have generated a severe threat for the re-emergence of 
measles (5, 510, 522).  
 
Vaccines are not available for every pathogenic virus, so the 
development and use of antivirals is critical (523-530). This is especially 
true for those viruses that circulate in non-human reservoirs and re-emerge 
in human populations periodically. However, effective antivirals can be 
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challenging to maintain, as many viruses have high mutation rates and multiple 
species transmission which makes these chances of resistance even higher (518, 
521, 527). These factors can contribute to the generation of highly pathogenic 
viruses resulting in outbreaks, epidemics, and in some cases leading to 
pandemics. This is particularly dangerous for viruses that have high mutation rates, 
which can result in vaccines or antiviral therapies losing the ability to combat the 
pathogen effectively (530-533). For IAV, these evolutionary changes result in the 
need for yearly vaccinations (534). Although the annual flu vaccine offers 
protection, with the levels varying by year, it is difficult to predict which strain will 
dominate and which epitopes are important for eliciting an immune response. In 
addition, mutations that enhance the infection and spread can occur and result in 
significant morbidity and mortality, such as those seen in the IAV pandemics (519, 
535, 536). Altogether, pandemic viruses can generate extreme morbidity and 
mortality and are difficult to prepare for given the vast number of variables that are 
unable to be controlled.  
 
Some viruses that have strong potential to cause outbreaks are poorly 
understood and others are likely still to be discovered. Bat species in particular 
harbor many viruses that have generated zoonotic transmission from an 
intermediate host, eventually infecting humans (537, 538). These viruses include 
Hendra (HeV) and Nipah (NiV) , which cause deadly respiratory disease and 
encephalitis in horses and pigs respectively (7, 11, 13, 539-541). While HeV and 
NiV are only responsible for a small amount of morbidity, the mortality rates of 
those infected range from 50-100%. Due to the small amount of cases and rapid 
epidemiologic analysis, further cases and outbreaks have been avoided and some 
treatment and prevention options are available (14, 15). Outbreaks like these bring 
up interesting questions as to what potential viruses are lying dormant in nature 
that have high potential for outbreaks in humans that can ultimately lead to novel 
a global pandemic.  
  
132 
 
One viral family, Coronaviridae, has been involved in several global pandemics in 
recent years. Coronaviruses (CoV) are enveloped, single stranded, positive sense 
RNA viruses that infects both animals and humans (542). The conserved 
components of CoV are the RNA-dependent-RNA polymerase (RdRp), membrane 
protein (M), envelope protein (E), spike protein (S), and nucleocapsid protein (N). 
Many strains also encode other accessory proteins that are less conserved, 
serving roles specific to the needs of the specific strain.  The first reports of 
endemic CoV in humans dates back to the 1960s (543, 544), when HCoV-OC43 
and HCoV-229E were first described, followed by HCoV-NL63 and HCoV-HKU1 
which were described in the early 2000s (545, 546). All four of these CoV strains 
cause mild to moderate cold-like symptoms in humans and typically follow a 
seasonal distribution (542). However, in late 2002, a novel CoV called severe 
acute respiratory syndrome (SARS-CoV) arose in China due zoonotic 
transmission from bat to civet, and from civet to human, likely due to exposure 
within food markets. SARS-CoV ultimately caused an epidemic affecting 
approximately 8,000 individuals, demonstrating a mortality rate of up to 10%, with 
individuals over 55 years of age significantly affected (547, 548). Since 2004, no 
cases of SARS have been reported and therefore the threat for a global pandemic 
was mitigated.  A second novel coronavirus caused an epidemic which began in 
2014 in the Middle East. Middle East respiratory syndrome (MERS-CoV) came 
from a zoonotic transmission from camels to humans, likely originating from bat 
species. This initially infected around 400 individuals and yielded a fatality rate of 
up to 35% (549, 550). Subsequently, in 2015, a large secondary outbreak was 
detected in South Korea, suggesting the potential for spread, but has not been 
detected outside of the Middle East and Asia due to the requirement of camels as 
the intermediate species. Unlike SARS, there have been annual cases reported in 
the Middle East every year since the initial epidemic, establishing a cyclical 
infectious cycle (550).  While both SARS-CoV and MERS-CoV are regarded as 
significant pathogens, both of these CoV epidemics were relatively small and short 
lived, and therefore, lack of funding for continued research resulted in no approved 
therapeutics or vaccines available.  
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In late 2019, another novel CoV emerged in Wuhan, China, presenting with 
respiratory distress symptoms (551-554). Genetic analysis suggested this viral 
strain shared high homology with SARS-CoV, but contained important genetic 
differences that lead to changes in spread and infection (554). Epidemiologic 
surveillance found that some CoV strains present in both bats and pangolins 
demonstrated high genetic similarity and may explain the point of origin (553, 555, 
556). Since the first case was reported, COVID19, caused by the virus SARS-CoV-
2, has spread to almost every country and the virus has infected millions of people, 
with cases increasing daily. Initially, the death rate was suspected to be close to 
that reported for SARS-CoV (557, 558). Similarly, the death rate associated with 
elderly individuals was significantly higher as well (553, 557, 558). Initial cases 
were diagnosed using lab developed tests (LDT) that utilize reverse transcriptase 
real-time polymerase chain reaction (RT-qPCR) against RNA isolated from patient 
samples, and the U.S. put forth FDA guidelines to aid diagnostic potential (559). 
However, there are currently no standard test kits available worldwide and 
therefore, detection of the virus as well as nucleic acid extraction platforms are 
being examined for emergency use. In addition, there are some commercially 
available kits from several companies that are highly sensitive and automated. 
However, these are either extremely long processes, have limited testing capacity, 
or are unavailable in many places, all of which decrease the high throughput 
testing needed for the current pandemic. 
 
In this chapter, we develop a RT-qPCR based testing platform for the diagnosis 
of SARS-CoV-2 for use in the University of Kentucky clinic. We used the Lyra, a 
currently available RT-qPCR platform for SARS-CoV-2 in conjunction with a 
magnetic bead based nucleic acid extraction kit to purify viral genetic material from 
patient samples. We determined that our lab developed test is both sensitive and 
precise and demonstrates a limit of detection of 400 copies/mL. In addition, when 
used with patient samples, we are able to accurately detect the presence of virus 
with similar sensitivity to currently approved diagnostic platforms.  
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Material and Methods 
Thermocycler and PCR kit: The Lyra SARS-CoV-2 RT-qPCR assay kit (Quidel) 
was used to complete the PCR testing on the QuantStudio 7 Flex (Thermofisher). 
The kit contains a positive control that was used for the accuracy and precision 
tests.  
 
RNA isolation: RNA from either patient samples or standard control was isolated 
using the Thermofisher MagMax viral and pathogen nucleic acid isolation kit 
(A42352) according to the manufacturer’s protocol. Briefly, 380µL of patient 
sample or standard with 20 µL of process control was placed into 550 µL of the 
binding buffer and bead slurry then treated with 10 µL of proteinase K. The positive 
control was 50 µL of Lyra kit positive control into 330 µL of saline buffer and 20 µL 
of process control. Sample mixing was completed at 1050 rpm for all steps. 
Samples were mixed for 2 min, incubated at 65°C for 5 min and mixed for 5 min 
then allowed to sit on a magnetic stand for 10 min or until the beads collected and 
the supernatant was aspirated. The beads were then washed with 1mL of wash 
buffer followed by mixing for 2 min, incubated until beads settled and supernatant 
was removed. This was completed two more times with 1mL and 0.5mL of 80% 
ethanol. After the second wash, the beads were dried by mixing for 2 min. 50 µL 
of elution buffer was placed in each sample, mixed for 5 min, incubated at 65°C 
for 5 min and then mixed for 5 additional min. Beads were collected on the 
magnetic stand for 3 min and the eluate was taken and moved into a new plate for 
RT-qPCR.  
 
Lyra RT-qPCR: The Lyra RT-qPCR was set up as designed by Quidel in the 
emergency use authorization for the Thermofisher quant studio 7 pro. Briefly, 135 
µL of rehydration buffer was added to each vial of dehydrated master mix (8 
samples/vial). 5 µL of isolated RNA was placed into each well with rehydrated PCR 
master mix and subsequently sealed and spun down. The PCR was performed 
using the 96-well fast insert at 20 µL total volume with the following settings: 1) 
55°C for 5 min 2) 60°C for 5 min 3) 65°C for 5 min 4) 92°C for 5 sec and 57°C for 
135 
 
40 sec 5) repeat step 4 for 10 cycles without capture 6) 92°C for 5 sec and 57°C 
for 40 sec 7) repeat step 6 for 30 cycles with capture. The threshold was set to 
automatic detection based on cycle 3-15 of the PCR.   
 
Limit of detection analysis: The limit of detection was established for the Quidel 
Lyra SARS-CoV-2 assay using heat inactivated virus at a stock concentration of 
1.7e7/mL in TE from BEI resources (NRC-52281 lot 70033641). Initial limit of 
detection ranges was completed in triplicate diluting the initial stock to 1e5/mL 
doing 1:2 dilutions from 100,000 copies/mL to 781 copies/mL. Subsequent LOD 
testing was completed using serial dilutions from 1.7e7/mL to 1.7e5/mL in DEPC 
water followed by diluting this stock into saline (0.9% NaCl) for 1600, 800, and 400 
copies/mL of genome into a total volume of 8mL of saline. 380 µL of this dilution 
was run 20 times through independent RNA isolation for RT-qPCR analysis.  
Results and Discussion: 
To generate a lab developed testing (LDT) platform for SARS-CoV-2, we 
combined the Lyra SARSCoV-2 RT-qPCR kit with the MagMax nucleic acid 
extraction platform. In order to achieve emergency use authorization (EUA) 
approval for our kit, there are several test metrics that must be conducted to ensure 
the platform is sensitive and accurate. First, we conducted an initial accuracy test 
of replicates within the sample experimental procedure to ensure that there was 
minimal variation. This accuracy test was composed of 10 positive and 10 negative 
samples independently isolated and analyzed using RT-qPCR. All positive control 
samples were detected at expected Ct values, with an average Ct value of 21.05 
while no negative samples showed signal for the SARS-CoV-2 (Fig A-1A). In 
addition, the internal isolation control standards were picked up at an average Ct 
value of 17 for both the positive and negative samples, confirming the isolation 
was successful and consistent.  
 
Next, we conducted a precision assay that assessed the consistency between 
runs completed over multiple days. To do this, 5 positive samples and 5 negative 
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samples were prepared on 5 separate days, followed by RNA isolation and 
analysis by PCR. The positive samples again showed an average Ct value of 
21.42, 20.93, 20.95, 20.81, and 20.16, consistent with the initial accuracy 
measurement (Fig A-1A and A-1B). There were no negative controls that 
demonstrated any signal for SARS-CoV-2 nucleic acids. Additionally, the 
internal controls showed high consistency with a Ct value of 17.68 ,17.32 
,17.35, 17.39, and 17.11 (Fig A-1B). These results suggest that the current 
testing platform is both accurate and precise while also demonstrating high 
sensitivity for detection.   
 
To ensure our findings were consistent with previous studies conducted 
during the initial Lyra test development, we examined a panel of four verification 
samples that contained nucleic acid material at known concentrations. These 
samples were provided to us blinded for testing purposes from Quidel. We 
isolated each member of this panel in duplicate and analyzed them by RT-
qPCR. The expected values for members 1 and 3 were 24 +/- 1 and members 
2 and 4 were expected at 27+/- 1. During our nucleic acid isolation and RT-
qPCR, we detected member 1 at a ct value of 19.44, member 2 at 22.50, 
member 3 at 20.95, and member 4 at 23.24, all of which were lower than the 
expected values for detection, suggesting that the current testing and extraction 
platform was operating with greater sensitivity than previously reported by the 
current Lyra testing platform (Fig A-1C).  
 
Lastly, in order to ensure that the test is sensitive and able to detect minimal 
amounts of viral nucleic acids present in the samples, we conducted a limit of 
detection (LOD) assay using gamma irradiated SARS-CoV-2 virus. Previously, 
this method was utilized by Quidel to determine the LOD on a variety of 
thermocycler platforms, including the Thermofisher Quantstudio 7 Pro, which 
is closely related to the QuantStudio 7 Flex used in these studies. The LOD 
established on these platforms demonstrated a detection limit at 800 copies/mL 
and were able to detect 20/20 isolations with an average Ct value of 27.3 (Fig 
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A-2A). Initially, we generated a stock of gamma irradiated virus at 100,000 
copies/mL and conducted a 1:2 dilution down to 781 copies/mL in triplicate. We 
were able to detect dilutions all the way down to 781 copies/mL which had an 
average Ct value of 24.2 (Fig A-2A). Data from the 6,250 and 1,562 copies/mL 
only yielded two data points per group due to loading error and internal control 
failure. 
 
Based on this initial LOD, we then proceeded to dilute gamma-irradiated virus 
at 2x LOD (1600 copies/mL), 1x LOD (800 copies/mL) and 0.5x LOD (400 
copies/mL) compared with the current established detection level. At 2x LOD, we 
were able to pick up all 20 replicates at an average Ct value of 20.96. We were 
also able to pick up all 20 replicates 1x LOD with an average Ct value of 22.37, 
which is 5 Ct values lower than the current assays detection. At 0.5x the LOD, we 
were able to detect 19/20 samples with an average Ct value of 23.02 which is still 
4 Ct values lower than the current lyra assay LOD (Fig A-2B). One sample from 
the 400 copies/mL group was lost during the extraction processes and therefore, 
only 19/20 samples were detected. However, based on the other datapoints within 
the set, the LOD may potentially be lower than 400 copies/mL.  
 
In this chapter, we developed a testing platform for the detection of the novel 
SARS-CoV-2 virus using a combination of a commercially available RT-qPCR kit 
coupled with a magnetic bead-based nucleic extraction platform for emergency 
use authorization. We were able to demonstrate that this test is able to deliver 
consistent results with minimal variation between tests confirming both accuracy 
and precision of detection. In addition, testing standards generated by Quidel 
specifically for the Lyra platform were detected at lower Ct values when compared 
to expected values, suggesting that this mechanism was more sensitive than the 
currently approved Lyra platform. Further supporting this, we were able to establish 
a LOD of 400 copies/mL compared with the current Lyra platform which has an 
LOD of 800 copies/mL. Our current testing capacity was initially limited by the time 
and capacity of currently available testing platforms. The LDT generated in this 
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study is able to utilize another platform to increase the testing capacity while 
ensuring that sensitivity, accuracy, and precision are conserved.  
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Figure A-1: The LDT demonstrates high precision and accuracy for SARS CoV 2 detection. 
The current LDT was able to detect the positive control both (A) accurately and (B) precisely, with 
minimal variation between samples within a single run or over multiple days of testing. (C) 
Validation samples (1-4) were provided in a blinded fashion for analysis and compared with 
expected outcomes from previous studies demonstrating that the LDT is more sensitive than the 
current testing platform. 
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Figure A-2: The limit of detection of SARS CoV 2 is highly sensitive. (A) The initial limit of 
detection was able to be determined using a 2-fold serial dilution starting from 100,000 copies/mL 
down to 781 copies/mL. (B) 20 replicates of 1600, 800, and 400 copies/mL were independently 
isolated and analyzed by RT-qPCR demonstrating a 95% confidence in the limit of detection at 400 
copies/mL.  
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Appendix 2: List of Abbreviations 
 
HMPV Human metapneumovirus 
RSV Respiratory syncytial virus 
IAV Influenza A virus 
RNP Ribonucleoprotein 
N Nucleoprotein 
F Fusion protein 
P Phosphoprotein 
L Large polymerase 
M Matrix protein 
SH Small hydrophobic protein 
G Attachment Protein 
IB(s) Inclusion Body/Bodies 
FISH Fluorescence in situ hybridization 
HAE Human airway epithelium 
GFP  Green fluorescent protein 
HRA Heptad repeat A 
HRB Heptad repeat B 
WT Wild type 
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Vita 
 
Employment Summit Biosciences 
Product Development Scientist 
Lexington, Kentucky 
 
(Current) 
Education Doctor of Philosophy 
Molecular and Cellular Biochemistry  
University of Kentucky, Lexington KY 
         
(2020) 
 Bachelor of Applied Science, Biological 
Sciences  
Bluefield State College, Bluefield WV 
 
(2015) 
Research Graduate Research Assistant 
Principal Investigator: Rebecca Dutch, 
Ph.D. 
 
(2016-Present) 
 Summer Research Assistant, Marshall 
University                                                                
WV-INBRE summer research internship. 
Principal Investigator: Piyali Dasgupta 
Ph.D. 
 
(2014) 
 Undergraduate Research Assistant, 
Bluefield State College                                                          
Principal Investigator: Tesfaye Belay Ph.D. 
 
(2013-2015) 
Publications 
 
 
 
 
 
 
 
 
 
 
 
 
First Authorship: “Respiratory Syncytial 
Virus (RSV) and human metapneumovirus 
(HMPV) infections in 3-D human airway 
tissues expose an interesting dichotomy in 
viral replication, spread, and inhibition by 
neutralizing antibodies”. Journal of 
Virology. 2020 August; JVI.01068-20.  
 
Co-First Authorship: “SPINT2 inhibits 
proteases involved in activation of both 
influenza viruses and 
metapneumoviruses”.  Virology.2020 
April;543:43-
45.10.1016/j.virol.2020.01.004. 
 
 
(2020) 
 
 
 
 
 
 
 
(2020) 
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First Authorship: “Human 
metapneumovirus fusion protein triggering: 
Increasing complexities by analysis of new 
HMPV fusion proteins” Virology. 2019 May; 
531:248-254. 10.1016/j.virol.2019.03.003 
 
 
  
(2019) 
 
Presentations Novel Concepts in Virology 
Oral presentation at the Novel Concepts in 
Virology international meeting in 
Barcelona, Spain 
 
American Society for Virology 
Oral presentation at the annual American 
Society for Virology meeting 
 
ISIRV 11th RSV Symposium 
Poster presentation at the 11th International 
Respiratory Syncytial Virus Symposium   
 
Infectious Diseases Research Day 
Poster presentation at the annual 
University of Kentucky Infectious Diseases 
Research Day 
 
FASEB-Virus Structure and Assembly 
Poster presentation at the Federation of 
American Societies for Experimental 
Biology: Virus structure and assembly 
meeting. 
 
SERVC  
Oral presentation at the annual 
Southeastern Regional Virology 
Conference. 
 
Infectious Diseases Research Day 
Poster presentation at the annual 
University of Kentucky Infectious Diseases 
Research Day 
 
American Society for Virology 
Poster presentation at the annual American 
Soceity for Virology meeting 
 
(2020) 
 
 
 
 
(2019) 
 
 
 
(2018) 
 
 
 
(2018) 
 
 
 
 
(2018) 
 
 
 
 
 
(2018) 
 
 
 
 
(2017) 
 
 
 
(2017) 
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ASBMB  
Poster presentation at the Annual Society 
of Biochemistry and Molecular Biology 
meeting 
 
ABRCMS                                        
Poster presentation of summer research 
project at the Annual Biomedical Research 
Conference for Minority Students  
 
 
WV-INBRE Oral Presentation 
Oral presentation at Marshall University 
studying “The role of capsaisin as a natural 
therapeutic for small cell lung cancer”. 
Research was conducted in the lab of Dr. 
Piylali Dasgupta. 
 
WV-INBRE Poster Presentation  
                                     
Poster presentation of the summer 
research project at the WV-INBRE 
research conference at West Virginia 
University  
 
(2017) 
 
 
 
 
(2014)
 
 
 
 
 
(2014) 
 
 
 
 
 
(2014) 
Honors/ 
Awards 
University of Kentucky Office of 
Biomedical Education travel award 
 
University of Kentucky Max Steckler 
Research Fellowship  
 
American Society of Virology travel 
award 
 
Annual Society of Biochemistry and 
Molecular Biology travel award 
 
University of Kentucky Graduate 
Student Travel Award 
 
Phi Eta Sigma Freshman Honor Society 
 
Bluefield State College President’s list 
 
Bluefield State College Dean’s list  
 
(2020) 
 
 
(2018) 
 
(2017) 
 
(2017) 
 
 
(2017) 
 
(Ind. 2012) 
 
(2012-2015) 
 
(2011)  
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Leadership Elected Director of IT- Biomedical 
Graduate Student Organization  
Director of Information Technology. Duties 
include creating and maintaining the 
organization website, integration and 
application of new technologies, aiding the 
compilation of contact information 
databases and serving on the executive 
board to vote on decisions for the 
organization 
 
Lab manager, Bluefield State College                                                                           
Principal Investigator: Dr. Tesfaye Belay 
Ph.D. 
Manage the research laboratory. Duties 
include ordering material, managing 
inventory, organizing work schedules, 
setting up labs for the professor, and 
assistance of two other senior level 
students with experiments as well as 
training of undergraduate students in the 
lab. 
 
 
Elected Secretary of the Bluefield State 
Biomedical Club Secretary of Biomedical 
Club at Bluefield State College 
Duties are to maintain club minutes and 
research opportunity library as well as 
communicate with students in the college of 
science. Was also part of the initial group 
that helped found this club.                                      
 
(2017-2019) 
 
 
 
 
 
 
 
 
 
 
(2013-2015)
 
 
 
 
 
 
 
 
 
 
 
 
(2014-2015) 
 
 
 
 
 
Service Ronald McDonald House 
Prepared dinner for families at the Ronald 
McDonald House along with the Biomedical 
Graduate Student Organization volunteers 
 
Poster Session Judge 
Volunteer judge for the University of 
Kentucky College of Medicine post-doctoral 
science poster competition. 
 
 
 
(2018) 
 
 
 
 
(2018) 
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Science Fair Judge 
Volunteer judge for the Kentucky American 
Water 2018 Science Fair in Lexington, 
Kentucky. 
 
Science Fair Judge 
Science fair judge for Pike View Middle 
School’s science fair with the involvement 
of our Biomedical Club at Bluefield State 
College. 
 
Breast Cancer Awareness    
Aided Bluefield State Biomedical Club in 
organizing a powder-puff football game 
charity event in conjunction with Bluefield 
College for breast cancer awareness 
month. 
 
Bluefield State College Scientific 
Community Outreach Program                                     
Completed 10 hours of scientific 
community outreach. This included 
informing individuals in the community on 
scientific information and opportunities for 
children and parents. 
 
(2018) 
 
 
 
 
(2014) 
 
 
 
 
 
(2014) 
 
 
 
 
 
 
(2014) 
Teaching/ 
Mentoring 
Mentor within the Dutch Laboratory at 
University of Kentucky 
Aid fellow graduate, undergraduates and 
high school students with experimental 
design and techniques as well as providing 
relevant background and understanding of 
the projects. 
(2016-2020) 
 
 
 
 
 
